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ABSTRACT 
 
 Cancer is a major worldwide public health issue and continues to be a leading 
cause of death in developed countries. On the top of incidence and mortality rates lies 
lung cancer (LC). This disease, caused mainly by tobacco smoking, has one of the lowest 
5-year survival rates among all types of cancers: only 15%. Despite the recent advances 
in systemic therapies, such as chemotherapy and targeted therapies, prognosis remains 
strongly linked to early diagnosis. Unfortunately, most patients are diagnosed in advanced 
stages, when curative options are limited. Consequently, there is a pressing need for 
detection methods that may allow the diagnosis of LC early in its natural history, 
especially among high-risk individuals such as smokers, particularly if chronic obstructive 
pulmonary disease (COPD) is also present. The primary risk factor for COPD is, as for 
LC, tobacco smoking. However, this inflammatory disease is an independent risk factor for 
the development of LC and some pathogenic processes are thought to be important in the 
development of both diseases. A better understanding of the molecular and cellular 
mechanisms by which chronic inflammatory diseases, such as COPD, lead to the initiation 
of LC, may identify early diagnostic biomarkers and screening tests, valuable targets, and 
more effective therapeutic strategies. 
 The search for early detection markers has gained an ally in the last several years.  
Proteomic technologies have begun to uncover the molecular complexity of lung tumours 
by allowing a rapid and complete analysis of the proteins that are expressed in the context 
of this disease. The analysis of lung samples from LC patients and high-risk patients by 
proteomic methodologies might allow us to gain more knowledge on the mechanisms of 
both diseases and possibly identify LC diagnostic biomarkers that could help in the clinical 
practice. The major aim of the present work was to study the protein profile of 
bronchoalveolar lavage fluid (BALF) in patients with LC and/or COPD using proteomic 
methodologies in an attempt to identify new LC biomarkers among high-risk patients. 
 Patients who had required flexible bronchoscopy for diagnostic purposes at the 
Hospital Universitario Virgen del Rocío (Seville, Spain) were recruited for this study. BALF 
samples were treated and submitted to different proteomic technologies such as two-
dimensional polyacrylamide gel electrophoresis (2D-PAGE), mass spectrometry (MS), 
western blot, antibody arrays, and enzyme-linked immunosorbent assay (ELISA).  
 The use of a 2D-PAGE MALDI-TOF/TOF MS methodology allowed the detection 
of 40 differentially expressed proteins between the control group (without LC or COPD) 
and the LC, COPD, and LC&COPD groups. Ingenuity pathway analysis (IPA) of these 
proteins revealed three top molecular mechanisms occurring in both LC and COPD: 
glycolysis and gluconeogenesis, free radical scavenging and oxidative stress response, 
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and inflammation. The major connector of all three pathways was the nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB), a key transcription factor in the 
inflammatory process and carcinogenesis. The importance of inflammation in LC and 
COPD was further evaluated by application of BALF samples to cytokine and growth 
factor antibody arrays. This analysis revealed IL-11 and CCL1 as markers for 
adenocarcinoma of the lung with areas under the curve (AUC) of 93 and 83%, 
respectively. Sensitivity and specificity values were 90 and 88% when evaluating IL-11 
and 80 and 74% when considering CCL1. 
 In conclusion, the present work has revealed the proteomic differences and 
similarities between LC and COPD. In addition, the proteomic methodology used has 
allowed the identification of two possible adenocarcinoma biomarkers that could be used 
to detect this type of LC. The application of a simple ELISA assay could be used to 
improve the diagnosis of lung adenocarcinoma in smokers, despite the presence or 
absence of COPD. The use of this assay in routine clinical practice, if validated in further 
studies, could in the future improve the early detection of lung adenocarcinoma, currently 
the most common form of NSCLC, and hopefully contribute to an increase of the 5-year 
survival rate associated with this disease. 
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RESUMO 
 
O cancro é um problema de saúde pública em todo o mundo e continua a ser uma 
das principais causas de morte nos países desenvolvidos. No topo das taxas de 
incidência e mortalidade encontra-se o cancro do pulmão. Esta neoplasia, causada 
principalmente pelo fumo do tabaco, tem uma das menores taxas de sobrevivência a 5 
anos entre todos os tipos de cancro: apenas 15%. Apesar dos recentes avanços nos 
tratamentos sistémicos como a quimioterapia e medicamentos direcionados, o 
prognóstico permanece fortemente ligado ao diagnóstico precoce. Infelizmente, a maioria 
dos pacientes é diagnosticada em estadios avançados da doença, onde as opções 
terapêuticas são limitadas. Consequentemente, há uma necessidade premente de 
encontrar métodos de detecção que permitiam o diagnóstico do cancro do pulmão no 
início de sua história natural, especialmente entre os indivíduos de alto risco, como 
fumadores e pessoas com doença pulmonar obstrutiva crónica. O principal fator de risco 
para a doença pulmonar obstrutiva crónica é, tal como para o cancro do pulmão, o fumo 
do tabaco. No entanto, esta doença inflamatória é um factor de risco independente para o 
desenvolvimento de cancro do pulmão e pensa-se que alguns processos patogénicos 
possam ser importantes para o desenvolvimento de ambas as doenças. Uma melhor 
compreensão dos mecanismos moleculares e celulares pelos quais doenças 
inflamatórias crónicas, como a doença pulmonar obstrutiva crónica, levam ao 
desenvolvimento de cancro do pulmão, pode identificar biomarcadores de diagnóstico 
precoce, alvos terapêuticos, e estratégias de combate à doença mais eficazes. 
A procura de marcadores de detecção precoce ganhou um forte aliado nos últimos 
anos. O uso de tecnologias proteómicas permitiu começar a descobrir a complexidade 
molecular dos tumores pulmonares, já que permitem uma análise rápida e completa das 
proteínas que são expressas no contexto desta doença. A análise de amostras de 
pacientes com cancro de pulmão e pacientes de alto risco através de técnicas 
proteómicas pode permitir um maior conhecimento sobre os mecanismos de ambas as 
doenças e possivelmente identificar biomarcadores de diagnóstico de cancro do pulmão 
que possam auxiliar na prática clínica.  
O principal objetivo do presente trabalho foi estudar o perfil proteómico de lavado 
bronco-alveolar em pacientes com cancro do pulmão e/ou doença pulmonar obstrutiva 
crónica através de métodos proteómicos, na tentativa de identificar novos biomarcadores 
diagnósticos de cancro do pulmão em pacientes de alto risco. 
Para o estudo foram recrutados pacientes aos quais tinham sido efectuadas 
broncoscopias para fins de diagnóstico no Hospital Universitário Virgen del Rocío 
(Sevilha, Espanha). Amostras de lavado bronco-alveolar foram tratadas e submetidas a 
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diferentes técnicas proteómicas, como a electroforese bidimensional em gel de 
poliacrilamida (2D-PAGE), espectrometria de massa (MS), western blot, arrays de 
anticorpos e ELISA. 
A utilização de uma metodologia 2D-PAGE MALDI-TOF/TOF MS permitiu a 
detecção de 40 proteínas com diferenças de expressão entre o grupo controlo (sem 
cancro do pulmão ou doença pulmonar obstrutiva crónica) e os grupos de pacientes com 
cancro de pulmão, doença pulmonar obstrutiva crónica e ambas as doenças. A análise  
através do programa IPA destas proteínas revelou três mecanismos moleculares 
importantes a ocorrer em ambas as doenças: glicólise e gluconeogénese, resposta a 
stress oxidativo e radicais livres e inflamação. A principal ligação entre as três vias foi o 
NF-kB, um fator de transcrição chave no processo inflamatório e na carcinogénese. A 
importância da inflamação no desenvolvimento de cancro do pulmão e doença pulmonar 
obstrutiva crónica foi avaliada mais em profundidade pela aplicação de amostras de 
lavado bronco-alveolar a arrays de citoquinas e factores de crescimento. Esta análise 
revelou as proteínas IL-11 e CCL1 como marcadores para adenocarcinoma de pulmão 
com AUC de 93 e 83%, respectivamente. Os valores de sensibilidade e especificidade 
foram de 90 e 88% quando se avaliaram os níveis de IL-11 e 80 e 74% quando se 
consideraram os níveis de CCL1 . 
O presente estudo proteómico revelou as diferenças e semelhanças entre o 
cancro do pulmão e a doença pulmonar obstrutiva crónica. Além disso, a metodologia 
utilizada permitiu a identificação de dois possíveis biomarcadores de adenocarcinoma 
que poderiam ser utilizados para detectar este tipo de cancro. O uso de um ensaio 
simples como o de ELISA pode melhorar o diagnóstico de adenocarcinoma do pulmão 
em fumadores, tendo estes doença pulmonar obstrutiva crónica ou não. Em conclusão, a 
futura utilização deste ensaio na rotina clínica poderia melhorar a detecção precoce de 
adenocarcinoma de pulmão, atualmente a forma mais comum cancro do pulmão e  
eventualmente contribuir para um aumento na taxa de sobrevivência a 5 anos associada 
a esta doença. 
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1. INTRODUCTION 
1.1. Lung cancer 
1.1.1. Epidemiology and causes 
 
The World Health Organization (WHO) declared cancer the leading cause of death 
in developed countries (1). According to the latest estimates from this organization, 
approximately 12.7 million people were diagnosed with cancer in 2008 (Figure 1) (2). 
Global cancer deaths are projected to increase from 7.1 million in 2002 to 11.5 million in 
2030 (3)  
Globally, lung cancer (LC) is on the top of the incidence and mortality rates around 
the world. Approximately 1.6 million people were diagnosed with lung cancer in 2008 and 
55% of new cases occurred in developing countries (4). In the same year, lung cancer 
was the leading cause of cancer related death in men and the second in women, with 
approximately 1.4 million reported deaths. The majority of cases and deaths occurred in 
men, although female rates have been rising along the years (4). Projections for 2030 
state that 3.1% of all deaths will be caused by LC, making it the 6th most common cause 
of death worldwide (3). 
 
 
 
Figure 1: Global estimates for new cancer cases and deaths in males and female, from 
Jemal et al. (2011). 
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Lung cancer was a rare disease in the beginning of the 20th century but the 
introduction of manufactured cigarettes with addictive properties caused a steep rise in 
cases beyond that period of time, revealing that the most important risk factor for the 
development of LC was tobacco smoking (5). This relationship was clearly established by 
the works of Doll and Mills in 1950 and later confirmed by the US Surgeon General in 
1964 (5-7). Epidemiological evidence demonstrates that two to three decades after a peak 
in smoking prevalence in a given population, there is a peak in lung cancer related deaths 
(8). Tobacco smoking causes approximately 85-90% of all lung cancer cases worldwide 
and smokers present a 15 to 30 fold increased risk to develop lung cancer compared to 
non-smokers (9-11).  
Tobacco smoke targets the central and peripheral compartments of the lung and 
chronically presents over 4800 different compounds, of which 66 are known carcinogens, 
to the airway epithelial cells. Substances like polycyclic aromatic hydrocarbons, tobacco 
specific nitrosamines, and nitric oxide, among many others, can initiate, promote and 
amplify oxidative DNA damage, and create DNA adducts (12). Cells are capable of 
removing and correcting the injuries caused by tobacco smoke components such as 
benzo[a]pyrene (BaP), NNK (Nicotine-derived nitrosamine ketone), NDMA (N-
nitrosodimethylamine), NNN (N’-nitrosonornicotine), ethylene oxide, and 4-aminobiphenyl, 
but the sustained exposure to these carcinogens can lead to the development of 
permanent molecular alterations and ultimately to LC and other airway diseases. The 
duration of smoking is the strongest determinant of risk to develop LC and increases 
proportionally with the number of cigarettes smoked (12). Although it is the number one 
cause of LC worldwide, only approximately 15% of smokers will eventually develop LC 
(13). 
Cancer is a complex multistep disease that develops over time, progressively 
accumulating genetic alterations that transform normal cells into malignant cells. The 
ability to escape apoptosis, the insensitivity to growth-inhibitory signals, limitless 
replicative potential, self-sufficiency in growth signals, sustained angiogenesis, and the 
ability to invade surrounding tissues and generate metastasis, are considered hallmarks of 
cancer development and are acquired by cells through a variety of mechanisms (Figure 
2). Evidence that cancer cells have deregulated cellular energy pathways and 
mechanisms to avoid their destruction by the immune system has been accumulating over 
the last years and are now also considered emerging hallmarks. Genomic instability and 
mutations and also inflammation are now considered to be enabling characteristics that 
drive the carcinogenic process (14). The acquisition of these abilities and the interactions 
between the altered cells and the surrounding microenvironment are relevant to all stages 
of cancer development, such as cancer initiation, promotion, and progression.  
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Figure 2: Hallmark capabilities and enabling characteristics of cancer, adapted from Hanahan and 
Weinberg (2010). 
 
1.1.2. Classification and staging 
 
The classification of lung cancer is based on histological characteristics identified 
by light microscopy. The most important and most relevant division is made between 
small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Between 15-25% 
of all lung cancer cases are classified as SCLC (15, 16). This histological subtype is 
characterized by small, oval shaped cells with limited cytoplasm and is considered to be a 
very aggressive carcinoma, clinically and biologically different from NSCLC (Figure 3A) 
(17, 18). It has a strong connection to smoking given that 98% of all SCLC cases are 
caused by tobacco smoke (19). 
The NSCLC category is a heterogeneous group that represents 75-85% of all 
diagnosed cases of lung cancer. This group is divided into three major histological types: 
adenocarcinoma, squamous cell carcinoma (SCC), and large cell carcinoma (LCC). In the 
last 20 years, the adenocarcinoma incidence has been rising making it the most 
predominant histological type in many countries, representing up to 50% of all NSCLC 
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cases. Adenocarcinomas are currently more often diagnosed in women, young males 
(<50 years old), non-smokers and Asians (20). This histological type is defined as a 
malignant epithelial tumour with glandular differentiation or mucin production and tends to 
arise in the periphery of the lungs and the alveoli (Figure 3B). There are several subtypes 
of adenocarcinoma, such as acinar, papillary, bronchioloalveolar, solid with mucin 
production, and mixed. However, most adenocarcinomas are histologically heterogeneous 
and consequently classified as mixed (20-22).  
Malignant epithelial tumours that show keratinisation and/or intercellular bridges 
are defined as SCC (23). Also known as epidermoid carcinomas, this group of lung 
tumours was the most frequent but now represents approximately 30% of all diagnosis 
(16). They are more common in men and smokers and the majority occur as slow growing 
tumours in the bronchial epithelium of the central airways (Figure 3C) (21). All NSCLCs 
that lack the cytological and architectural characteristics of the adenocarcinomas or SCCs 
are classified as LCCs (24). They represent approximately 10% of all lung cancer cases 
and their incidence is decreasing most likely due to improved diagnostic techniques 
(Figure 3D) (25). Although the accurate classification of a lung tumour is extremely 
important step in the evaluation of a patient, the correct determination of extent of the 
patients’ disease is also necessary to determine the course of treatment and prognosis.  
 
 
Figure 3: Histological patterns of LC. (A) Small cell lung cancer, from Jackman et al. (2005); (B) 
adenocarcinoma, from Colby et al. (2004); (C) squamous cell carcinoma, from Hammar et al. 
(2004); (D) large cell carcinoma, from Hammar et al. (2004). 
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Lung cancer staging is based on the TNM classification for malignant tumours 
(TNM). This classification was originally proposed by Mountain and adopted by the 
American Joint Committee on Cancer (AJCC) in 1973 and one year later by the Union for 
International Cancer Control (UICC) (26). The TNM system is used for the majority of 
malignant tumours and is based on the extent of the disease. Its goal is to assist 
treatment planning, evaluation of treatment outcomes, and prognosis determination (27). 
The letter T stands for primary tumour and determines the size and degree of locoregional 
invasion. The N indicates the extent of regional lymph node involvement, and the M 
reveals the presence or absence of intrathoracic or distant metastasis (27, 28). The latest 
edition of the TNM classification of lung cancer can be found on Figure 4. 
 
 
Figure 4: Chart of the latest TNM classification of lung cancer, from Uybico et al. (2010). 
 
1.1.3. Diagnosis and treatment 
 
Lung cancer diagnosis includes evaluation of clinical history, several routine blood 
exams such as anaemia and liver enzymes, bronchoscopy to allow the evaluation of the 
extent of the disease in the tracheobronchial tree, and the tumour identification after 
biopsy (29). Information on tumour size and local invasion are obtained by chest 
radiography (30). Computerized tomographies (CT) have been of great help in LC staging, 
given that they offer 3D information of the disease extent such as mediastinal invasion, 
chest wall invasion, or the presence of other pulmonary nodules (29). Mediastinum 
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staging is further amended by endobronchial ultrasound, endoscopic ultrasound, 
mediastinoscopy, and positron emission tomography. The latter is also a sensitive method 
to detect metastatic spread of the tumour. Following the classification and staging of a 
patients’ tumour, course of treatment is decided, selecting between the available 
therapeutic options: surgery, radio and chemotherapy, used separately or in different 
combinations.  
Lung cancer is usually asymptomatic during its development and this causes the 
majority of patients to be diagnosed at advanced stages of the disease. The accurate 
diagnosis of LC, including classification and staging, is essential to the correct treatment 
and prognosis of a given patient.  
Tumour resection by surgery is the most successful curative option available for 
patients with early stage disease: stage I, II, and selected patients with stage IIIA. 
Nonetheless, the survival rate of these patients varies greatly depending on their disease 
stage (28). Stages IIIB and IV, the grand majority of diagnoses, are considered inoperable 
and other treatments, such as radiotherapy and chemotherapy, are applied.  
Radiotherapy is a valuable therapeutic option for patients who, despite the 
presence of early disease, are medically unfit or refuse to undergo surgical resection. It is 
also of use as adjuvant therapy for patients with incomplete resection or node-positive 
disease and as palliative therapy, providing symptomatic improvement (31).  
Chemotherapy was initially used in patients with advanced metastatic disease as a 
palliative measure. Since then, the application of drugs (cisplatin, taxanes, 
antimetabolites, topoisomerase inhibitors, among others) has been used with curative 
intent combined with surgery, neoadjuvant or adjuvant, and/or radiotherapy, in an attempt 
to improve the survival of NSCLC patients (32). In addition to these traditional drugs, 
targeted therapy has been improving in the last years, gathering information from 
molecular studies that identified specific alterations in groups of LC patients. The greatest 
achievements of this targeted therapy have been the development of monoclonal 
antibodies and tyrosine kinase inhibitors against the epidermal growth factor receptor 
(EGFR), such as cetuximab and erlotinib, and the vascular endothelial growth factor 
(VEGF), such as bevacizumab and sorafenib, among others (Figure 5) (33). In addition, 
novel agents that target the echinoderm microtubule-associated protein-like 4 (EML4) and 
the anaplastic lymphoma kinase (ALK) gene fusion, for example crizotinib, the insulin-like 
growth factor-1 receptor (IGF-1R), such as cixutumumab or linsitimib, the mammalian 
target of rapamycin (mTOR), for example deforolimus, and the hepatocyte growth factor 
receptor (MET), such as tivantinib, are currently being investigated in NSCLC clinical trials 
(Figure 5) (33). 
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Although a lot of progress has been made, the 5-year survival rate for lung cancer 
is still approximately 15%, reinforcing the need for diagnostic markers that can aid in the 
early detection of this tumour.  
 
 
Figure 5: Most relevant pathways in NSCLC and developed targeted therapies, adapted from Pal et 
al. (2010). 
 
1.2. Chronic obstructive pulmonary disease 
1.2.1. Epidemiology and causes 
 
Chronic obstructive pulmonary disease (COPD) is, according to the Global 
Initiative for Chronic Obstructive Pulmonary Disease (GOLD), a “preventable and 
treatable disease with significant extrapulmonary effects. The pulmonary component of 
COPD is characterized by a progressive airflow limitation associated with an atypical 
inflammatory response of the lungs to noxious particles and gases” (34). The airflow 
limitation present in COPD patients is the result of damages to the small and large 
airways (chronic bronchiolitis and bronchitis, Figure 6A) and to the pulmonary 
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parenchyma (emphysema, Figure 6B) (35). The majority of patients present signs of both 
bronchitis and emphysema instead of one component exclusively (36).  
 
 
Figure 6: Histological patterns of bronchitis with increased number of glands and thicker smooth 
muscle bundles (A) and emphysema with enlarged airway spaces (B), from Macnee et al. (2007). 
 
COPD is a leading cause of worldwide morbidity and mortality, apart from being a 
major economic and social burden. The WHO estimated that COPD was the fifth leading 
cause of death in 2006 and is expected to rise to fourth place by 2020 (3). It is clearly 
more frequent in men and the elderly, but incidence is increasing in women reflecting 
changes in their exposure to COPD risk factors since the middle of the 21st century 
The primary risk factor for COPD is, as for LC, tobacco smoking. The WHO 
assessed that 40 to 70% of all COPD mortality is related to smoking (37). Age of smoking 
initiation, pack-years smoked, and current smoking status, influence COPD development, 
prognosis, and mortality (38). Even so, reports state that 15-50% of smokers will develop 
some form of COPD over time (36, 37). There is a natural decline in lung function with 
age, but active smokers have an accelerated rate of deterioration that can be reversed to 
normal levels of decline with sustained smoking cessation.  
 
1.2.2. Diagnosis, classification, and treatment 
 
COPD is a multicomponent and heterogeneous disease that varies within a group 
of patients with respect to lung pathology, disease progression, and comorbidities. Given 
that the clinical presentation is far from uniform, healthcare practitioners should consider 
the diagnosis of COPD if any patient is over 40 years of age, has been exposed to the 
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aforementioned risk factor, and presents symptoms such as breathlessness during 
exercise, increased effort to breath, cough, or excessive mucus production (39, 40). If 
these symptoms are present, physical examination and spirometric tests are required to 
make the accurate diagnosis and disease staging.  
Spirometry is the gold standard for the detection of COPD, given its high 
reproducibility and availability (38). It is a simple and non-invasive test that measures lung 
function: the amount (volume) and/or speed (flow) of air that can be inhaled and exhaled. 
The evaluated parameters are: post-bronchodilator forced expiratory volume in 1 second 
(FEV1) and the ratio between FEV1 and forced vital capacity (FEV1/FVC). These two 
measurements are used to detect COPD and assess its severity by comparison with 
reference values that vary with age, gender, race and height (34).  
The classification of COPD ranges from mild to very severe. A normal spirometry 
implies a FEV1/FVC ratio superior to 70% and a FEV1 superior to 80%. COPD is 
diagnosed when the FEV1/FVC ratio is below 70% and its severity varies from mild to 
very severe depending on the reduction of post-bronchodilator FEV1 compared to the 
predicted in a healthy population (Table 1) (41). Radiological imaging can be used in the 
assessment of COPD severity since it can provide an accurate characterization of 
changes in the lung parenchyma and airway wall thickness, as well as exclude alternative 
diagnoses (42). Arterial blood gas measurement, α1-antitrypsin deficiency screening, and 
the six minute walk test are also useful in the diagnosis of this disease (34). 
 
Table 1: COPD classification for patients with a FEV1/FVC ratio below 70%  
Gold stage Description FEV1 values 
GOLD 1 Mild FEV1 ≥ 80% predicted 
GOLD 2 Moderate 50% ≤ FEV1 < 80% predicted 
GOLD 3 Severe 30% ≤ FEV1 < 50% predicted 
GOLD 4 Very severe FEV1 < 30% predicted 
 
Given that no cure is currently available and there are no therapies than can halt 
the lung function decline, the treatment of COPD varies enormously across patients. The 
main goals of the treatment are to reduce symptoms and improve quality of life, reduce 
the frequency and severity of the exacerbations, and reduce mortality (43). One of the first 
steps in the treatment and management of these patients is smoking cessation. Non-
pharmacological treatments include long term oxygen therapy (that can modify long term 
lung function decline), non-invasive ventilation, lung volume reduction surgery (for patients 
with emphysema), and pulmonary rehabilitation that can provide relief from dyspnoea, 
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increases exercise tolerance, and improves quality of life (34). Pharmacological 
treatments are patient-specific and can include the use of antibiotics, bronchodilators, 
corticosteroids, and mucolytic agents, alone or in combinations (34, 42).   
 
1.3. Links between LC and COPD 
 
Lung cancer and COPD are two of the major causes of mortality in the world. Apart 
from being caused by the same major etiological factor, tobacco smoking, epidemiological 
data demonstrates a clear connection between both diseases. The odds ratio (OR) value 
for LC increases 2.8 fold in patients with moderate to severe COPD (44). Independently of 
smoking history, reduced FEV1 is associated with an increased risk for developing LC: 
even small changes in this parameter, such as 10% differences, raise LC risk by 30-60% 
(45). Indeed, 50 to 70% of all LC patients have spirometric evidences of COPD (46). In 
addition, the presence of mild emphysema, also independent of cigarette smoking and 
history of other lung diseases, confers a greater risk to develop LC (47). Since only a 
fraction of long-term smokers develop these diseases, complex mechanisms and 
interactions are thought to determine an individual’s risk of developing COPD, LC, or both.  
At a first glance, it is difficult to envision any common mechanism between both 
diseases: LC is characterized by unlimited cell proliferation, sustained angiogenesis and 
self-sufficiency in growth factors, tissue invasion, evasion of apoptosis, and insensitivity to 
anti-growth signals, whereas COPD has increased levels of apoptosis, extracellular matrix 
degradation, limited angiogenesis, and ineffective tissue repair (48, 49). Understanding 
the shared mechanisms between these two dissimilar diseases is critical for developing 
new methods of early diagnosis and treatment of LC.  
Throughout the years specific processes have been suggested to be of importance 
in the pathogenesis of both COPD and LC (Figure 7). Reactive oxygen species (ROS) 
caused by tobacco smoke are produced in excess in the setting of COPD and can 
ultimately produce DNA alterations that lead to LC development. The balance between 
cellular proliferation and cell death is also important in the lung given its contribution to the 
development of both diseases. Hypoxia and angiogenesis can also affect the 
development of COPD and LC: airflow limitation can lead hypoxia that may cause 
destruction of alveolar capillaries and airway enlargement, in addition to being capable of 
promoting, through angiogenesis, the progression and metastasis of lung tumours (46, 
50). However, these processes are all influenced by and interact with a major mechanism 
activated by tobacco smoking that is inflammation. 
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Figure 7: Mechanisms and pathways potentially involved in the development of COPD and LC, 
adapted from Yang et al. (2011). 
 
Inflammation is one of the body’s natural protective mechanisms against harmful 
stimuli. It is the result of complex interactions between immune cells and soluble factors 
that arises in tissues as a response to infections, trauma, or toxic substances such as the 
ones present in tobacco smoke (51). Its major role is to remove the source of aggression 
and to initiate the healing process. Nevertheless, a persistent inflammatory response in 
the lung can result in the development of lung diseases, such as COPD and lung tumours. 
COPD was early recognized as an inflammatory disease, with profound 
abnormalities in the inflammatory pathways, and that airway inflammation starts at an 
early stage, many years prior to the onset of clinical symptoms. Tobacco smoke induces 
inflammation in all smokers, but those who develop COPD have a greater degree of 
inflammation that persists even after smoking cessation (50). Tobacco smoke is a 
complex mixture of thousands of chemicals generated by tobacco combustion such as 
carcinogenic toxins, addictive substances, and more than 1014 oxidants and free radicals 
(46). These compounds first interface with the lungs at the mucosal surfaces lining the 
airways. There they can damage epithelial cells and resident inflammatory cells by 
inducing peroxidation of lipids and other cell membrane constituents, activate oxidative-
sensitive cellular pathways, induce DNA damage, and activate epithelial cell intracellular 
signalling cascades that lead to inflammatory gene activation (52). The release of these 
inflammatory mediators initiates the recruitment and activation of more pro-inflammatory 
cells such as neutrophils, macrophages, and lymphocytes that propagate the 
inflammatory response by releasing more cytokines, for example interleukin 8 (IL-8) and 
tumour necrosis factor α (TNF-α), and ROS, generating a vicious cycle of persistent 
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inflammation. Interestingly, the immune cells and mediators that drive chronic 
inflammation and the progression of COPD are also known to promote a tumour friendly 
microenvironment (53). 
The observation of a relationship between cancer and inflammation is not a recent 
one. Almost 2000 years ago, Galenus described the similarities between inflamed tissue 
and cancerous tissue. Rudolph Virchow, in the year of 1863, reported the infiltration of 
leukocytes in malignant tissues and suggested that cancers arise in sites of chronic 
inflammation (54). More than one hundred years later Dvorak observed that cancer and 
inflammation share some developmental mechanisms and types of infiltrating immune 
cells, apart from classifying tumours as “wounds that do not heal” (55).  
The ultimate recognition of inflammation as a major player in cancer development 
came with the 2011 update article on cancer hallmarks by Hanahan and Weinberg where 
it was classified as an enabling characteristic of tumours. The evidence gathered over the 
last years showed that inflammation contributes to the appearance of multiple cancer 
hallmark capabilities by supplying important molecules to the tumour microenvironment. 
Those molecules include growth factors that sustain the proliferative signalling, survival 
factors that limit apoptosis, pro-angiogenic factors, extracellular matrix-modifying enzymes 
that favour angiogenesis, invasion, and metastasis. Furthermore, inflammation manifests 
itself at the earliest stages of tumour progression and is capable of nurturing insipient 
neoplasias into developed cancers. In addition, inflammatory cells can release a number 
of chemicals, such as ROS, that are actively mutagenic and promote malignancy even 
further (14).  
Studies on LC and chronic inflammation have revealed that the likelihood of 
developing LC was increased in patients with higher levels of C-reactive protein (CRP), an 
acute-phase protein that is a marker for inflammation (56). Also, the risk for developing LC 
was decreased among COPD patients who had been treated with inhaled corticosteroids 
(57). Studies on animal models have showed that, after infection by Haemophilus 
influenza, mice develop a bronchial inflammation similar to COPD and a subsequent 
predisposition to lung carcinogenesis (58). The constant lung injury and repair cycle 
triggered by chronic inflammation, such as the one that occurs in COPD, can enhance cell 
proliferation and genetic damage accumulation, epithelial to mesenchymal transition 
(EMT), and ultimately lung carcinogenesis (46).  
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1.4. Proteomics 
 
In the last several years genomic and proteomic technologies have begun to 
uncover the molecular complexity of lung tumours by allowing a rapid and complete 
analysis of the genes and proteins that are expressed in the context of this disease. The 
use of genomic technologies such as microarrays and quantitative reverse transcription 
polymerase chain reaction (RT-PCR) on LC studies has allowed the separation of 
adenocarcinoma patients into new molecular sub-classes with different outcomes, the 
early identification of high risk patients, and the detection of molecular signatures 
associated with metastasis (59). 
While genomic technologies have revealed important data regarding the biology of 
LC, the direct evaluation of proteins offers information that is not obtainable through the 
study of DNA and RNA. Proteins are crucial operators in the majority of biological systems 
and signalling pathways. Although they can determine the cells’ phenotype, RNA levels 
often poorly correlate with protein expression (60).  
 
1.4.1. Introduction to proteomics  
 
The proteome is defined as the entire collection of proteins that is produced by a 
cell or tissue in a given time, making it a very dynamic entity: the type of expressed 
proteins, their relative abundance, and their subcellular location depend on the 
physiological state of a cell or tissue (61).  
Proteomics, the analysis of the proteome, is performed through a variety of 
technologies that are continuously evolving. Traditional protein analysis technologies 
include approaches such as western blot, immunohistochemistry (IHC), and enzyme-
linked immunosorbent assay (ELISA). Protein microarrays, which consist of large number 
of antibodies robotically immobilized on a slide, have a higher throughput and allow the 
identification of several proteins at a time in the same sample (62). Protein microarrays 
are rapid, automated, economical, and highly sensitive, consuming small quantities of 
samples and reagents. However, the previous techniques are target driven, meaning they 
require a previous knowledge of the proteins that are expected to appear in a given 
sample. In contrast to these techniques, two methods do not require a previous 
assumption of the identity or number of proteins in a sample and are considered classical 
proteomic technologies: two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) 
and mass spectrometry (MS). The use of electrospray ionization (ESI) and liquid 
chromatography, second generation proteomics or shotgun proteomics, has more recently 
allowed the identification of complex and so far unknown proteomes.  
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First developed in 1975 by O’Farrel, 2D-PAGE has been the preferred method for 
proteomic analysis given its relative low cost and high applicability. It allows proteins to be 
separated in two dimensions: isoelectric point and molecular weight (63).  
In the first dimension, also called isoelectric focusing, the separation of proteins 
occurs when electric current is applied to a protein sample in a pH gradient: proteins will 
move until they reach a pH that is similar to their isoelectric point. The second dimension 
is based on the traditional electrophoresis process in polyacrylamide gels: proteins 
separated in the first dimension are given negative electric charges by the use of sodium 
dodecyl sulfate (SDS) and migrate through the gel, when current is applied, accordingly to 
their molecular weight. This technique has some associated limitations that include small 
sensitivity to very low or very high molecular weight proteins and isoelectric points, 
samples with high salt contents, the under-representation of membrane proteins, and gel-
to-gel variation (64, 65).  
Two-dimensional difference gel electrophoresis (2D-DIGE), a variation of 2D-
PAGE, allows the analysis of three samples (test, control, reference) in the same gel and 
the evaluation of quantitative differences among them by the use of fluorescent dyes 
(Cy3, Cy5, and Cy2) (64). A representation of the common 2D-PAGE and 2D-DIGE 
workflow is depicted in Figure 8 (66). Alternatively, SDS-PAGE alone can be used and 
obtained protein bands can be excised and analysed by MS. Gel-free separation 
techniques include liquid chromatography and high-performance liquid chromatography. 
Typically samples are digested and peptides are separated by this technique, with the 
resulting fractions being analysed by MS (67).  
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Figure 8: A typical 2D-PAGE and 2D-DIGE protocol followed by MS, from Pastor et al. (2013). 
 
The use of labelling methods has allowed protein quantitation in a gel-free setting, 
as seen on Figure 9 (66). Stable isotope labelling with amino acids in cell culture (SILAC) 
is based on the metabolic incorporation of “heavy” and “light” forms of amino acids into the 
proteins of living cultured cells (68). Following trypsin digestion, peptides are analysed by 
MS and the light and heavy peptides appear in two distinct peaks and, by comparing the 
signal intensities differences, relative quantitation is achieved. Isotope-coded affinity tags 
(ICAT) is generally used to compare pairs of samples. Extracted proteins are labelled with 
the light or heavy ICAT reagent, mixed, trypsin digested, fractionated, and analysed by 
MS (69). Isobaric tags for relative and absolute quantitation (iTRAQ) can analyse 4 to 8 
samples (4-plex, 8-plex) in the same experiment. After trypsin digestion, samples are 
independently labelled with the iTRAQ reagent. During MS analysis, the reporter groups 
of the iTRAQ reagents separate from the peptides and generate small fragments for each 
sample with mass-to-charge (m/z) of 114, 115, 116, and 117 for 4-plex, plus 113, 118, 
119, and 121 for 8-plex. The intensity of each peak correlates with the quantity of each 
reporter group and thus with the quantity of the peptide (70). 
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Figure 9: Gel-free quantitative approaches in proteomics, SILAC, ICAT, and iTRAQ, from Pastor et 
al. (2013). 
 
The MS analysis of proteins and peptides is one of the pillars of current proteomic 
analysis and has revolutionized the field since the 1990s (61). It provides the accurate 
measurement of their molecular weight and charge (m/z ratio) that allows their 
identification. In order to obtain these measurements, samples are ionized by an ion 
source and travel through a mass analyser and then to a mass detector (71).  
The most common ionization method in proteomic studies is matrix-assisted laser 
desorption ionization (MALDI). Proteins or peptides are mixed with an energy-absorbing 
matrix and spotted on a metal plate. After drying, the matrix and sample crystallize and 
are then hit by a laser to be ionized (64). Ionization by MALDI allows and easy and rapid 
data analysis, high resolution for large molecules, and sensitivity to small amounts of 
sample. However, small molecules may not be detected (64, 65, 71). Alternatives to 
MALDI include ESI, in which the protein sample is dissolved in a volatile buffer, passed 
through a high performance liquid chromatography column and turned into a fine aerosol 
by the electric current applied to a metallic capillary tube. Although ESI allows the 
identification of proteins in large complex samples, MALDI is still currently used given its 
tolerance to sample contaminants (72). Surface-enhanced laser desorption/ionization 
(SELDI), a variation of MALDI, uses chromatographic chip arrays that allow the analysis of 
a more complex sample by selectively binding subsets of proteins (64, 65).  
After ionization samples pass through a mass analyser that separates ions 
according to their m/z ratio. The most commonly used for proteomic studies is the time-of-
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flight (TOF) analyser. In this analyser, ions are accelerated by an electric field and the 
time that each ion takes to reach the detector is measured to determine the particles m/z 
ratio (71). The addition of a second mass analyser (tandem mass spectrometry) results in 
the identification of the amino acid sequence of peptides: the first analyser allows the m/z 
ratio measurement of whole peptides and the second analyser measures the ratios of the 
fragmented peptides. The obtained spectra are then compared against protein sequence 
databases to allow protein identification (65). 
 
1.4.2. Proteomics of COPD  
 
The progressive deterioration of pulmonary function caused by COPD and the fact 
that this disease is an important risk factor for the development of LC, independent of 
tobacco smoking, has driven researchers to discover and validate biomarkers of COPD. 
The use of 2D-PAGE and MALDI-TOF-MS has been the most common approach to 
biological COPD samples, although other techniques are used.  
Several studies have evaluated tissue samples, often considered the optimal 
sample for studying lung diseases, by this technique revealing heat shock protein 27, 
cyclophilin A, matrix metallopeptidase 13, and surfactant protein A as possible tissue 
diagnostic markers of COPD (73-75). Plasma samples, that can reflect the systemic 
alterations caused by this disease, have revealed by different proteomic techniques 
diagnostic (aldolase, catalase, haptoglobin, among others) and prognostic (serum amyloid 
A) biomarkers of COPD (76-79). Induced sputum is a good sample for research and 
clinical diagnosis and disease monitoring, although the sampling protocol is a crucial step. 
Proteomic studies on COPD using this sample have identified diagnostic biomarkers, such 
as apolipoprotein A1, lipocalin 1, and polymeric immunoglobulin receptor, among others 
(80, 81). 
 
1.4.3. Proteomics of LC 
 
 Proteomic technologies allow the analysis of thousands of cancer-related proteins 
and promise to improve the knowledge of LC biology and pathogenesis, and aid in the 
development of new early detection biomarkers and the identification of protein profiles 
associated with prognosis and drug resistance. 
The most common proteomic workflow for LC biomarker discovery has been the 
use of 2D-PAGE followed by MALDI-TOF-MS analysis. Nowadays, with the development 
of shotgun proteomics, that allow a rapid and accurate characterization of several 
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thousands of proteins in a single study, a great deal of data is being generated in LC 
proteomic studies. However, 2D-PAGE and MALDI-TOF-MS are still widely used given its 
low cost and easier implementation in a laboratory setting when compared to liquid 
chromatography-MS approaches (82). 
The proteomic studies on LC so far have used a variety of samples and 
techniques. When considering the studies aimed at identifying LC diagnostic biomarkers, 
blood based proteomics has been a major focus of research. Blood has the grand 
advantage of being easily obtainable and its collection is minimally invasive. Analysis of 
plasma or serum assumes that the perfusion of tumours or host response contributes to 
the modification of circulating proteins and peptides, and that tumour-derived proteins may 
be in circulation. However, due to the abundance of plasma proteins, depletion of these 
proteins is necessary to reveal the presence of less abundant ones, the ones likely to be 
tumour-specific markers (67). Some LC blood diagnostic biomarkers have been identified 
by proteomic studies: acute phase proteins, such as haptoglobin β chain and serum 
amyloid A (83, 84), glycosylated proteins, for example kallikrein, insulin-like growth factor-
binding protein 3, prostaglandin D synthase (lipocalin-type), glycosylated forms of 
apolipoprotein C-III (85-87), and finally blood proteomic profiles, given that a combination 
of proteins is more reliable than a single marker (88-90). 
Pleural effusion is the pathological accumulation of fluid that occurs in 
inflammatory conditions and in LC settings. In this case, pleural effusions are often 
drained to search for cancer cell infiltration. It has a similar protein composition to that of 
plasma, but its proximity to tumour cells makes it useful for lung cancer biomarker 
detection by proteomic techniques. A few proteomic studies have used this type of sample 
to search for LC diagnostic markers: they have found important proteins such as 
Niemann–Pick disease type C2 and membrane glycoprotein-2, among others (91, 92). 
The use of tissue samples presents inherent difficulties: the lung is a 
heterogeneous organ composed by many different cell types (bronchial, alveolar, and 
inflammatory) and vascular structures, which implies that tumour tissue samples will likely 
have adjacent non-tumour cells, inflammatory cells, stromal components, among others, 
that can result in non-tumour protein contamination. However, LC proteomic studies have 
shown the over-expression of proteins involved in the energy-production and anti-
oxidation pathways (93), of the macrophage migration inhibitory factor and cyclophilin A 
proteins (94), and of the pyruvate kinase M1, manganese superoxide dismutase and 
peroxiredoxin proteins (95). 
A recent study in saliva samples identified three proteins (haptoglobin, calprotectin, 
and zinc-α-2-glycoprotein) capable of discriminating LC patients from healthy controls with 
high specificity and sensitivity (96). 
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 In addition to LC diagnostic biomarkers, proteomic technologies have also been 
applied to the development of prognostic and predictive biomarkers. Some studies have 
identified proteins involved in cancer metabolisms, proliferation, differentiation, and 
apoptosis (97-100). Others have focused on the metastasis process, where proteins such 
as S100A11, annexins 2 and 3, cytokeratins, cathepsins D, thymosin β4 and β10, among 
others, have been associated with a lung cancer metastatic phenotype (101-105). Similar 
to what has been used for diagnostic purposes, prognosis can also be obtained based on 
a combination of proteins, and proteomic signal signatures have been identified that allow 
the discrimination between good and bad prognosis of LC patients (106, 107).  
Lastly, the study of LC predictive biomarkers has focused on two major therapeutic 
options available for LC treatment: studies evaluating the response to traditional 
chemotherapy and the response to EGFR inhibitors. Regarding the traditional 
chemotherapy, a group of 14 proteins was identified and related to gemcitabine resistance 
(108), a five-peak pattern that distinguished platinum chemotherapy-resistant patients 
from chemotherapy-sensitive patients was observed (109), and a 13-peptide signature 
was able to discriminate NSCLC patients with short or long progression-free survival after 
treatment with cisplatin-gemcitabine in combination with bortezomib (110). When it comes 
to identifying patients who might benefit from treatment with EGFR inhibitors, an 8-peak 
profile was predictive of outcome in patients with NSCLC, after treatment with gefitinib and 
erlotinib (89). In conclusion, and despite some technical difficulties, several protein profiles 
with diagnostic, prognostic, and predictive value for LC have been identified. However, the 
identity of only a small proportion of the detected peaks has been achieved and for many 
of these identified proteins, their role in LC development is not yet known.  
Considering all proteomic researches in LC, one type of sample in particular has 
been overlooked in these types of studies. Obtained during fiberoptic bronchoscopy, 
bronchoalveolar lavage fluid (BALF) is generally used to perform cell counts, cytology, 
and cultures, allowing the evaluation of pulmonary diseases. This biological sample 
contains airway cells and soluble components that can indicate possible inflammatory, 
infectious, or neoplastic processes that could be occurring in the lung or the alveoli. 
Excess BALF is normally discarded after it has been used for standard pathologic 
procedures, but can be used to search for biomarkers that could assist the diagnosis of 
pulmonary diseases (111). The use of BALF in proteomic studies has been limited to non-
malignant conditions such as cystic fibrosis (112), asthma (113), acute lung injury (114), 
interstitial lung diseases (115), acute respiratory distress syndrome (116), among others. 
So far, the analysis of the proteomic profiles of BALF to diagnose LC has not been 
explored in depth. Moreover, to the best of our knowledge, no studies have evaluated the 
proteomic differences associated with COPD patients.  
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The analysis of the proteomic profiles of LC and COPD patients might allow us to 
gain more knowledge on the mechanisms of both diseases, to identify possible LC 
proteomic diagnostic biomarkers, as well as elucidate why some COPD patients end up 
developing LC. 
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2. HYPOTHESIS 
 
           There are differences in the protein expression (inflammation and/or other 
pathways) of BALF among patients with LC and/or COPD as compared to healthy 
individuals. These differentially expressed proteins could help to understand the molecular 
pathogens of LC and COPD, and may provide useful biomarker for diagnosis.  
 
 
3. OBJECTIVES 
 
3.1. Main objective 
 
The present work focused on identifying new biomarkers as well as biological 
pathways involved in the development of LC and/or COPD among high-risk 
patients by using proteomic methodologies, focusing particularly on the 
inflammatory pathway. 
 
3.2. Specific objectives 
 
3.2.1. Identification of differently expressed proteins in BALF from patients 
with LC, COPD, COPD with LC, and without LC or COPD by 
comparative proteomic analysis. 
 
3.2.2. Analysis of the differential expression of inflammation related proteins 
(cytokines and growth factors) in LC and COPD patients. 
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4. MATERIALS AND METHODS 
4.1. Patient selection and sample collection 
 
From 2009 to 2011, a total of 925 patients who had required flexible bronchoscopy for 
diagnostic purposes at the Hospital Universitario Virgen del Rocío (Seville, Spain), were 
collected for this prospective study. From the original first group only 419 patients 
respected the selection criteria: 1) patients were under pneumologist consultation due to 
haemoptysis and/or a pulmonary nodule; 2) patients were requested by their physician to 
perform a flexible bronchoscopy for diagnostic purposes; 3) patients were smokers or ex-
smokers of more than 20 pack-years; 4) patients had to be older than 40 years of age. 
Exclusion criteria included: 1) diagnosis of a neoplastic disease other than lung cancer; 2) 
active pulmonary tuberculosis; 3) previous lung resection; 4) history of drug abuse; 5) 
presence of other acute or chronic inflammatory diseases. 
The study protocol was conducted in agreement with the Helsinki declaration and 
approved by the Hospital's Ethical Committee, and a written informed consent was 
obtained from all patients prior to their addition to the study. 
Subjects were prepared with a combination of topical anaesthesia (20% 
benzocaine spray to the pharynx plus 2% topical lidocaine as needed) and conscious 
sedation using midazolam and meperidine according to institutional guidelines. All BALF 
samples were obtained by instillation and aspiration of 40 to 60 ml aliquots of 0.9% sterile 
saline in the appropriate bronchopulmonary segment. Recovered fluid was immediately 
passed through a 100 µm sterile nylon filter (Becton Dickinson, San Jose, CA) to remove 
mucus and transported on ice to the laboratory. The total volume was then centrifuged for 
10 min at 1800xg and 4ºC. The supernatant was aliquoted into 2 ml tubes and frozen at –
80ºC until further use. 
 
4.2. Sample processing 
4.2.1. Sample concentration 
 
The amount of proteins in BALF samples is very small, diluted in the sterile saline 
used for its recovery. In order to use these samples for proteomics, they required 
concentration and this was accomplished by the use of a Concentrator Plus vacuum 
concentrator (Eppendorf, Hamburg, Germany). BALF samples were thawed on ice with a 
protease inhibitor cocktail kit (Pierce, Thermo Scientific, Rockford, IL, USA). Samples 
were then aliquoted into new tubes and placed on the vacuum concentrator. The initial 
volume of the samples, usually 4-8 ml, was reduced to 250-450 µl in 2-6 hours. 
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4.2.2. Protein quantitation 
 
A number of colorimetric methods were tested, such as bicinchoninic acid assay 
(BCA from Pierce, Thermo Scientific, Rockford, IL, USA, Rockford, IL, USA), Bradford 
(Bio-Rad, Hercules, CA, USA) and RC-DC (Bio-Rad, Hercules, CA, USA). The RC-DC 
method was selected given that it was reducing agents and detergent compatible. It is 
based on the principle of Lowry estimation where proteins react with alkaline copper and 
subsequently reduce the folin reagent, leading to colour development.  
Protein quantitation was assessed according to the manufacturer’s instructions. 
Absorbance was measured at 750 nm and the linear equation created by different bovine 
serum albumin (BSA) dilutions allowed the determination of the protein concentration in 
our samples. Protein quantitation was assessed before and after sample concentration, 
depletion of high abundance proteins, and sample cleaning procedures, which will be 
described in the following corresponding sections. 
 
4.2.3. Depletion of high abundance proteins 
 
The presence of high abundance plasma proteins obscures the presence of low 
abundant ones of possible interest. Revealing these important proteins required that a 
depletion process be applied for the analysis of BALF proteomes.  
Several commercial kits of depletion columns were tested: Proteominer (Bio-Rad, 
Hercules, CA, USA), ProteoPrep (Sigma-Aldrich, St. Louis, MO, USA), and SpinTrap (GE 
Healthcare, Waukesha, WI, USA). The latter one showed the best results in albumin and 
immunoglobulin G removal in our samples.  
Depletion protocol followed the manufacturer’s instructions. The SpinTrap columns 
were inverted repeatedly to resuspend the storage medium, and then centrifuged to 
remove it. Binding buffer was added and centrifuged out to wash the column before the 
addition of the concentrated BALF sample. The sample was allowed to incubate for 5 
minutes to let the existent albumin and immunoglobulin G bind to the column. The column 
was then centrifuged and the eluate collected. Binding buffer was added twice to the 
column and the eluate was again collected. The depleted BALF samples were cleaned 
immediately or frozen at -80ºC until further use. 
 
4.2.4. Sample cleaning 
 
After the depletion step BALF samples required the removal of salts, thiols, 
denaturants, and other contaminants that could be present and interfere with the 2D-
PAGE protocol. Of all available methods to clean protein samples (trichloroacetic acid 
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precipitation, two-step precipitation, ultra filtration, and dialysis) and taking into account 
their advantages and disadvantages, depleted samples were cleaned by the 2-D clean-up 
kit (GE Healthcare, Waukesha, WI, USA) following the manufacturer’s directions. At the 
end, the protein pellet was rehydrated with a solution containing urea at 7M, thiourea at 
2M, and 2% CHAPS, suitable for 2D-PAGE (all three reagents from GE Healthcare, 
Waukesha, WI, USA). 
 
4.3. Two-dimensional gel electrophoresis 
 
Two-dimensional gel electrophoresis is a protein analysis method that allows the 
separation of proteins according to two innate characteristics: isoelectric point (IP) and 
molecular weight (MW).  
In the first dimension, also described as isoelectric focusing (IEF), proteins are 
separated in a gel strip that contains a predetermined pH range, allowing the proteins to 
separate according to their isoelectric point. In the second dimension, the strip is placed 
on a SDS-PAGE gel in which the focused proteins migrate according to their molecular 
weight. The final result is a SDS-PAGE gel where, after staining, protein spots are 
observed.  
 
4.3.1. Isoelectric focusing 
 
Treated BALF samples (n=60), equally distributed among four groups of patients 
(controls, LC, COPD, and LC&COPD), were independently submitted to IEF in 7 cm IPG 
DryStrips with a 3-11 NL pH range.  
A mixture of 75 µg of protein from each sample, DeStreak rehydration solution, 
and 0.5% of 3-11 NL pH IPG Buffer, in a final volume of 125 µl, was prepared. This 
mixture was then applied to the strip holder. The strip’s cover foil was carefully removed 
from the positive end and the strip placed, gel-side down and positive end first, onto the 
strip holder, distributing the solution evenly under the strip. The strip was then overlaid 
with cover fluid and the strip holders placed on the Ettan IPGphor II for the IEF protocol 
(Table 2). All reagents and instruments were from GE Healthcare (Waukesha, WI, USA).  
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Table 2: Isoelectric focusing protocol 
Step Voltage Duration 
1 30 V 14 hours 
2 500 V 250 V/hour 
3 1000 V 500 V/hour 
4 5000 V 8500 V/hour 
5 5000 V 30 minutes 
V: volts 
 
4.3.2. Strip equilibration 
 
After the IEF protocol and before the SDS-PAGE protein separation, the focused 
IPG strips required an equilibration procedure in an appropriate buffer. Equilibration 
solution was prepared with double-distilled water, 6M of urea, 75 mM of 1,5 M Tris-HCl 
(pH 8.8) solution, 29.3% of glycerol (Sigma-Aldrich, St. Louis, MO, USA), 2% SDS 
(Sigma-Aldrich, St. Louis, MO, USA), and trace amounts of bromophenol blue (Bio-Rad, 
Hercules, CA, USA). 
Focused IPG strips were equilibrated with dithiothreitol (DTT) (Bio-Rad, Hercules, 
CA, USA) equilibration solution (100 mg per 10 ml of equilibration solution) for 7.5 minutes 
(2x), to break disulphide bonds, and later with iodoacetamide (Bio-Rad, Hercules, CA, 
USA) equilibration solution (250 mg per 10 ml of equilibration solution) for 7.5 minutes (2x) 
to prevent the reformation of the disulphide bonds. 
 
4.3.3. 2D- PAGE 
 
The second dimension was performed in 12.5% acrylamide mini gels (1.5 mm) that 
were prepared for each strip and then topped with water. For one gel, 1587.5 µl of double-
distilled water, 1250 µl of 1.5M Tris-HCl (pH 8.8), and 2087.5 µl of 30% acrylamide (Bio-
Rad, Hercules, CA, USA) were mixed in an appropriate container. Then, 50 µl of SDS at 
10% (Sigma-Aldrich, St. Louis, MO, USA), 5 µl of TEMED (Bio-Rad, Hercules, CA, USA), 
and 25 µl of ammonium persulfate (Bio-Rad, Hercules, CA, USA) at 10% were mixed in. 
The mixture was then poured into the 1.5 mm gel slides to solidify. 
Electrophoresis Tris/Glycine/SDS Buffer running buffer (1x) was prepared (Bio-
Rad, Hercules, CA, USA) and used to produce a 0.5% low melting agarose solution (USB, 
Affymetrix, Santa Clara, CA, USA) with bromophenol blue. This solution was gently 
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heated and placed on top of the cast gels. Equilibrated strips were quickly dipped on 
running buffer 1x for lubrication and then placed on the 0.5% agarose gel, with gel-side to 
the front, and gently pushed down until they had a good contact with the 12.5% 
acrylamide gel below.  
Electrophoresis was performed at 20 mA per gel in mini gel electrophoresis cells 
(Bio-Rad, Hercules, CA, USA). Five 2D-PAGEs were performed at a time, each one with 
the respective sample from every group (control, COPD, LC, and LC&COPD) and the fifth 
gel with a 2D standard (Bio-Rad, Hercules, CA, USA) to act as an electrophoresis control.  
 
4.3.4. Gel staining and imaging 
 
After the second dimension, gels required staining to allow the visualization of the 
spots and subsequent analysis.  
Several staining methods were tested, such as coomassie, silver (GE Healthcare, 
Waukesha, WI, USA), and SYPRO® (Bio-Rad, Hercules, CA, USA). However, 
considering that protein spots, after being removed from the SDS-PAGE gel, were to be 
submitted to MS analysis, the staining method needed to be compatible with this 
procedure. SYPRO® staining is MS friendly, therefore gels were SYPRO® stained 
according to the manufacturer’s instructions. Gels were fixed for a minimum of 30 minutes 
with a water mixture of 10% ethanol (Panreac, Barcelona, Spain) and 7% glacial acetic 
acid (Sigma-Aldrich, St. Louis, MO, USA). Then, gels were covered with SYPRO® and left 
overnight in the dark to stain. Afterwards, gels were de-stained in the dark for 30 minutes 
in a water mixture of 10% ethanol and 7% glacial acetic acid. Gels were then washed in 
the dark with water for 10 minutes and revealed in a Typhoon 9400 (GE Healthcare, 
Waukesha, WI, USA). Gels were preserved until further use in a 7% glacial acetic acid 
solution. 
A diagram of the 2D-page protocol can be found below on Figure 10. 
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Figure 10: 2D-PAGE protocol. 
 
4.3.5. Gel image analysis 
 
The process of analysing 2D-PAGE images, detection of spots, spot matching, and 
semi-quantitative statistical analysis was performed using the Progenesis SameSpots 
software v4.0 (Nonlinear Dynamics, Newcastle upon Tyne, UK).  
Gel images from the control, COPD, LC, and LC&COPD groups (separated in the 
same electrophoresis run) were uploaded to the program and submitted to image quality 
assessment to correct possible positional errors (Figure 11A). Gel images were then 
aligned to allow the matching of protein spots (Figure 11B). After computerized matching, 
detected spots were manually edited for greater accuracy. Gel images were analysed and 
the detection of the differentially expressed protein spots was performed using the INCA 
volume test (Figure 11C). Only proteins that were 2 fold or higher differentially expressed 
were considered for further analysis. Protein spots of interest were extracted from the 
stained gels using the ProXcision robot (Perkin Elmer, Waltham, MA, USA) and sent for 
MS analysis (Figure 11D). 
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Figure 11: Gel image analysis overview. Adapted from Progenesis SameSpots v4.0  
 
4.4. Mass spectrometry 
 
4.4.1. MS sample preparation and analysis 
 
Following their removal, spots were washed with water and the digestion protocol 
employed was the one used by Shevchenko and co-workers with minor variations (117). 
Gel spots were washed with 50 mM ammonium bicarbonate in 50% methanol and 70% 
acetonitrile and dried in a vacuum concentrator. Trypsin (Promega) was added to carry 
out protein digestion at 37°C overnight. Peptide extraction was carried out using 60% 
acetonitrile and 0.1% formic acid. An aliquot of the digestion solution was mixed with α-
Cyano-3-hydroxycinnamic acid (Sigma) in 30% aqueous acetonitrile, 2-propanol 15%, and 
0.1% trifluoroacetic acid. This mixture was deposited on a MALDI -TOF plate (Applied 
Biosystems) and left to crystalize at room temperature. After sample preparation, the 
MALDI plate was then placed into the mass spectrometer and irradiated. When the laser 
strikes the matrix crystals, the matrix crystals absorb the energy to ionize the sample. 
After ion creation in the MALDI ion source, they were accelerated into the TOF mass by 
flying through a field-free drift tube prior to impacting the detector. The total flight time of 
an ion traveling through the system is a combination of the flight time spent in the ion 
source and the flight time spent in the drift tube before hitting the detector. Larger 
molecules will reach the detector slower than smaller molecules. Once the ions hit the 
detector, spectra were recorded as the m/z of the ions and their relative intensities. MS 
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spectra and MS/MS data were obtained on a Voyager System DE-STR 7307 MALDI-
TOF/TOF mass spectrometer (Applied Biosystems, Carlsbad, CA, USA).  
4.4.2. Protein identification 
 
Peptide matching and protein search were performed against the Swiss-Prot 
database using the Mascot search engine (www.matrixscience.com) with a mass 
tolerance over 50 parts per million. Protein scores higher than 60 indicated identity or 
extensive homology (p<0.05) and were considered significant.  
From each spot, only proteins with a probability higher than 95% and at least two 
unique peptides matched were considered in the analysis (except for keratins which were 
not considered). The experimental molecular weight and isoelectric point of each identified 
protein were determined based on the location of the original spot in the 2D-PAGE gel by 
the Progenesis software.  
A graphic representation of the proteomic analysis of BALF from LC and COPD 
patients by 2D-PAGE MALDI-TOF/TOF can be found below on Figure 12. 
 
 
Figure 12: Workflow of the employed 2D-PAGE MALDI-TOF/TOF methodology.  
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4.5. Antibody arrays 
 
Sixty BALF samples from the test cohorts were applied to the commercially 
available antibody array Quantibody® Human Cytokine Antibody Array 1000 (RayBiotech, 
Norcross, GA, USA). The human cytokine array assay, that allowed the simultaneous 
detection of 40 cytokines and 40 growth factors (Table 3), was performed according to the 
instructions provided by the manufacturer.  
The glass chip was removed from the box, and let to equilibrate to room 
temperature inside the sealed plastic bag for 20-30 minutes. Afterwards, the slide was 
removed from the plastic bag, the cover film was peeled off, and the glass slide was 
allowed to air dry at room temperature for another 2 hours. In order to block the glass 
slide, sample diluent was applied to each well and left to incubate at room temperature for 
30 min. The sample diluent was decanted from all wells and the cytokine/growth factor 
standards or BALF samples were added to each corresponding well to incubate at room 
temperature for 2 hours. Samples were removed from the wells and these were washed 5 
times (5 minutes each) with 150 µl of 1x Wash Buffer I at room temperature with gentle 
shaking, completely removing the wash buffer in each wash step. Detection antibodies 
were reconstituted by adding 1.4 ml of sample diluent to each tube. Eighty µl of the 
detection antibody cocktail were added to each well and allowed to incubate at room 
temperature for 2 hour. Samples were again removed from the wells and these were 
washed 5 times with 150 µl of 1x Wash Buffer I and then 2 times with 150 µl of 1x Wash 
Buffer II at room temperature with gentle shaking, completely removing the wash buffer in 
each wash step. After a brief spin down, 1.4 ml of sample diluent were added to the Cy3 
equivalent dye-conjugated streptavidin tube and mixed gently. Eighty µl of Cy3 equivalent 
dye-conjugated streptavidin were then applied to each well. The device was then covered 
with aluminium foil to avoid exposure to light and incubated at room temperature for 1 
hour. Samples were removed from each well, and washed 5 times with 150 µl of 1x Wash 
Buffer I at room temperature with gentle shaking, completely removing the wash buffer in 
each wash step. The device was disassembled by pushing clips outward from the slide 
side and the slide was carefully removed from the gasket. The slide was then placed 
inside the slide Washer/Dryer (a 4-slide holder/centrifuge tube), 30 ml of 1x Wash Buffer I 
was added to cover the whole slide, and then gently shaken at room temperature for 15 
minutes. The Wash Buffer I was removed and replaced by 30 ml of 1x Wash Buffer II and 
gently shaken at room temperature for 5 minutes. Water droplets were removed from the 
slide by centrifuging the slide Washer/Dryer at 1,000 rpm for 3 minutes without its cap. 
The intensity of each signal was visualized through the use of a laser scanner model 
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GenePix 4100 A (Molecular Devices, Sunnyvale, CA, USA), which was also used to 
perform data extraction. 
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Table 3: Cytokines and growth factors evaluated by the antibody array 
Cytokine 
symbol 
Cytokine  
name 
Growth factor 
symbol 
Growth factor  
name 
BLC B-cell lymphoma AR Androgen receptor 
Eotaxin Eotaxin BNDF Brain-derived neurotrophic factor 
Eotaxin2 
(CCL24) 
Eotaxin 2 bFGF Basic fibroblast growth factor 
G-CSF Granulocyte colony-stimulating factor BMP4 Bone morphogenetic protein 4 
GM-CSF Granulocyte-macrophage colony-stimulating factor BMP5 Bone morphogenetic protein 5 
I309 (CCL1) Chemokine (C-C motif) ligand 1 BMP7 Bone morphogenetic protein 7 
ICAM-1 Inter-Cellular Adhesion Molecule 1 B-NGF Beta nerve growth factor 
IFN γ Interferon-gamma EGF Epidermal growth factor 
IL-1α Interleukine-1 alpha EGFR Epidermal growth factor receptor 
IL-1β Interleukine-1 beta EG-VEGF 
Endocrine gland-derived vascular 
endothelial growth factor 
IL-1Ra Interleukin-1 receptor antagonist FGF4 Fibroblast growth factor 4 
IL-2 Interleukine-2 FGF7 Fibroblast growth factor 7 
IL-4 Interleukine-4 GDF15 Growth differentiation factor 15 
IL-5 Interleukine-5 GDNF Glial cell-derived neurotrophic factor 
IL-6 Interleukine-6 GH Growth hormone 
IL-6sR Interleukine-6 soluble receptor HB-EGF Heparin-binding EGF-like growth factor 
IL-7 Interleukine-7 HGF Hepatocyte growth factor 
IL-8 Interleukine-8 IGFBP1 
Insulin-like growth factor-binding protein 
1 
IL-10 Interleukine-10 IGFBP2 
Insulin-like growth factor-binding protein 
2 
IL-11 Interleukine-11 IGFBP3 
Insulin-like growth factor-binding protein 
3 
IL-12p40 Interleukine-12 p40 IGFBP4 
Insulin-like growth factor-binding protein 
4 
IL-12p70 Interleukine-12 p70 IGFBP6 
Insulin-like growth factor-binding protein 
6 
IL-13 Interleukine-13 IGF-1 Insulin-like growth factor 1 
IL-15 Interleukine-15 Insulin Insulin 
IL-16 Interleukine-16 MCFR Macrophage chemotactic factor receptor 
IL-17 Interleukine-17 NGFR Nerve growth factor receptor 
MCP-1 (CCL2) 
Monocyte chemotactic protein-1/ 
Chemokine (C-C motif) ligand 2 
NT-3 Neurotrophin 3 
MCSF Mouse stem cell factor NT-4 Neurotrophin 4 
MIG (CXCL9) 
Monokine induced by IFN-Gamma/ 
Chemokine (C-X-C motif) ligand 9 
OPG Osteoprotegerin 
MIP-1α 
(CCL3) 
Macrophage inflammatory protein 1 alpha/ 
Chemokine (C-C motif) ligand 3 
PDGFAA Platelet-derived growth factor AA 
MIP-1β 
(CCL4) 
Macrophage inflammatory protein 1 beta/ 
Chemokine (C-C motif) ligand 4 
PIGF 
Phosphatidylinositol-glycan biosynthesis 
class F 
MIP-1δ Macrophage inflammatory protein 1 delta SCF Stem cell factor 
PDGFBB Platelet-derived growth factor BB SCFR Stem cell factor receptor 
Rantes 
(CCL5) 
Regulated upon Activation, Normal T-cell Expressed, and 
Secreted/ Chemokine (C-C motif) ligand 5 
TGF-α Transforming growth factor alpha 
TIMP-1 Tissue inhibitor of metalloproteinases 1 TGF-β1 Transforming growth factor beta 1 
TIMP-2 Tissue inhibitor of metalloproteinases 2 TGF-β3 Transforming growth factor beta 3 
TNF-α Tumour necrosis factor alpha VEGF Vascular endothelial growth factor 
TNF-β Tumour necrosis factor beta VEGFR2 
Vascular endothelial growth factor 
receptor 2 
TNFRI Tumour necrosis factor receptor 1 VEGFR3 
Vascular endothelial growth factor 
receptor 3 
TNFRII Tumour necrosis factor receptor 2 VEGFD Vascular endothelial growth factor D 
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4.6. Western blot 
 
Western blot analyses were performed to allow the validation of results from the 
previous experiments,  
The BALF samples were prepared with Laemmli buffer 4X that contained a Tris-
HCl 250 mM solution with a pH of 6.8, SDS at 4% (w/v), glycerol at 60% (v/v), and 2-
mercaptoethanol at 10% (v/v). They were submitted to SDS-PAGE separation after boiling 
for 5 min at 100ºC to denature proteins. Depending on the molecular weight of the protein, 
SDS-PAGE separating gels (1.5 mm) were made with 7.5, 10, and 12.5% acrylamide as 
previously described. Gels were covered with water and left to polymerize. As soon as the 
gels were set, a stacker gel with 4% acrylamide was made and placed on top of the 
separating gels with a comb to create wells. The electrophoresis cell was filled with 1x 
Tris/Glycine/SDS Buffer running buffer (Tris-Base 25mM, GIycine 192mM, SDS 0.1% 
(w/v)) (Bio-Rad, Hercules, CA, USA) and the electrophoresis began. The run started at a 
low voltage (30-50 V) until the samples had left the stacker gel. Then, the voltage was 
raised to 100-120 V and was kept constant until the end of the run.  
Gels were then transferred to polyvinylidene fluoride (PVDF) membranes (Bio-
Rad, Hercules, CA, USA) in a transfer cell with 1x Tris/Glycine transfer buffer (25 mM Tris, 
192 mM glycine, 0.1% SDS, and 20% methanol) (Bio-Rad, Hercules, CA, USA), at 4ºC for 
3-4 hours. The membranes were then removed from the transfer cassettes and blocked 
for 1 hour in Tris-buffered saline (TBS) with 0.05% Tween-20 (Sigma-Aldrich, St. Louis, 
MO, USA) (0.05% TBST) and with 5% BSA (Sigma-Aldrich, St. Louis, MO, USA). 
Afterwards, the blots were incubated overnight at 4ºC with their corresponding primary 
antibody (in TBST with 1% BSA), in the appropriate proportion. The used antibodies and 
their respective ratios can be seen on Table 4. Membranes were then washed to remove 
the excess primary antibodies and the secondary antibody, in the suitable ratio, was 
applied to the membranes for 1 hour in TBST with 1% BSA, at room temperature. 
Membranes were then washed to remove the excess secondary antibodies and placed on 
water.  
Membranes were revealed using enhanced chemiluminescence ECL according to 
the instructions provided by the manufacturer (GE Healthcare, Waukesha, WI, USA) and 
the membranes were exposed in the image analyser Mini LAS-3000 (Fujifilm, Tokyo, 
Japan). The relative protein levels were calculated by comparison to the amount of β-actin 
protein (1:1000 Abcam, Cambridge, MA, USA). The experiments were repeated three 
times independently. The analysis of the different expression values of the 8 proteins 
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obtained by western blot was performed by densitometry. The densitometry analysis of 
the scanned blots was done using Image J software (118). Results were normalized with 
the expression of the control protein (β-actin).  
 
Table 4: Western blot validation antibodies and used ratios 
Purpose Name Ratios 
2D-PAGE validation 
Anti-HSP70, Anti-AKR1B10, Anti-PRDX1 
(Epitomics, Burlingame, CA, USA), Anti-
PKM2, Anti-NF-κBp65, Anti-pNF-κBp65 
(Cell Signaling, Beverly, MA, USA) 
1/1000 
Antibody array validation 
Anti-IL-11, Anti-CCL1 (I309) (Abcam, 
Cambridge, MA, USA) 
1/200 
 
4.7. Enzyme-Linked Immunosorbent Assay 
 
Proteins previously validated by western blot were evaluated by ELISA in a first 
validation cohort of 139 patients and later in a second validation cohort of 160 patients. 
BALF samples were applied as instructed by the manufacturer, using sandwich ELISA kits 
(RayBiotech, Norcross, GA, USA).  
All reagents were placed at room temperature (18 - 25°C) before use. Standards 
were prepared at different concentrations to create a standard curve. One hundred ml of 
each standard and samples were added into their respective wells. All samples and 
standards were assayed in duplicate and the same plate was used. The ELISA plate was 
covered and left to incubate for 2.5 hours at room temperature with gentle shaking. The 
wells were washed 4 times with 1x Wash Solution by filling each well with Wash Buffer 
(300 µl). After the last wash, the plate was inverted and blotted against clean paper towels 
to remove all excess Wash Solution. The 1x prepared biotinylated antibody was added to 
each well (100 µl) and left to incubate for 1 hour at room temperature with gentle shaking. 
The wells were then washed 4 times, as previously described. Prepared Streptavidin 
solution (100 µl) was added to each well and incubated for 45 minutes at room 
temperature with gentle shaking. The wells were then washed 4 times, as previously 
described. Finally, 100 µl of TMB One-Step Substrate Reagent were placed on each well. 
Incubation was performed for 30 minutes at room temperature in the dark with gentle 
shaking. The Stop Solution was then added to each well and plates were read at 450 nm 
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immediately on an EMax Microplate Reader (Molecular Devices, Minneapolis, Minn., 
USA). The mean absorbance for each set of duplicate standards and samples was 
subtracted by the average zero standard optical density. The standard curve was created 
on an Excel spread sheet, with the standard concentration on the x-axis and absorbance 
on the y-axis. Sample concentration was calculated by using the equation provided by 
linear trend graph. 
A graphic representation of the proteomic analysis of BALF from LC and COPD 
patients by antibody arrays and ELISA can be found below on Figure 13. 
 
Figure 13: Workflow of the employed antibody arrays and ELISA methodology. 
 
4.8. Bioinformatics analysis and statistical analysis 
4.8.1. 2D-PAGE bioinformatics analysis 
 
The proteins selected from the 2D-PAGE experiments and subsequently identified 
by MS were analysed by the Ingenuity Pathway Analysis (IPA) web-based application 
(www.ingenuity.com, Ingenuity® Systems, Redwood City, CA, USA). It uses a database 
that contains up-to-date information on thousands of genes and proteins, over one million 
biological interactions, and one hundred canonical pathways. This allows the identification 
of relationships, biological mechanisms, functions, and relevant pathways associated with 
the studied proteins. The IPA Core analysis allows the assessment of the pathways and 
biological processes most significantly altered in our dataset, the associated diseases and 
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disorders, the most important molecular and cellular functions, and the identification of the 
signalling and metabolic pathways most relevant in our data set. Only proteins identified 
by the IPA software were submitted to core analysis, that revealed the most important 
biological functions and pathways associated with our proteins, and also created 
interaction networks between them. 
 
4.8.2. Antibody arrays statistical analysis 
 
All continuous variables of patients’ characteristics were expressed as a median for 
each variable (interquartile [IQR] range) and categorical variables as number of cases and 
percentage. The mean and SD of selected proteins were calculated for every patient in all 
study groups. The differences among groups were evaluated by the Mann–Whitney U 
test. Differences were considered statistically significant if their p value was ≤0.05 
(*p≤0.05, **p<0.01, ***p<0.001).  
Statistical analysis was performed using the Statistical Package for the Social 
Sciences software (SPSS 17, Chicago, Illinois, USA). 
 
4.8.3. Antibody arrays expression data analysis 
 
Hierarchical supervised clustering analysis was performed using the function 
UPGMA (Unweight Pair Group Method with Arithmetic Mean). Before statistical analysis, 
protein expression levels were standardized, protein by protein, across all conditions 
using the medians and standard deviation (SD) values. The sample conditions were 
clustered using euclidean distance metric tests. The results were visualized and analysed 
with Babelomics 4.2 (babelomics.bioinfo.cipf.es) (119). The expression level of each 
protein, relative to its median expression level across all conditions, was represented by a 
colour, with red representing expression greater than the median, blue representing 
expression lesser than the median, and various intermediate colour intensities 
representing the magnitude of variance from the median. 
 
4.8.4. Diagnostic test validity analysis 
 
Receiver operating characteristics curves were constructed to assess sensitivity, 
specificity, and respective areas under the curve (AUCs) with 95% confidence interval (CI) 
of possible LC biomarkers.  We investigated the optimum cut-off value, which was chosen 
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in order to reflect the best cooperation between sensitivity, specificity, positive predictive 
value, negative predictive value, and likelihood ratio to predict the diagnosis of lung 
adenocarcinoma. To test the diagnostic accuracy of several biomarkers measured 
together, the chi-squared test was used. 
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5. RESULTS 
5.1. First specific objective: Identification of differently expressed proteins in BALF 
from patients with LC, COPD, COPD with LC, and without LC or COPD by 
comparative proteomic analysis. 
5.1.1. Selection of patients 
 
Sixty samples from the patients in the test cohort were divided into four groups: 
control (without LC or COPD), COPD, LC, and LC&COPD. The principal characteristic 
from test cohort, were all male, with a median age of 61 (41-80) years. The majority of 
patients were current smokers, with similar pack-years 30 (28.6- 37.2). In the COPD 
group, the majority of patients had moderate and severe cases of COPD, and in the 
LC&COPD group, over half of patients had mild COPD. The adenocarcinoma histology 
was the predominant histology of LC in the LC and LC&COPD groups (Table 5). Overall 
patient characteristics were well matched among the four study groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Proteomic	  characterization	  of	  lung	  cancer	  and	  chronic	  obstructive	  pulmonary	  disease:	  a	  bronchoalveolar	  lavage	  fluid	  analysis	  
	  
Ana	  Barbosa	  de	  Sousa	  Nogal	  	   	   48	  
	  
Table 5: Characteristics of the patients analysed in the test cohort by the 2D-PAGE methodology  
 
Controls 
n=15 
COPD 
n=15 
LC 
n=15 
LC&COPD 
n=15 
Gender     
Male 100.0% (15) 100.0% (15) 100.0% (15) 100.0% (15) 
Female 0.0% (0) 0.0% (0) 0.0% (0) 0.0% (0) 
 Age (years) 
[range] 
61.3  
[41.0-80.0] 
61.5  
[45.0-78.0] 
60.7  
[46.0-69.0] 
60.7  
[49.0-68.0] 
Smoking status     
Smokers 73.3% (11) 53.3% (8) 53.3% (8) 80.0% (12) 
Ex-smokers 26.7% (4) 46.7% (7) 46.7% (7) 20.0% (3) 
Pack-years 
[range] 
21.82 
[18.6-25.4] 
32.20 
[28.6-37.2] 
35.21 
[31.3-41] 
30.78 
[27.5-33.5] 
COPD     
Mild 0.0% (0) 20.0% (3) 0.0% (0) 53.3% (8) 
Moderate 0.0% (0) 33.3% (5) 0.0% (0) 26.7% (4) 
Severe 0.0% (0) 26.7% (4) 0.0% (0) 0.0% (0) 
Very severe 0.0% (0) 20.0% (3) 0.0% (0) 20.0% (3) 
LC Histology     
Adenocarcinoma 0.0% (0) 0.0% (0) 73.3% (11) 66.7% (10) 
SCC 0.0% (0) 0.0% (0) 26.7% (4) 33.3% (5) 
SCC: squamous cell carcinoma 
 
5.1.2. Proteomic profiling 
 
The identification of the differentially expressed proteins between patients with LC 
and COPD was accomplished by analysing BALF samples from 4 distinct groups of 
patients (controls, COPD, LC, and LC&COPD) by 2D-PAGE.   
The software Progenesis SameSpots carried out the proteomic analysis of the 2D-
PAGE gels. This program applied a t-test with a value of p <0.05 to show the proteins with 
significant expression differences. These proteins were then later detected by MALDI-
TOF/TOF and identified by comparing the obtained MS data to the one integrated in the 
database Swiss-Prot using the MASCOT software. Once the protein had been identified, 
different variables such as the isoelectric point, molecular weight, peptide matching, and 
sequence coverage were use to ascertain their correct identification. 
A total of 123 proteins were identified across 60 gels. Out of these, 40 proteins 
were differentially expressed between the groups of patients with LC and/or COPD and 
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the control group, presenting changes in expression of over 2 fold and a p value <0.05. 
The spots corresponding to these 40 selected proteins can be found on Figure 14. Circled 
spots correspond to proteins later selected for validation by western blot. The detailed 
information on these proteins can be found on (Table 6). 
 
Figure 14: A 7 cm Sypro® stained 2D-PAGE gel of proteins in the 3-11 non lineal pH range of a 
representative patient. Circled spots correspond to proteins selected for western blot validation. 
Identification of protein spots can be seen on Table 6. 
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Table 6: Differentially expressed proteins identified by 2D-PAGE-MALDI-TOF/TOF MS 
Protein name (spot number) Protein symbol 
 gi| 
number 
Protein 
MW 
Protein 
IP 
Peptide 
count 
Protein 
score* 
Total ion 
score* 
Aldehyde dehydrogenase (1) ALDH3A1 178375 50702.9 5.99 15 445 339 
Aldo-keto reductase family 1 member B10 
(2) AKR1B10 4503285 37111.1 7.13 7 108 70 
Aldo-keto reductase family 1 member C3 (3) AKR1C3 24497583 37229.0 8.06 10 248 186 
Aldolase A (4) ALDOA 28614 39706.4 8.34 11 229 156 
Alpha enolase (5) ENO1 2661039 36627.7 6.53 9 128 70 
Alpha amylase 1A precursor  (6) AMY1A 40254482 58415.2 6.47 18 469 326 
Alpha amylase 2A (7) AMY2A 224980 58443.2 6.47 15 323 221 
Annexin 1 (8) ANXA1 4502101 38918.1 6.57 17 495 354 
Annexin 2 (9) ANXA2 18645167 38779.9 7.57 20 326 159 
Annexin 5 (10) ANXA5 4502107 35971.4 4.94 19 472 301 
Calsyphosin 2 (11) CAPS2 4757908 21068.3 4.74 11 543 460 
Carbonic anhydrase 1 (12) CA1 4502517 28909.4 6.59 14 770 627 
Catalase (13) CAT 4557014 59946.8 6.90 13 310 234 
Cathepsin D pro-protein (14) CTSD 4503143 45036.8 6.10 8 135 95 
Tubulin polymerization-promoting protein 
family member 3 (15) TPPP3 4680715 19144.7 9.10 8 79 30 
Cofilin-1 (16) CFL1 5031625 18718.7 8.22 6 98 57 
Complement C3  (17) C3 119589476 144417.1 8.24 25 472 332 
C-reactive protein (18) CRP 1942435 23146.7 5.28 8 341 281 
Ezrin (19) EZR 46249758 69312.7 5.94 18 250 175 
Fructose-1,6-biphosphatase (20) FBP1 3293553 37058.9 6.60 6 124 101 
Glutathione reductase (21) GSR 119583848 61464.6 8.71 7 131 108 
Glutathione S-transferase alpha 1 subunit 
(22) GSTA1 163310943 25628.7 8.72 15 384 268 
Glutathione S-transferase alpha 2 subunit 
(23) GSTA2 257476 25589.6 8.81 7 105 70 
Glutathione S-transferase pi 1 (24) GSTP1 4504183 23569.1 5.43 10 633 541 
Glycogen phosphorylase (25) PYGM 225897 97386.8 6.57 17 515 436 
Heat shock protein 70 (26) HSP70 4529893 70280.1 5.48 12 325 269 
Isocitrate dehydrogenase 1 (27) IDH1 89573979 42091.0 6.19 8 62 29 
Serpin peptidase inhibitor, clade B, member 
1 (28) SERPINB1 13489087 42828.7 5.90 18 403 274 
Lipocalin 2 (29) LCN2 119608155 28089.4 9.53 9 513 426 
Peptidylprolyl isomerase A (30) PPIA 1633054 18097.9 7.82 10 260 159 
Peroxiredoxin 1 (31) PRDX1 55959887 19134.7 6.41 8 170 98 
Peroxiredoxin 5 (32) PRDX5 6166493 22261.6 8.85 11 638 537 
Peroxiredoxin 2 isoform a (33) PRDX2 32189392 22049.3 5.66 12 451 325 
Phosphatidylethanolamine-binding protein 4 
(34) PEBP4 4505621 21157.7 7.01 11 311 209 
Pyruvate kinase 2 (35) PKM2 35505 58411.2 7.58 22 416 249 
Rho GDP dissociation inhibitor 2 (36) ARHGDIB 56676393 23030.6 5.10 7 215 170 
Selenium-binding protein 1 (37) SELENBP1 197097476 52987.9 6.13 12 278 207 
Thioredoxin (38) TXN 135772 12345.0 7.93 10 241 203 
Transketolase (39) TKT 388891 68528.0 7.89 17 405 246 
Ubiquitin carboxyl-terminal hydrolase 
isozyme L1 (40) UCHL1 21361091 25150.6 5.33 7 126 76 
MW: molecular weight; IP: isoelectric point; *: 100% confidence 
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The distribution of the differentially expressed proteins across the LC, COPD, and 
LC&COPD groups can be seen on Figure 15. The Venn diagram depicted in this figure 
represents the shared proteins between all the disease groups and also the unique 
proteins that characterize each disease group individually. 
Out of the 40 differentially expressed proteins among the disease groups (compared 
to the control group), a total of 24 proteins were found to be over or under-expressed in 
the three disease groups (LC, COPD, and LC&COPD). Two proteins, CAPS2 and CFL1, 
were found to be under-expressed in the COPD group and over-expressed in the LC and 
LC&COPD groups. A set of 7 proteins were found to be differentially expressed only in the 
LC group AKR1B10, ALDOA, CTSD, EZR, FBP1, and TKT were over-expressed, and 
SELENBP1 was under-expressed in this group of patients, compared to the control group. 
Five proteins were observed as differentially expressed in both the LC and the LC&COPD 
group: ALDH3A1, AKR1C3, PYGM, PKM2, and PPIA were over-expressed in these 
groups compared to the control group. Catalase, PRDX1, PRDX2, and PRDX5 were 
found to be over-expressed in the COPD and LC&COPD groups, compared to the control 
group. The fold variations between the control group and the disease groups can be found 
on (Table 7).  
 
Figure 15: Venn diagram showing the over or under-expressed proteins in each pathological group, 
compared to the control group. The ↑ sign precedes over-expressed proteins and the ↓ sign 
precedes under-expressed proteins. The * sign marks proteins under-expressed in the COPD 
group but over-expressed in the LC and LC&COPD groups 
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Table 7: Expression fold variation of the differentially expressed proteins in the disease groups 
compared to the control group 
Protein symbol 
COPD 
Expression fold variation 
LC 
Expression fold variation 
LC&COPD 
Expression fold variation 
ALDH3A1 - ↑ 2.9 ↑ 2.9 
AKR1B10 - ↑ 4.0 - 
AKR1C3 - ↑ 2.5 ↑ 2.1 
ALDOA - ↑ 2.0 - 
ENO1 ↑ 2.0 ↑ 2.5 ↑ 2.3 
AMY1A ↑ 2.1 ↑ 2.3 ↑ 2.2 
AMY2A ↑ 2.5 ↑ 2.2 ↑ 2.9 
ANXA1 ↑ 2.3 ↑ 2.2 ↑ 2.3 
ANXA2 ↑ 2.5 ↑ 2.3 ↑ 2.7 
ANXA5 ↑ 2.4 ↑ 2.2 ↑ 2.1 
CAPS2 ↓ 2.2 ↑ 2.8 ↑ 2.6 
CA1 ↑ 2.2 ↑ 2.5 ↑ 2.7 
CAT ↑ 2.5 - ↑ 2.8 
CTSD - ↑ 3.0 - 
TPPP3 ↑ 2.4 ↑ 2.0 ↑ 2.1 
CFL1 ↓ 3.0 ↑ 2.2 ↑ 2.8 
C3 ↑ 2.4 ↑ 3.0 ↑ 2.6 
CRP ↑ 3.0 ↑ 3.2 ↑ 2.7 
EZR - ↑ 3.0 - 
FBP1 - ↑ 2.5 - 
GSR ↑ 2.8 ↑ 3.1 ↑ 2.0 
GSTA1 ↓ 3.0 ↓ 3.2 ↓ 3.8 
GSTA2 ↓ 2.5 ↓ 3.0 ↓ 2.6 
GSTP1 ↓ 2.2 ↓ 2.4 ↓ 2.5 
PYGM - ↑ 3.0 ↑ 2.1 
HSP70 ↑ 4.0 ↑ 3.1 ↑ 3.8 
IDH1 ↑ 2.2 ↑ 2.1 ↑ 2.5 
SERPINB1 ↑ 2.7 ↑ 2.6 ↑ 2.5 
LCN2 ↓ 3.0 ↓ 3.5 ↓ 2.9 
PPIA - ↑ 2.2 ↑ 2.6 
PRDX1 ↑ 5.0 - ↑ 4.2 
PRDX5 ↑ 2.3 - ↑ 2.4 
PRDX2 ↑ 3.0 - ↑ 2.9 
PEBP4 ↑ 2.9 ↑ 2.3 ↑ 2.6 
PKM2 - ↑ 3.0 ↑ 3.2 
ARHGDIB ↑ 2.9 ↑ 2.6 ↑ 2.3 
SELENBP1 - ↓ 2.2 - 
TXN ↑ 2.4 ↑ 2.3 ↑ 2.1 
TKT - ↑ 2.5 - 
UCHL1 ↓ 2.7 ↓ 2.2 ↓ 2.8 
↑- Over-expression; ↓-Under-expression 
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5.1.3. Selection of proteins and western blot validation 
 
Once the 2D-PAGE experiments were concluded and the MALDI-TOF/TOF 
identification of the differentially expressed proteins was acquired, the next step was to 
validate our results. This was accomplished by western blot, the preferred method to 
confirm protein expression levels. Considering the obtained results from the 2D-PAGE 
analysis and taking into account the levels of expression and score of each protein 
present (Tables 6 and 7), we chose for the validation process one protein representative 
of each disease category LC, LC and COPD, COPD, without LC and COPD. The proteins 
validated by western blot were AKR1B10, HSP70, PRDX1, and PKM2. Figure 16 shows 
the expression of these proteins across all groups and the different intensities between 
them. 
 
 
Figure 16: Different densities of spots 2, 26, 31, and 35 in each evaluated group of patients. Spots 
correspond to MS identified proteins ARK1B10, HSP70, PRDX1, and PKM2, respectively. 
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The western blot analysis of the selected proteins, together with the levels of the 
reference protein β-actin, are shown in Figure 17. The samples used for western blot 
validation were randomly selected.  
Our results showed that the AKR1B10 protein had increased expression only in 
the LC group. On the other hand, HSP70 was over-expressed by all disease groups when 
compared to the control group. The PRDX1 protein showed an increased expression in 
the COPD and LC&COPD groups compared to the LC and control groups. Finally, PKM2 
was clearly over-expressed in the BALF of the patients in the LC and LC&COPD groups 
compared to those in the COPD and control groups. The results of the western blot 
validation process confirmed those obtained by the 2D-PAGE experiments. 
 
 
Figure 17: Western blots for AKR1B10, HSP70, PKM2, PRDX1, and β-actin in the control, COPD, 
LC, and LC&COPD groups. Differences in expression, normalized with the β-actin protein, are 
illustrated by a bar chart on the right. 
 
5.1.4. LC and COPD pathway analysis 
 
The connections and interactions between our 40 differentially expressed proteins 
and also the biological mechanisms, functions, and pathways in which they were possibly 
involved in were evaluated by the IPA software. In addition, the association between 
certain diseases and disorders and our data set were also analysed by IPA.  
Core analysis was performed to include direct and indirect connections, and 
endogenous chemicals, and to consider only molecules and/or associations, creating an 
interaction network that can be seen on Figure 18. Cellular compartments as designated 
by IPA (gene ontology based), indicated that the majority of identified proteins were of 
cytoplasmatic origin.  
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Figure 18: IPA interaction network considering the differentially expressed proteins between the 
control, LC, COPD, and LC&COPD groups. 
 
The mapping of our differentially expressed proteins onto known molecular 
pathways and biological functions revealed three top processes occurring in the BALF 
samples from our four groups of patients: inflammation, free radical scavenging and 
oxidative stress response, and glycolysis and gluconeogenesis. Together with these 
findings, the recognition of the NF-kB complex as the major connection node between 
these three mechanisms was also accomplished.  
The majority of identified proteins, a total of 22 proteins, were associated to 
inflammatory mechanisms (AKR1B10, AKR1C3, ALDOA, ANXA1, ANXA2, ANXA5, 
ARHGDIB, CA1, CAT, CFL1, CRP, ENO1, EZR, GSR, HSP70, LCN2, PEBP4, PPIA, 
PRDX1, PRDX2, SELENBP1, and TKT), 16 proteins were related to free radical 
scavenging and oxidative stress (ARHGDIB, CAT, CRP, CTSD, EZR, GSR, GSTA1, 
GSTA2, GSTP, IDH1, PPIA, PRDX1, PRDX2, PRDX5, SERPINB1, and TXN), and 8 
proteins were found to be connected to the glycolysis and gluconeogenesis processes 
(ALDH3A1, ALDOA, ENO1, FBP1, IDH1, PEBP4, PKM2, and PYGM), as seen on Figure 
19.  
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Figure 19: Top biological functions and pathways identified by IPA; inflammation related proteins (p 
value: 1,35*10-08–1,42*10-02), free radical scavenging and oxidative stress response (p value: 
4,93*10-11–1,27*10-02), and glycolysis and gluconeogenesis related proteins (p value: 7,39*10-09–
1,58*10-02). 
 
5.1.5. NF-kB functional analysis 
 
NF-κB was the main connector between the differentially expressed proteins, even 
though this protein was not identified as differentially expressed among the four groups of 
patients analysed by 2D-PAGE. 
 Consequently, we analysed NF-kB in BALF samples from the control, COPD, LC, 
and LC&COPD groups of patients, by measuring the expression levels of the NF-κBp65 
protein and its phosphorylated (activated) form, pNF-κBp65, by western blot (Figure 20). 
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Figure 20: Western blots for NF-κBp65, p NF-κBp65, and β-actin in the control, COPD, LC, and 
LC&COPD groups. Differences in expression, normalized with the β-actin protein, are illustrated by 
a bar chart on the right. 
 
 
High expression levels of NF-κBp65 were detected in all groups, with a slightly 
higher intensity in the COPD group. The phosphorylated form of NF-κBp65 showed higher 
expression levels only in the disease groups (COPD, LC, and LC&COPD), with the LC 
group presenting the highest intensity. These western blot analyses are compatible with 
the fact that activation of NF-κBp65 might be involved in the pathogenesis of both 
diseases. 
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5.2. Second specific objective: Analysis of the differential expression of 
inflammation related proteins (cytokines and growth factors) in LC and COPD 
patients. 
 
5.2.1. Patient selection.  
 
The antibody array methodology was applied to samples from 60 patients, whose 
characteristics can be found on Table 8. All selected patients were male, with median 
ages around 61 (41-80) years. The majority of patients were current smokers, with similar 
pack-years smoking exposure. Moderate and severe COPD were the most common 
stages in the COPD group of patients, and mild COPD was predominant in the LC&COPD 
group of patients. The adenocarcinoma histology was the most common among the 
patients in the LC group, contrary to the patients in the LC&COPD group, who had been 
predominantly diagnosed with the SCC histology. All other characteristics were well 
matched among the study groups. 
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Table 8: Characteristics of the discovery cohort patients for the antibody arrays methodology 
 
Controls 
n=16 
COPD 
n=15 
LC 
n=17 
LC&COPD 
n=12 
Gender     
Male 100.0% (16) 100.0% (15) 100.0% (17) 100.0% (12) 
Female 0.0% (0) 0.0% (0) 0.0% (0) 0.0% (0) 
Median age 
[range] 
61.3 
[41.0-80.0] 
61.5 
[45.0-78.0] 
60.7 
[46.0-69.0] 
60.7 
[49.0-68.0] 
Smoking status     
Smokers 68.8% (11) 53.3% (8) 52.9% (9) 83.3% (10) 
Ex-smokers 31.2% (5) 46.7% (7) 47.1% (8) 16.7% (2) 
Pack-years 
[range] 
38.8 
[31.0-53.2] 
50.0 
[42.0-65.0] 
58.2 
[41.0-65.7] 
52.3 
[41.0-63.2] 
COPD     
Mild 0.0% (0) 20.0% (3) 0.0% (0) 58.3% (7) 
Moderate 0.0% (0) 33.3% (5) 0.0% (0) 25.0% (3) 
Severe 0.0% (0) 26.7% (4) 0.0% (0) 0.0% (0) 
Very severe 0.0% (0) 20.0% (3) 0.0% (0) 16.7% (2) 
LC Histology     
Adenocarcinoma     
    Stages I-II 0.0% (0) 0.0% (0) 11.8% (2) 0.0% (0) 
    Stages III-IV 0.0% (0) 0.0% (0) 58.8% (10) 33.3% (4) 
SCC     
    Stages I-II 0.0% (0) 0.0% (0) 5.9% (1) 8.3% (1) 
    Stages III-IV 0.0% (0) 0.0% (0) 23.5% (4) 58.4% (7) 
SCC: squamous cell carcinoma 
 
To validate the results obtained by the training cohort, a group of 299 patients was 
selected and two distinct validation cohorts were created. The first validation cohort was 
made up of 139 patients that were separated into four distinct groups. The patients in this 
cohort had similar clinical and pathological characteristics to those in the training cohorts 
(Table 9).  
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Table 9: Characteristics of the patients in the first validation cohort 
 
Controls 
n=20 
COPD 
n=29 
LC 
n=40 
LC&COPD 
n=50 
Gender     
Male 60.0% (12) 86.2% (25) 82.5% (33) 96.0% (48) 
Female 40.0% (8) 13.8% (4) 17.5% (7) 4.0% (2) 
Median age 
[range] 
52.3 
[42.0-58.0] 
65.2 
[45.0-78.0] 
61.2 
[48.0-75.0] 
64.3 
[48.0-75.0] 
Smoking status     
Smokers 100.0% (20) 51.7% (15) 50.0% (20) 52.0% (26) 
Ex-smokers 0.0% (0) 48.3% (14) 50.0% (20) 48.0% (24) 
Pack-years 
[range] 
41.8 
[33.0-57.2] 
52.8 
[41.0-69.2] 
55.0 
[39.0-73.2] 
57.0 
[43.0-75.2] 
COPD     
Mild 0.0% (0) 27.6% (8) 0.0% (0) 26.0% (13) 
Moderate 0.0% (0) 51.7% (15) 0.0% (0) 50.0% (25) 
Severe 0.0% (0) 20.7% (6) 0.0% (0) 24.0% (12) 
Very severe 0.0% (0) 0.0% (0) 0.0% (0) 0.0% (0) 
LC Histology     
Adenocarcinoma     
    Stages I-II 0.0% (0) 0.0% (0) 10.0% (4) 10.0% (5) 
    Stages III-IV 0.0% (0) 0.0% (0) 27.5% (11) 36.0% (18) 
SCC     
    Stages I-II 0.0% (0) 0.0% (0) 25.0% (10) 30.0% (15) 
    Stages III-IV 0.0% (0) 0.0% (0) 37.5% (15) 24.0% (12) 
SCC: squamous cell carcinoma 
 
The characteristics of the 160 patients in the second validation cohort can be seen 
on Table 10. This cohort was significantly different from the first one given that it did not 
include a group of patients with only COPD and that the LC groups had patients 
diagnosed not only with adenocarcinoma and SCC, but also LCC and SCLC. 
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Table 10: Characteristics of the patients in the second validation cohort 
 
Controls 
n=20 
LC 
n=66 
LC&COPD 
n=74 
Gender    
Male 60.0% (12) 83.3% (55) 94.6% (70) 
Female 40.0% (8) 16.7% (11) 5.4% (4) 
Median age 
[range] 
52.3 
[42.0-58.0] 
61.2 
[48.0-75.0] 
64.3 
[48.0-75.0] 
Smoking status    
Smokers 100.0% (20) 50.0% (33) 52.7% (39) 
Ex-smokers 0.0% (0) 50.0% (33) 47.3% (35) 
Pack-years 
[range] 
33.6 
[30.0-51.2] 
58.8 
[41.0-77.2] 
62.0 
[43.0-79.2] 
LC Histology    
Adenocarcinoma    
    Stages I-II 0.0% (0) 4.5% (3) 2.7% (2) 
    Stages III-IV 0.0% (0) 18.2% (12) 13.6% (10) 
SCC    
    Stages I-II 0.0% (0) 6.1% (4) 8.1% (6) 
    Stages III-IV 0.0% (0) 12.1% (8) 5.4% (4) 
LCC    
    Stages I-II 0.0% (0) 4.5% (3) 8.1% (6) 
    Stages III-IV 0.0% (0) 7.6% (5) 10.8% (8) 
SCLC    
    Limited stage 0.0% (0) 19.7% (13) 21.6% (16) 
    Extensive stage 0.0% (0) 27.3% (18) 29.7% (22) 
SCC: squamous cell carcinoma; LCC: large cell carcinoma; SCLC: small cell lung cancer 
 
5.2.2. Expression of cytokines and grow factors in BALF from LC and COPD patients. 
 
The initial protective response, elicited by the damaging complex mixture of 
chemicals present in tobacco smoke, can generate the release and recruitment of more 
pro-inflammatory immune cells and cytokines and create a chronic inflammation scenario 
and a tumour friendly microenvironment. So, we aimed at analysing which inflammatory 
proteins had altered expression in our four groups of patients. For this purpose we used 
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antibody arrays that measured the levels of 80 cytokines and growth factors implicated in 
the inflammatory process.  
A total of 15 cytokines and growth factor arrays were carried out and the data 
analysis was performed by measuring the different expression levels between the 80 
inflammatory proteins and the positive controls present in the arrays. Protein expression 
levels were then standardized, protein by protein, across all conditions by using the 
medians and SD values. Results were visualized and analysed with Babelomics 4.2 
(babeIomics.bioinfo.cipf.es). We created a hierarchical supervised clustering analysis of 
the protein arrays using the UPGMA function. The generated dendograms of the 
cytokines and growth factors expression levels and the groups of patients, and heatmap 
are represented below in Figure 21.  
The original four groups of patients (control, COPD, LC, and LC&COPD) were sub-
divided into six groups taking into consideration the histological sub-types of NSCLC; 
control, COPD, adenocarcinoma (ADC), SCC, ADC&COPD, and SCC&COPD. Analysis 
revealed that 20% of the evaluated proteins in the cytokine and growth factor arrays were 
over-expressed in the disease groups compared to the control group. These 16 proteins 
were MIP-1β, MIG, IGFBP1, EGF, VEGF, TNFRI and TNFRII, IL-6Sr, GDF15, IL-1Ra, 
MCP-1, Eotaxin2, PDGFAA, IGFBP2, IL-11, and CCL1.  
A first group of proteins (MIP-1β, MIG, IGFBP2, and EGF) was highly expressed 
across all disease groups, compared to the control group. A second group of proteins 
(VEGF, TNFRI and TNFRII, IL-6Sr, GDF15, IL-1Ra, MCP-1, Eotaxin2, and PDGFAA) also 
had a higher expression in the disease groups, but not as high as the previous group of 
proteins. Interestingly, there were clear differences in protein expression between the 
adenocarcinoma histological subtype and the other groups. In fact, the expression of IL-11 
and CCL1 was increased differentially in adenocarcinoma. 
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Figure 21: Heatmap of the differences in protein expression across the disease groups, compared 
to the control group, obtained from the inflammatory protein arrays; protein expression levels 
relative to its median expression level across all conditions, are represented by a colour, with red 
representing expression greater than the median, blue representing expression lesser than the 
median, and various intermediate colour intensities representing the magnitude of variance from 
the median. 
 
Statistical analysis of the cytokine and growth factor arrays, seen on Figure 22, 
revealed significant statistical differences (p≤0.05) among groups for the majority of 
proteins, despite the existing dispersion between them due to patient variability.  
Among the 16 inflammatory proteins that had statistically significant different 
expression levels when compared between the patients of the disease groups and the 
control group patients, IL-11 and CCL1 were observed to have a similar behaviour. These 
two proteins were only over-expressed in the BALF samples from patients with ADC and 
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patients with both ADC and COPD, and the differences of expression were statistically 
significant (p<0.001). 
 
 
Figure 22: Statistical analysis of the antibody arrays data (*p≤0.05, **p<0.01, ***p<0.001). 
 
5.2.3. Analysis of Il-11 and CCL1 as adenocarcinoma biomarkers 
 
The confirmation of the observed altered expression of IL-11 and CCL1 was 
accomplished by the application of western blot to the same samples used in the protein 
arrays.  
The IL-11 and CCL1 proteins were found to be over-expressed in the ADC and 
ADC&COPD groups of patients when compared to the remaining groups, confirming the 
results observed in the cytokine arrays. Results of the western blot analysis can be seen 
on Figure 23. 
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Figure 23: Western blot analysis of IL-11 and CCL1. 
 
The reproducibility of IL-11 and CCL1 as adenocarcinoma markers was assessed 
by the use of the ELISA methodology on BALF samples from the first validation cohort 
patients (Table 9). This technology was chosen given its high sensitivity and specificity, 
simple and fast procedure, the fact that it requires small amounts of sample, and also 
because of its likelihood of implementation in a clinical setting. 
 Results showed that the IL-11 quantities were significantly higher in the ADC group 
of patients compared to the other groups of patients (median 107 pg/ml, IQR 60.5-195.5; 
p<0.0001) as well as in the ADC&COPD group (median 72 pg/ml, IQR 51-136.52; 
p<0.0001), as seen on Figure 24. The levels of CCL1 were likewise significantly elevated 
in the ADC group of patients (median 82.25 pg/ml, IQR 47.25-117; p<0.0001) and 
ADC&COPD group (median 62.5 pg/ml, IQR 39-85; p<0.0001) when compared to the 
remaining groups.  
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Figure 24: IL-11 and CCL1 expression levels measured by ELISA in the first validation cohort. 
Statistically significant expression differences (p<0.0001), obtained by the Mann-Whitney U test, 
were found between the ADC groups and all remaining groups, although only the differences 
between the control group and the ADC groups are represented. 
 
The performance of IL-11 and CCL1 as biomarkers of lung adenocarcinoma was 
evaluated by receiver operating characteristic (ROC) curve analysis, a commonly used 
method in medicine to determine a cut-off value for a clinical test that is able to 
discriminate patients with and without a given condition. 
 In the first validation cohort the optimum diagnostic cut-off value for IL-11 was 42 
pg/ml (AUC – 0.93; 95%CI: 0.90 – 0.97), with sensitivity values reaching 90% and 
specificity values of 88%. These results imply that a patient with adenocarcinoma will 
have higher levels of IL-11 than 93% of controls. They also show that 90% of patients with 
adenocarcinoma would be correctly identified as so by measuring the levels of IL-11 and 
88% of controls would be correctly classified as such (Figure 25).  
The estimated cut-off value of CCL1 was 39.5 pg/ml (AUC – 0.83; 95%CI: 0.75 – 
0.90). The AUC indicates that an adenocarcinoma patient would have higher levels of 
CCL1 than 83% of controls. The sensitivity and specificity values for CCL1 as a biomarker 
of adenocarcinoma were 80% and 74%, respectively, meaning that 80% of patients with 
lung adenocarcinoma would be classified as so and 74% of patients without lung 
adenocarcinoma would be classified as controls.  
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Figure 25: Diagnostic outcomes for IL-11 and CCL1 levels in BALF in the diagnosis of 
adenocarcinoma (versus all groups) in the first validation cohort. 
 
Predictive values and likelihood ratios for IL-11 and CCL1 in the first validation 
cohort are shown in Table 11. Overall, approximately 90%, 80%, 71%, and 96.1% of 
patients with adenocarcinoma had positive levels of IL-11, CCL1, IL-11 and CCL1, and IL-
11 and/or CCL1, respectively (Figure 26). Specificity and positive predictive value (PPV) 
increased when both markers were analysed together compared to measuring each one 
in separate (94.4% and 86% respectively). Increased values of sensitivity (94.3%) and 
negative predictive value (NPV) (96.4%) were observed when the evaluation of only one 
marker was required to positively predict the adenocarcinoma outcome. On the other 
hand, specificity (74,1%) and PPV (64,1%) decreased. 
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Table 11: Analysis of IL-11 and CCL1 levels as diagnostic markers of adenocarcinoma in BALF of 
patients from the first validation cohort 
Adenocarcinoma 
vs all patients 
IL-11 CCL1 
IL-11 
 and CCL1 
IL-11  
and/or CCL1 
AUC (95%CI) 
0.93 
(0.896-0.975) 
0.83 
(0.749-0.902) 
- - 
Sensitivity 
(95%CI) 
90.2%  
(79-95.7%) 
80%  
(66.4-87.7%) 
71.2%  
(57.7-81.7%) 
94.3%  
(84.6-98.1%) 
Specificity  
(95%CI) 
88.7% 
(80.6-93.5%) 
74.1% 
(63.9-82.2%) 
94.4% 
(88.4-97.4%) 
74.1% 
(65.1-81.4%) 
PPV  
(95%CI) 
80.7% 
(68.7-88.9%) 
72.1% 
(59.2-73.4%) 
86% 
(72.7-93.4%) 
64.1% 
(53-73.9%) 
NPV  
(95%CI) 
94.5% 
(87.8-97.6%) 
86.3% 
(76.6-92.4%) 
87.2% 
(79.9-92.1%) 
96.4% 
(89.9-98.8%) 
Positive LR 
7.95 
(4.53-13.98) 
3.02 
(2.05-4.47) 
12.8 
(5.77-28.41) 
3.64 
(2.63-5.04) 
Negative LR 
0.11 
(0.05-0.26) 
0.29 
(0.17-0.52) 
0.31 
(0.20-0.47) 
0.08 
(0.03-0.23) 
AUC= area under curve. PPV= positive predictive value. NPV= negative predictive value. LR= likelihood ratio. 
The diagnostic cut-off values of IL-11 and CCL1 were 42 pg/ml and 39.5 pg/ml respectively. 
 
 
 
Figure 26: Proportion of adenocarcinoma patients from the first validation cohort with positive levels 
of IL-11, CCL1, IL-11 and CCL1, and IL-11 or CCL1. 
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The analysis of IL-11 and CCL1 together revealed that there was a correlation 
between the levels of both proteins in samples from patients with adenocarcinoma as 
seen on Figure 27 (Pearson r2 0.76; p=0.001). However, approximately 5.5% of patients 
with low levels of IL-11 were positive for CCL1, and 7.2% of patients with low levels of 
CCL1 were positive for IL-11.  
 
 
Figure 27: Correlation between IL-11 and CCL1 levels in BALF samples from the first validation 
cohort. 
 
 The validation of IL-11 and CCL1 as specific adenocarcinoma biomarkers was 
obtained by analysing their expression in the second validation cohort. The 160 patients 
that made up this validation cohort had distinct characteristics from the two training 
cohorts training and the first validation cohort and this was intentional. We decided to 
exclude a COPD group from this cohort because no differences were found between the 
adenocarcinoma and adenocarcinoma with COPD groups. On the other hand, we 
included other histological subgroups, such as LCC and SCLC, in order to study the 
performance of these proteins across all histological LC groups.  
Results showed that the levels of IL-11 were significantly increased in the BALF 
samples of adenocarcinoma patients as compared to the control group and remaining 
lung cancer histological types (median 103.5 pg/ml, IQR 52.75-166; p<0.0001), as seen 
on Figure 28. Similarly, the levels of CCL1 were significantly higher in patients with 
adenocarcinoma (median 75.25 pg/ml, IQR 42.37-102.3; p<0.0001) than in the remaining 
groups. Among these, the BALF samples from the SCC group of patients had significantly 
higher levels of CCL1 than the control, LCC, and SCLC groups of patients (median 34.75, 
IQR 22-45; p=0.04). 
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Figure 28: IL-11 and CCL1 expression levels measured by ELISA in the second validation cohort. 
Statistically significant expression differences (p<0.0001), obtained by the Mann-Whitney U test, 
were found between the ADC groups and all remaining groups. 
 
The ROC curve analysis of the second validation cohort can be seen on Figure 29. 
This analysis revealed that the optimum diagnostic cut-off value for IL-11 was 29.5 pg/ml 
(AUC – 0.95; 95%CI: 0.92 - 0.98). The AUC associated with this cut-off indicated that a 
patient with lung adenocarcinoma had higher levels of IL-11 than 95% of controls. The 
estimated cut-off value for CCL1 was 24.25 pg/ml (AUC – 0.91; 95%CI: 0.87 - 0.96), 
which showed that a lung adenocarcinoma patient would have higher levels of CCL1 than 
91% of patients in the control group.  
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Figure 29: Diagnostic outcomes for IL-11 and CCL1 levels in BALF in the diagnosis of 
adenocarcinoma (versus all groups) in the second validation cohort. 
 
In order to further validate the results from cohort validation first, the cut-off values 
from the first cohort were applied to the data from the second validation cohort. Predictive 
values and likelihood ratios for IL-11 and CCL1 in the second validation cohort can be 
found on Table 12.  
Positive levels of IL-11, CCL1, IL-11 and CCL1, and IL-11 and/or CCL1 were 
detected on approximately 91%, 92%, 71%, and 92% of patients with lung 
adenocarcinoma (Figure 30). These percentages were similar to those obtained in the first 
validation cohort. Likewise, specificity and PPV increased when both markers were 
analysed together compared to measuring each one in separate (96.3% and 84.1% 
respectively). Increased values of sensitivity (92.3%) and NPV (98.1%) were observed 
when the evaluation of only one marker was required to positively predict the 
adenocarcinoma outcome, similar to what occurred with the first validation cohort. 
Specificity (84%) and PPV (62.5%) also increased in this case, contrary to what occurred 
in the first validation cohort. 
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Table 12: Analysis of IL-11 and CCL1 levels as diagnostic markers of adenocarcinoma in BALF of 
patients from the second validation cohort, with cut-off values from the first validation cohort 
Adenocarcinoma 
vs all patients 
IL-11 CCL1 
IL-11 
 and CCL1 
IL-11  
and/or CCL1 
AUC (95%CI) 
0.95 
(0.92-0.98) 
0.91 
(0.87-0.96) 
- - 
Sensitivity 
(95%CI) 
90.6%  
(79.7-95.9%) 
91.7%  
(80.4-96.7%) 
71.2%  
(57.7-81.7%) 
92.3%  
(82.6-98.1%) 
Specificity  
(95%CI) 
83% 
(80.8-87.7%) 
77.5% 
(71.0-82.9%) 
96.3% 
(92.5-98.2%) 
84% 
(78-88.5%) 
PPV  
(95%CI) 
60.8% 
(49.7-70.8%) 
51.2% 
(40.8-61.4%) 
84.1% 
(70.6-92.4%) 
62.5% 
(51.5-72.3%) 
NPV  
(95%CI) 
96.8% 
(92.7-98.6%) 
97.3% 
(93.3-99%) 
92.3% 
(87.7-95.3%) 
98.1% 
(94.6-99.4%) 
Positive LR 
5.32 
(3.81-7.41) 
4.08 
(3.09-5.04) 
19.1 
(9.0-41.13) 
5.88 
(4.21-8.22) 
Negative LR 
0.11 
(0.05-0.26) 
0.11 
(0.04-0.28) 
0.3 
(0.19-0.46) 
0.07 
(0.02-0.20) 
AUC= area under curve. PPV= positive predictive value. NPV= negative predictive value. LR= likelihood ratio. The 
diagnostic cut-off values of IL-11 and CCL1 were 42 pg/ml and 39.5 pg/ml respectively. 
 
 
 
Figure 30: Proportion of adenocarcinoma patients from the second validation cohort with positive 
levels of IL-11, CCL1, IL-11 and CCL1, and IL-11 or CCL1.  
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6. GENERAL DISCUSSION AND MAIN CONCLUSIONS 
 
Lung cancer is one of the most commonly diagnosed malignancies and kills more 
patients than any type of cancer in the world. Approximately 90% of all these LC types are 
attributable to one major factor: tobacco smoking. 
The diagnosis of LC is a crucial step given its influence in the prognosis of a 
patient. The use of chest radiographies, bronchoscopies, among other tests, is common 
when searching for LC. Afterwards, available therapeutic options include surgery, radio 
and chemotherapy, used separately or in different combinations. However, LC is usually 
asymptomatic during its development and this causes the majority of patients to be 
diagnosed at advanced stages of the disease, limiting therapeutic options and prognosis. 
When a patient is diagnosed at an early stage, the 5-year survival rate lies between 43-
73%. With a stage II diagnosis, 25-45% of people will live for at least 5 years. When 
considering more advanced stages, the outcomes change dramatically: only 7-24% of 
patients diagnosed with stage III will live more than 5 years after their initial diagnosis; 
stage IV, characterized by the presence of metastasis, has a 5-year survival rate between 
2 and 13% (120).  
Radiological screenings have been used for many years for the early detection of 
LC. Still, data from several screening trials has revealed that performing annual chest 
radiographies in smokers, former smokers, and non-smokers is not effective in reducing 
LC mortality and cannot be recommended for clinical practice (121). More recently, low 
dose CT scanning was associated with a significant reduction in LC mortality (20%), in 
one large study of high-risk individuals. However, more data are needed on the cost 
effectiveness of screening that takes into account the frequency of screening and both the 
benefits and harms (such as false positives and over diagnosis) before large-scale 
screening programmes are created (122).  
In addition to radiological methods, the cytological analysis of certain samples is 
also helpful to the diagnosis of LC. However, pulmonary cytology has variable sensitivity 
and specificity values, and false positive diagnoses are somewhat common, giving that 
the cytological evaluation of the lungs has some limitations (123). The use of 
bronchoscopy to localize lesions and early LC presents some challenges: SCC is mostly 
detected in the central areas of the lungs, whereas adenocarcinomas, the most common 
type of LC in recent years, are mostly found in the peripheral airways of the lungs, 
unreachable to the majority of bronchoscopes. In conclusion, the diagnosis of LC involves 
a combination of the radiological and histological evaluation of a symptomatic patient or a 
suspicious lesion, requiring the cytological examination sputum or in bronchoscopy 
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obtained samples, such as biopsies and BALF (124). These tests are sometimes 
inconclusive, making it necessary to perform invasive surgical procedures in patients that 
may or may not have the disease.  
The abovementioned classical methods of diagnosing LC are currently evolving to 
less invasive, molecular oriented approaches to the detection of this disease. The use of 
autofluorescence bronchoscopy, lung tissue molecular markers, blood based LC markers, 
airway based biomarkers, among others, are currently being evaluated for the early 
detection of LC. Although some recent studies have shown that these molecular 
biomarkers can have a positive impact in the improvement of LC diagnosis, extensive 
validation of the most promising molecules that arise from these studies is crucial before 
they can be used to screen individuals at high risk of developing LC (125-127). 
Apart from being the major cause of LC development, cigarette smoke is also 
responsible for another common illness that affects the respiratory system, which is 
COPD. For a long time it was though that the link between both diseases was their 
aetiological factor. Nonetheless, the observation that COPD patients had high LC mortality 
rates challenged that concept. Despite the increased attention given to the study of the 
commonalities between both diseases, either by clinical studies and research, the true 
nature of the link that connects both diseases, remains elusive. However, as discussed 
below, there are key shared mechanisms that may represent links between the two 
diseases, and potentially diagnostic and therapeutic targets.  
Some common genetic alterations play a role in the development of COPD and 
LC, for example, the α1 antitrypsin protein inhibits the neutrophil elastase that degrades 
elastin and has anti apoptotic capabilities. The α1 antitrypsin deficiency causes the 
development of emphysema and increases the risk of developing LC by 70% (128). Other 
genes that have been associated with LC and COPD include those that code proteinases, 
detoxifying enzymes, nicotine receptors, and inflammatory proteins (129). The enzymes 
that contribute to the metabolism of the compounds found in tobacco smoke can 
occasionally transform these molecules into more harmful substances, such as 
carcinogens and ROS. The action of these metabolites in the lung epithelial cells can 
promote the development of both LC and COPD.  
Another seemingly important mechanism connecting both diseases is 
inflammation. Macrophage and neutrophil infiltration is a common occurrence in all 
smokers, but those who have COPD develop a more marked inflammatory response that 
correlates with disease severity (130). In addition, the cells that contribute to the 
development of, for example, emphysema exist both in the airways and alveolar airspaces 
and can therefore contribute to the development of proximal and distal LC (129). Although 
both diseases have chronic inflammation as a feature, the nature of the microenvironment 
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in COPD and LC is different and contributes to the distinct behaviours that characterize 
both diseases. The COPD microenvironment is more cytotoxic, genotoxic, and has more 
matrix degrading capabilities than the LC microenvironment, which is more angiogenic 
and growth promoting (129).  
There are still many unanswered questions concerning LC and COPD and the 
links between both diseases. In addition, a pressing need exists to discover new 
molecular biomarkers that can aid in the early detection of LC. This latter area of research 
has been granted a major ally with the development and the improvement of certain 
analytical technologies, such as genomics and proteomics. Both technologies were 
designed to perform the rapid and complete analysis of the genes and proteins that are 
expressed in a given cell or tissue in a given time. Despite the better understanding of the 
genetic alterations present in LC given by genomic approaches, such as mutations and 
polymorphism in key genes, the importance of the evaluation of proteins cannot be 
overlooked.  
Proteomics complements the genomic-based approaches by providing additional 
information that cannot be obtained by the study of genes alone. One of the most 
important advantages of the proteomic approach in cancer research is based on the fact 
that there is generally a poor correlation between the transcriptional levels of many genes 
and the relative abundance of the corresponding protein. Furthermore, due to differential 
splicing, one gene can encode several protein variants with distinct properties (131). In 
addition to relative abundance, the activity of a given protein is not a direct consequence 
of its genetic expression, but the result of post-translational modifications such as 
phosphorylation, glycosylation, methylation, ubiquitination, cleavage, and acetylation 
(132). Despite the many advantages when compared to other approaches, the use of 
proteomic technologies has to be applied carefully in order to provide relevant biological 
results and to be successfully translated into the clinical practice. Challenges associated 
with proteomics include the heterogeneity of cells that exist in the lungs, which can be 
malignant or normal, the broad dynamic range of protein abundances in proximal body 
fluids and serum that difficult the identification of biomarkers in those types of samples, 
and finally the need for extensive validation of the molecular changes in independent 
cohorts of patients using different techniques (131).     
Proteomic methodologies can be applied to the discovery of new LC biomarkers as 
well as aid with the prognosis, prediction and monitoring of a patient response to a given 
therapeutic intervention. Such markers of disease can be released directly from cancer 
cells or can be attributable to the host’s response against the malignancy itself. The 
detection of these candidate biomarkers can be performed in a variety of body fluids 
collected by a non-invasive method. Biomarkers obtained by these methods are usually 
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more sensitive, more specific, and more easily detected than invasive biomarkers 
(obtained by procedures such as surgery). In addition, they are associated with less 
anxiety and discomfort to the patients. Samples such as blood, urine, serum, and saliva 
are major sources of non-invasive biomarkers and commonly used in cancer research. 
Although more invasive than the previous samples, BALF is a great source of possible 
biomarkers of lung diseases given that it is thought to reflect most faithfully the protein and 
cell composition of the pulmonary airways among the non-invasive techniques (133). The 
present work aimed at evaluating this particular type of sample by different proteomic 
techniques with the aim of identifying proteins that could be used as biomarkers for the 
diagnosis of LC, something that to the best of our knowledge has not been done before.  
The first proteomic technique used in this study was 2D-PAGE. This tool has been 
the driving force behind the development of proteomics and protein analysis throughout 
the years. This technique has been extensively tested and compared between different 
laboratories throughout the years makes it one of the most robust proteomic methods.  
Our results showed that the protein composition of BALF was different among the 
four groups of studied patients, especially when we compared the control group to the 
disease groups. A total of 40 were differentially expressed among the four groups of 
patients and the expression changes were superior to 2 fold (p<0.05). The distribution of 
these differentially expressed proteins allowed us to determine the specific proteomic 
profiles of the various groups of patients. 
Seventeen proteins were over-expressed in all the patients from the disease 
groups (LC, COPD, and LC&COPD) compared to those in the control group. These 
proteins were AMY1A, AMY2A, ANXA1, ANXA2, ANXA5, ARHGDIB, CA1, CRP, C3, 
ENO1, GSR, HSP70, IDH1, PEBP4, SERPINB1, TPPP3, and TXN. The expression of 
HSP70, which in the present study had an average over-expression of 3.6 fold across the 
three disease groups, was also found significantly elevated in serum samples from COPD 
patients, when compared to controls (134). It has also been linked to the number of 
cigarettes smoked daily in a study of lung adenocarcinoma in smokers (135). The use of 
proteomic approaches has revealed the association between the over-expression of 
HSP70 and the differentiation level and/or aggressiveness of several types of cancer, 
such as gastric adenocarcinomas, hepatocarcinomas, and oesophageal cancer (136-
138). Furthermore, various oncoproteomic studies have correlated the elevated levels of 
HSP70 with therapeutic resistance (139-142). 
Another important protein in this group is CA1. This protein is a marker of cellular 
hypoxia, which is a natural phenotype of solid tumours. Several studies have investigated 
the potential of carbonic anhydrases as cancer diagnostic, prognostic, and therapeutic 
markers (143). Recently, the over-expression of CA1 was reported in carcinoma cell lines 
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from multiple organs, such as lung, breast, cervix, bladder, oesophagus, colorectal, 
kidney, and head and neck (144). PEBP4 which plays a role in the inhibition of the 
mitogen-activated protein kinase (MAPK) signalling pathway but is also involved in the 
inhibition of the c-Jun N-terminal kinases (JNK) pathway that promotes the activation of 
protein kinase B (AKT), was recently associated with an increased invasion and 
metastasis in NSCLC and colorectal tumours (145-147).  
The IDH1 enzyme is essential for cell metabolism and energy production, given its 
role in the Krebs cycle. In the present study, the IDH1 protein had an average over-
expression of 2.3 fold in the disease groups. The oncogenic potential of this enzyme has 
been studied in acute myeloid leukaemia (148). An also recent report has observed the 
over-expression of IDH1 in more than 70% of NSCLC tumours. It was also correlated with 
lower 5-year survival rates and considered an independent unfavourable prognostic 
marker for overall survival of NSCLC patients in a multivariate analysis (149). In addition, 
IDH1 plasma levels were considered a biomarker for lung adenocarcinoma with relatively 
high sensitivity and specificity (150). 
The next group of differentially expressed proteins appeared in the LC and 
LC&COPD groups of patients. In the LC group of patients the AKR1B10, ALDOA, CTSD, 
EZR, FBP1, and TKT proteins were over-expressed when compared to the control group 
and the SELENBP1 protein was under-expressed in this group of patients compared to 
those in the control group. A number of studies have associated the presence of CTSD, 
Ezrin, and SELENBP1 with increased cancer growth, invasion, and metastasis in various 
types of tumours (151-153). Furthermore, three different studies have highlighted the 
importance and potential role of these proteins as prognostic biomarkers of lung tumours 
(154-156). Another over-expressed protein in our results was the AKR1B10 protein. In 
other studies, this over-expression was associated in most cases with smoking, 
suggesting a possible involvement of this enzyme in tobacco-induced LC (157-159). In 
fact, AKR1B10 has a high catalytic efficiency for the reduction of retinoids, and retinoic 
acid deficiency has been linked to airway epithelial squamous metaplasia and epithelial-
to-mesenchymal transition (160). In addition, AKR1B10 has also been recently involved in 
the resistance to different chemotherapeutic drugs, such as cisplatin (161).  
Apart from these differentially expressed proteins, the LC group of patients 
together with the LC&COPD group of patients, had an over-expression of the following 
proteins when compared to the control group; ALDH3A1, AKR1C3, PYGM, PKM2, and 
PPIA. The ALDH3A1 protein is a phase II drug-metabolizing enzyme that is highly 
expressed in the lung, stomach, keratinocytes, and cornea. Cytosolic ALDH3A1, which is 
induced by polycyclic aromatic hydrocarbons or chlorinated compounds (present in 
tobacco smoke), is thought to play an important role in alveolar pneumocyte physiology, 
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and increases during carcinogenesis (162). On the other hand, the TKT, FBP1, ALDOA, 
PYGM, and PKM2 proteins are involved in the regulation of glycolysis and are probably 
contributing to the Warburg effect that leads to a state that has been termed "aerobic 
glycolysis". Previous studies have showed that the PKM2 protein has a role in the 
production of lactic acid through glycolysis rather than producing energy through 
mitochondrial oxidative phosphorylation. This may help tumour cells to survive in low 
glucose and low oxygen environments, and facilitate tumour invasion (163, 164). 
Lastly, a total of four proteins were found to be over-expressed in the COPD and 
LC&COPD groups of patients: CAT, PRDX1, PRDX2, and PRDX5. These proteins are 
enzymatic antioxidants and represent the first line of defence against oxidative stress. The 
evaluation of the role of these proteins and the development of COPD has generated 
some conflicting results. Some studies have observed a down-regulation of enzymatic 
antioxidants, such as peroxiredoxins and catalase, in COPD patients (165-167), while 
others claim their up-regulation in the same conditions (168). Other studies on LC have 
observed that the up-regulation of different peroxiredoxins correlates with a poor 
prognosis (95, 169, 170). 
The identified 40 differentially expressed proteins in our groups of patients were 
submitted to an additional analysis to ascertain the common biological functions they 
might share, their presence in known pathways, and any possible connection between 
them. Our results showed three major pathways: inflammation, free radical scavenging, 
and glycolysis and gluconeogenesis.  
Altered glucose metabolism has been observed in cancer cells. To support 
continuous cell growth and proliferation, these cells exhibit high rates of aerobic 
glycolysis, a phenomenon known as the Warburg effect (171). Some oncogenes and 
transcription factors that are frequently altered in cancer are also responsible for the 
increased expression of glycolytic enzymes and glucose transporters, altering the glucose 
metabolism in cancer cells (172). 
Free radicals such as ROS are involved in a variety of diseases, degenerative 
changes, and tissue degradation, a hallmark of carcinogenesis (173). In a metabolically 
active cell the redox system pathways maintain the balance between oxidant and 
antioxidant factors, by regulating the activation of specific transcription factors and the 
production of substances that neutralize oxidants (174, 175). However, in cancer settings, 
alterations in these redox pathways occur and the cell is no longer able to produce 
antioxidant substances to adjust the balance between oxidant and antioxidant factors. 
Alterations in the physiological pathways involved in the regulation of the redox system 
have been identified in tumours (176). Several proteins detected in our samples are 
involved in this system; such as the PPIA protein is secreted in response to ROS from 
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vascular smooth muscle cells (177). It is a chaperone protein that has several functions 
including protein trafficking, such as the nuclear translocation of extracellular-signal-
regulated kinases 1/2 (ERK1/2) (178) and apoptosis-inducing factor (AIF) (179). There is 
also evidence that PPIA might be a valuable biomarker. Up-regulation of PPIA in small 
cell lung cancer, pancreatic cancer, breast cancer, colorectal cancer, squamous cell 
carcinoma, and melanoma has been reported (180). In addition, knockdown of PPIA in 
vivo was found to correlate with slower growth, decreased proliferation, and a greater 
degree of apoptosis of lung tumours (181). Another over-expressed protein in our results 
was TXN that is a potent growth and cell survival factor, which activates specific 
transcription factors such as NF-kB, p53, hypoxia-inducible factor a (HIFa), and activator 
protein 1 (AP-1). TXN regulates the production of substances that protect cells from 
oxidative stress induced by oxygen free radicals (182, 183).   
The final mechanism identified was inflammation, one of the body’s natural 
mechanisms against harmful stimuli. However, the components present in tobacco smoke 
can induce an inflammatory response of the lungs that can become persistent, promoting 
the development of COPD and a tumour friendly microenvironment. Inflammation is 
currently considered an enabling characteristic of tumours, given that it contributes to the 
appearance of multiple cancer hallmark capabilities by supplying important molecules to 
the tumour microenvironment.  
A total of 22 were associated with the inflammatory pathway. The ANXA2 protein 
is highly expressed in NSCLC and is positively correlated with a poor prognosis, apart 
from promoting cell proliferation in LC (184). The expression levels of the CFL1 gene have 
been considered prognostic and drug resistance markers of NSCLC (185). Elevated levels 
of CRP, a systemic marker of chronic inflammation, were associated with subsequently 
increased LC risk (186). The LCN2 protein, a member of the lipocalin family that 
transports small lipophilic ligands, has gained recent attention as both a potential 
biomarker and a modulator of human cancers. High levels of LCN2 are common at sites 
of inflammation and its over-expression reduced the apoptosis of a LC cell line (187). 
The principal core of all identified pathways was NF-κB. This transcription factor is 
known to regulate genes that express cytokines, adhesion molecules, angiogenic factors, 
anti-apoptotic factors, and matrix metalloproteinases (MMPs). These proteins are involved 
in distinct aspects of cellular physiology, such as inflammation, cell survival and 
proliferation (188). 
Nuclear factor-kappa B represents a family of transcription factors that include five 
members in mammalian cells: p65 (RelA), RelB, c-Rel, p50/p105 (NF-kappaB1), and p52 
(NF-kappaB2). Most commonly, NF-kB exists as a p65/p50 heterodimer that is retained in 
its inactive state by its association with IkBα, an inhibitory protein. NF-kB is activated by a 
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wide variety of stimuli that phosphorylate IkBα, dissociating it from the p65/p50 
heterodimers. These stimuli can be for example DNA damage or the presence of certain 
cytokines. Then, the NF-kB protein, free from its inhibitory regulator, is transported to the 
nucleus, where it regulates transcription (189).  
The NF-kB protein is thought to play a role in the multiple steps of carcinogenesis. 
In the initiation process, the multiple irritants present in tobacco smoke can cause DNA 
damage in lung epithelial cells via the generation of ROS. When cells fail to repair the 
damaged DNA, they are subjected to apoptosis. However, these same environmental risk 
factors can simultaneously induce chronic inflammation in lung tissue, which is 
accompanied by the activation of cell survival signalling pathways. As a key player of the 
inflammatory process, NF-kB is activated in these conditions and can induce autocrine 
production of the inflammatory cytokine IL-6 and activation of the transcription factor 
STAT3, causing spontaneous lung cancer in vivo (190). The NF-kB protein also plays a 
role in promoting LC by activating the transcription of several growth factors necessary for 
angiogenesis (188).  
The importance of the inflammatory process observed in our results, either by the 
amount of inflammation related proteins identified or by the presence of NF-kB as the 
major connector between the most of identified proteins, encouraged further investigation. 
It has been suggested that NF-kB promotes LC mainly by promoting the secretion of 
inflammatory cytokines that establish a cancer-prone inflammatory microenvironment 
(191). The NF-κB complex induces cytokines that regulate the immune response (such as 
TNFα, IL-1, IL-6 and IL-8), as well as adhesion molecules, which lead to the recruitment of 
more leukocytes to sites of inflammation (192). The better understanding of the 
mechanisms by which chronic inflammation, such as the one occurring in COPD patients, 
leads to the initiation of LC may identify early diagnostic biomarkers and screening tests, 
in addition to identifying more effective therapeutic strategies and targets.  
In order to search for proteomic markers involved in inflammation and in the 
pathogenesis of the two most prevalent and devastating smoking associated respiratory 
diseases, BALF samples from 60 patients with LC and/or COPD and a control group were 
applied to an inflammation antibody array. With this strategy we were able to identity 16 
proteins differentially expressed in BALF fluid in patients with LC, COPD, or both diseases 
as compared to healthy controls. Remarkably two proteins, IL-11 and CCL1, were almost 
selectively expressed in adenocarcinoma BALFs, regardless of the presence or absence 
of COPD. These results were fully validated by western blotting of the same samples and 
individually validated by ELISA in two additional patient cohorts. ROC curves showed the 
optimum diagnostic cut-off levels in BALF were 42 pg/ml for IL-11 and 39·5 pg/ml for 
CCL1. The diagnostic accuracy for adenocarcinoma was confirmed for each biomarker. 
Proteomic	  characterization	  of	  lung	  cancer	  and	  chronic	  obstructive	  pulmonary	  disease:	  a	  bronchoalveolar	  lavage	  fluid	  analysis	  
	  
	  
Ana	  Barbosa	  de	  Sousa	  Nogal	  	   	   83	  
	  
Even though there was a positive correlation between the BALF levels of IL-11 and CCL1, 
the measurement of both proteins seemed to optimize the sensitivity and specificity of the 
diagnostic to level of 90% and 89%, respectively. A recent study analysed the so far best 
known LC tumour markers: squamous cell carcinoma antigen (SCCA), carcinoembryonic 
antigen (CEA), cytokeratin 19 fragment antigen 21-1 (CYFRA21-1), and neuron specific 
enolase (NSE) (193). These markers have been extensively analysed and their 
importance in the detection, prognosis and follow-up of LC has been revealed (194-199). 
However, the ROC curve analysis of these markers revealed AUC between 0.601 and 
0.726 and low values of sensitivity (below 30%). Interestingly, both proteins were similarly 
predictive of adenocarcinoma, regardless the presence of concurrent COPD. They were, 
however, not useful for other histological subtypes such as SCC. Studies in human 
tumours have suggested the existence of specific molecular networks and subtype-
specific differences between lung adenocarcinoma and SCC subtypes. Another study 
focusing on human tumours has suggested that the genes expressed by SCC present 
higher levels of methylation than the genes expressed by adenocarcinomas (200), 
probably accounting for the differential expression of 178 proteins between the two 
histological subtypes reported in a recent study (201). Furthermore, it has been suggested 
the existence of specific molecular networks and subtype-specific differences between 
lung adenocarcinoma and SCC subtypes, mostly found in cell cycle, DNA repair, and 
metabolic pathways (202). Our findings firmly suggest differences at inflammatory 
networks between both histological subtypes.  
Interleukin-11 is a member of the IL6-type cytokines. Epithelial cells, fibroblasts, 
and airway smooth muscle cells are known to produce IL-11 in response to certain stimuli. 
Functions of this cytokine include the stimulation of hematopoiesis, thrombopoiesis, and 
megakaryocytopoiesis, the regulation of macrophage differentiation, the mucosal 
protection after chemotherapy and radiation therapy, among others (203). The cellular 
action of IL-11 is mediated by its specific receptor (IL-11Rα), also a receptor for IL-6. 
Following the connection between ligand and receptor, gp130 proteins are activated and 
phosphorylate the janus kinase (JAK) family of tyrosine kinases. These in turn activate 
STAT3 and STAT1, resulting in their subsequent translocation to the nucleus. Here they 
bind DNA in a sequence-specific context and elicit transcriptional activation of target 
genes that play a role in multiple cellular mechanisms such as proliferation, survival, 
angiogenesis, and inflammation (204). Regarding STAT3, its aberrant or persistent 
activation has been observed in human cancers and is associated with poor outcome 
(205). Apart from STAT3, the expression of IL-11 in cancer cells is also regulated by 
another transcription factor: AP-1 (206, 207). The AP-1 proteins are composed of homo or 
heterodimers of Jun or Fos family member. Most AP-1 proteins may be associated with 
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oncogene-induced transformation and are up-regulated by oncogenic Ras (208-210). A 
recent cell lines study suggested that both phosphatidylinositide 3-kinase (PI3K) and Raf 
pathways are necessary for the expression of IL-11, and that JNK, p38, and Stat3 also 
contribute to oncogenic Ras-induced IL-11 expression (211).  
The expression of IL-11 and its receptor has been described in several human 
malignancies, including ovarian, prostate, breast, colorectal, and gastric carcinoma (212-
216). The regulation of IL-11 expression and its contribution to tumour development is still 
not fully understood. A recent study has demonstrated the action of IL-11 in the 
development of gastrointestinal cancers, casting some light on the importance of this 
protein in the development of inflammation-associated neoplasias. Putoczki and co-
workers revealed that increased expression of IL-11 was associated with excessive 
STAT3 activation in gastrointestinal cancers and that this excess resulted in epithelial 
tumorogenesis and submucosa invasion. The possible use of IL-11 as a therapeutic agent 
was assessed and the pharmacologic inhibition of this protein alleviated STAT3 activation, 
supressed tumour cell proliferation, and reduced the invasive capacity and growth of 
gastrointestinal tumours. In addition, they observed that gastric tumours arising from the 
glandular epithelium might be biased toward IL-11 responsiveness (217). Another study 
has detected IL-11 mRNA and protein after incubating human cancer cell lines under 
hypoxic conditions and has discovered that HIF-1 is involved in the regulation of IL-11 
expression (218). Interestingly, it has been recently shown that IL-11 increases HIF-1α 
nuclear translocation and transcriptional activity, suggesting the existence of a positive 
feedback loop between IL-11 and HIF (219).  
In the lungs, IL-11 is produced by a variety of structural cells and eosinophils in 
response to a variety of stimuli, including TGF-β, ROS, and viruses. The targeted 
expression of this cytokine in the lungs of mice resulted in airway remodelling and 
inflammatory cell infiltration (220). Furthermore, IL-11 was found to be selectively 
expressed in eosinophils and epithelial cells in patients with moderate and severe asthma 
where expression correlates directly with disease severity and inversely with FEV1 (221). 
To the best of our knowledge, the expression of IL-11 in the context of LC has not been 
evaluated so far. On the other hand, its close relative IL-6 has been analysed in LC 
patients. Yeh and co-workers also found higher expression of IL-6 in the pleural fluids of 
patients with lung adenocarcinoma (222). In a study with lung adenocarcinoma, STAT3 
activation in mutant EGFR–expressing cell lines occurred, in part, through mutant EGFR–
mediated transcriptional up-regulation of the IL-6 gene, which, in turn, activates the 
gp130/JAK signalling pathway (223). A similar situation might be also occurring with IL-11, 
given the existing overlap between IL-11 and IL-6 targets. In addition, STAT3 and its 
downstream genes have been showed to serve as biomarkers for lung adenocarcinoma 
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and COPD diagnosis and prognosis in mice and humans (224).  In conclusion, the local 
expression of IL-11 in the lungs and the consequent activation by it of STAT3, might 
contribute to the development of an inflammatory microenvironment, a positive feedback 
loop, and ultimately to the development of a carcinogenic process similar to what has 
been proven to occur in other types of cancers. 
The other protein that predicted lung adenocarcinoma in our BALF samples was 
CCL1. It is a chemokine produced by activated T lymphocytes, monocytes, and mast 
cells, which binds selectively to the CCR8 receptor. Unfortunately, insights to its function 
are less than the ones referring to IL-11.  
CCL1 has been known to act as a potent monocyte and lymphocyte 
chemoattractant and is thought to play a major role in inflammatory processes (225). The 
CCL1-CCR8 axis may play a role in the initiation and amplification of atopic skin 
inflammation (226). This chemokine was also shown to bind to endothelial cells and to 
stimulate differentiation, chemotaxis, and invasion, indicating a possible role for this 
chemokine in angiogenesis (227). The role of this protein in cancer has been described in 
leukaemia, where it is ascribed to activate the anti-apoptotic function of the RAS/MAPK 
pathway (228, 229). More recently, a report by Das and co-workers revealed that tumour 
cell migration to lymphatic endothelial cells in vitro was inhibited by the blocking of CCR8 
or CCL1 and that the pro-inflammatory mediators TNF, IL-1β, and lipopolysaccharides 
(LPS) increased CCL1 production by lymphatic endothelial cells and tumour cell migration 
to these same cells (230). Furthermore, the CCL1/CCR8 axis was identified as a 
component of cancer-related inflammation and may contribute to immune evasion in 
human urothelial and renal cancers (231). 
The role of CCL1 in lung diseases has been evaluated in a few studies. 
Measurements of CCL1 using ELISA showed that levels of this cytokine were significantly 
elevated in BALF from asthmatics compared with normal individuals (232). A study 
evaluating the effects of specific tobacco smoke components revealed that polycyclic 
aromatic hydrocarbons, well known to regulate expression of pro-inflammatory cytokines 
such as IL-1β and TNF-α, markedly increased mRNA expression and secretion of CCL1 
in primary human macrophage cultures (233). When evaluating COPD, Takabatake and 
co-workers identified polymorphic variants of the CCL1 gene that were associated with 
susceptibility to acute exacerbations, a major cause of morbidity and mortality in patients 
with this disease (234). Another study revealed the presence of CCR8 on inflammatory 
macrophages in human COPD lung tissue and that CCL1 induced the production of pro-
inflammatory cytokines TNF-α and IL-6 (235). 
Overall, the existing data on the involvement of IL-11 and CCL1 in lung 
carcinogenesis is not prominent. However, the evidence provided by the present study is 
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encouraging. The present work, through the application of a 2D-PAGE MALDI-TOF/TOF 
methodology, identified distinct proteomic profiles characteristic of LC, COPD and 
LC&COPD, which were later validated. The bioinformatics analysis of the 40 differentially 
expressed proteins identified in BALF suggested that LC and COPD shared some 
pathogenic pathways such as inflammation, free radical scavenging and oxidative stress 
response, and glycolysis and gluconeogenesis. In addition, IPA analysis exposed a major 
connector of these pathogenic mechanisms: the NF-kB transcription factor. The further 
exploration of the inflammatory process in our patients revealed that the determination of 
IL-11 and CCL1 levels in BALF samples by a simple ELISA assay, could be used to 
improve the diagnosis of lung adenocarcinoma in smokers, regardless the presence or 
absence of COPD. The application of this assay to routine clinical practice could in the 
future improve the early detection of lung adenocarcinoma, the currently most common 
form of NSCLC, and possibly contribute to an increase in the 5-year survival rate 
associated with this disease.  
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7. FUTURE PERSPECTIVES 
 
The search for molecular biomarkers in easily accessible samples is of vital 
interest in LC research. The diagnosis of LC is currently commonly obtained in advanced 
stages of the disease and is unfortunately associated with poor survival and a lack of 
therapeutic options.  
Our results revealed the existence of different proteomic profiles between patients 
with LC and COPD. The proteins included in these signatures deserve further validation 
and investigation as potential biomarkers for early diagnosis and prognosis, and possibly 
as therapeutic targets. The exploration of the inflammatory process in the samples from 
our patients revealed the potential of two proteins as LC biomarkers. Higher levels of IL-
11 and CCL1 in BALF from smokers were associated with the presence of 
adenocarcinoma of the lung.  
Future studies aiming at validating the findings in the present work should include 
a larger sample size, both in LC cases and controls. Further validation of the diagnostic 
performance of IL-11 and CCL1 in more accessible fluids such as plasma would be 
desirable and more practical for eventual screening programs or routine diagnosis. In 
addition, the evaluation of IL-11 and CCL1 as prognostic and therapeutic markers should 
also be addressed in future investigations. Furthermore, the performance of the IL-11 and 
CCL1 proteins on the differential diagnosis of pleural effusions (between lung 
adenocarcinoma, mesothelioma, adenocarcinoma of other origins, and non tumoral) 
would also be useful. The association of these two proteins with the development of other 
types of inflammation-related cancers should also be of interest. 
Finally, the functional role of IL-11 and CCL1 in the carcinogenic process should 
also be assessed. Studies aiming at evaluating the capabilities of these two proteins in 
different cell lines and animal models could shed some light on their action in the lung 
carcinogenic process and also uncover new possible targeted therapies.  
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Abstract The correct understanding of tumour develop-
ment relies on the comprehensive study of proteins. They
are the main orchestrators of vital processes, such as sig-
nalling pathways, which drive the carcinogenic process.
Proteomic technologies can be applied to cancer research
to detect differential protein expression and to assess dif-
ferent responses to treatment. Lung cancer is the number
one cause of cancer-related death in the world. Mostly
diagnosed at late stages of the disease, lung cancer has one
of the lowest 5-year survival rates at 15 %. The use of
different proteomic techniques such as two-dimensional
gel electrophoresis (2D-PAGE), isotope labelling (ICAT,
SILAC, iTRAQ) and mass spectrometry may yield new
knowledge on the underlying biology of lung cancer and
also allow the development of new early detection tests and
the identification of changes in the cancer protein network
that are associated with prognosis and drug resistance.
Keywords Lung cancer  Proteomics  Diagnostic
biomarkers  Prognostic biomarkers  Predictive biomarkers
Lung cancer overview
Lung cancer was a rare disease in the beginning of the 20th
century, but environmental and lifestyle changes have
prompted it to the top of the world cancer incidence and
mortality rates. European estimates for 2012 indicate that
over 262,000 people will die from lung cancer [1]. The
major contributor to the development of this disease is
tobacco smoking. Approximately 85–90 % of all lung
cancer cases are attributed to this habit and smokers have a
15–30-fold increase risk to develop this disease [2].
Tobacco smoking allows over 4,000 compounds, 66 of
which are known carcinogens, to enter the airways and
cause damage that can lead to the development of lung
cancer. Individual variation in the susceptibility to carcin-
ogens and the presence of previous lung diseases also play
a part in the pathogenesis of this disease [2]. Other risk
factors for lung cancer development include passive
smoking, indoor radon, heavy metals, outdoor pollution,
asbestos, and fumes from cooking stoves and fires [3].
Current lung cancer classification makes use of histo-
logical data. The majority of these tumours are firstly
divided into two categories: small cell lung cancer (SCLC)
that comprises approximately 15 % of all lung cancer cases
and non-small cell lung cancer (NSCLC). This latter group,
with 85 % of cases, is sub-divided into adenocarcinoma,
squamous cell carcinoma (SCC) and large cell carcinoma
(LCC). The SCC type used to be the most common, but in
the past years adenocarcinoma has become the most pre-
valent form of NSCLC [3]. This useful histological clas-
sification can every so often be inadequate since it does not
take into consideration the heterogeneity of lung tumours.
Important molecular and genetic alterations between SCLC
and NSCLC or between the NSCLC sub-types could, for
example, imply different treatments and outcomes for lung
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cancer patients [4]. The genetic instability that character-
ises lung cancer can occur in the chromosomes, nucleo-
tides, and in the transcriptome. These alterations arise in
proto-oncogenes, tumour suppressor genes, DNA repair
genes, etc. For example, the activation of the TERT gene,
that codifies the catalytic sub-unit of telomerase, is present
in 80 % of NSCLC and almost all SCLC cases [5].
Mutations of the genome guardian gene TP53 are detected
in 50–70 % of NSCLC and over 75 % of SCLC [6].
Amplifications of the EGFR and PI3KCA genes are more
frequent in SCC and mutations of the KRAS and LKB1
genes are more common in adenocarcinomas. In addition,
more frequent in adenocarcinomas is the ALK-EML4 gene
fusion [6], although a number of new gene mutations in
lung cancer are being identified [7]. The discovery and
further research of these alterations have allowed the
development of specific drugs, such as kinase inhibitors
and monoclonal antibodies, which improved survival of
lung cancer patients, highlighting the importance of the
molecular characterisation of lung tumours to improve
detection, treatment and better outcome of these patients.
Regardless of the advances that have been made, a grand
majority of lung cancers is still diagnosed at advanced
disease stages when curative therapeutic options are no
longer successful. This fact is demonstrated by one of the
lowest 5-year survival rates among cancers with 15 %,
making it necessary to uncover new diagnostic biomarkers
and therapeutic targets that could assist in the early diag-
nosis and treatment of lung cancer [3].
In the last several years, genomic and proteomic tech-
nologies have begun to reveal the molecular complexity of
lung tumours by allowing a rapid and complete analysis of
the genes and proteins that are expressed in the context of
this disease. The use of genomic technologies such as
microarrays and quantitative RT-PCR on lung cancer has
generated a great deal of knowledge. It has allowed the
separation of adenocarcinoma patients into new molecular
sub-classes with different outcomes, the early identification
of high risk patients, and the detection of molecular sig-
natures associated with metastasis, among many more
discoveries that improve patient management and treat-
ment [4]. While genomics has provided a great deal of
information on lung cancer biology, the proteomic
approach opens a new window to the better understanding
of this disease, given that the direct evaluation of the
expressed proteins offers information that is not obtainable
through the study of DNA and RNA. The phenotype of a
cell is determined by proteins and RNA levels are often
poorly correlated with protein expression [8]. Furthermore,
common post-translational modifications, such as phos-
phorylation and glycosylation, go undetected in genomic
studies in spite of their importance in the modification of
protein function and in the phenotype of a cell or tissue [8].
In conclusion, the new proteomic technologies that allow
the analysis of thousands of cancer-related proteins will
improve the knowledge of lung cancer biology and path-
ogenesis, and aid in the development of new early detec-
tion biomarkers and the identification of protein profiles
associated with prognosis and drug resistance. This review
describes the current proteomic approaches to the study of
lung cancer and also the so far discovered proteomic bio-
markers for this disease.
Proteomics in lung cancer: technologies and samples
The major proteomic approaches typically involve elec-
trophoresis and/or chromatography combined with chemi-
cal or metabolic labelling and mass spectrometry (MS)
analysis. It is important to recognise that all of them have
advantages and disadvantages and that, when choosing a
proteomic method, one must consider the most suitable for
the sample and hypothesis at study.
Gel-based proteomics
Two-dimensional gel electrophoresis (2D-PAGE) has been
the preferred method for proteomic analysis given its rel-
ative low cost and high applicability. It allows proteins to
be separated by two dimensions. Briefly, in the first
dimension (isoelectric focusing) solubilised, denatured
proteins are separated by their isoelectric point in a poly-
acrylamide gel strip with a specific pH range. Then, the
focused strip is placed on a sodium dodecyl sulphate
polyacrylamide gel (SDS-PAGE) to allow the separation of
the focused proteins by molecular weight. Proteins gener-
ate spots than can be identified by comparison with gel
maps in databases, by western blot, or by MS. This tech-
nique can separate complex samples with good resolution
and allows the comparison of multiple gels. Nonetheless,
limitations include a small sensitivity to very low or very
high molecular weight proteins and isoelectric points,
samples with high salt contents, the under-representation of
membrane proteins, and gel-to-gel variation [9, 10]. A
variation of 2D-PAGE is two-dimensional difference gel
electrophoresis (2D-DIGE). It allows the marking of pro-
teins from a test, control, and reference sample with fluo-
rescent dyes (Cy3, Cy5, and Cy2) that are mixed together
before 2D-PAGE. Although the disadvantages when com-
pared to 2D-PAGE remain the same, advantages include
the analysis of different samples in the same gel, the
evaluation of quantitative differences in the same gel, and
the use of the reference sample that can reduce gel-to-gel
variation [10]. At the final stage of these two methods,
protein spots are digested with trypsin prior to their MS
analysis. The use of two-dimensional alternative separation
672 Clin Transl Oncol (2013) 15:671–682
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methods such as liquid chromatography (LC) has become
popular given its ability to separate and allow the prior MS
identification of complex samples. Typically samples are
digested and the resulting peptides are separated by LC,
with the resulting fractions being analysed by MS [11].
Multidimensional protein identification technology (Mud-
PIT) uses high-performance LC to separate peptides online
with the ion source of the mass spectrometer, allowing the
separation and identification of peptides [12].
Isotope labelling proteomics
Developed to allow protein quantitation in a gel-free set-
ting, isotope labelling techniques involve the metabolic
incorporation of the labels in vivo in cell cultures or the
global labelling of samples before or after protein
digestion.
Stable isotope labelling with amino acids in cell culture
(SILAC) is, as the name states, based on the metabolic
incorporation of ‘‘heavy’’ and ‘‘light’’ forms of amino acids
into the proteins of living cultured cells [13]. Typically,
heavy (13C or 15N) arginine or lysine are used in the
culture medium of a cell culture, while the other cell cul-
ture is supplied with regular amino acids, allowing these
amino acids to be incorporated into the newly synthesised
proteins. Following trypsin digestion, peptides are analysed
by MS and the light and heavy peptides appear in two
distinct peaks and, by comparing the signal intensities
differences, relative quantitation is achieved. Isotope-
coded affinity tags (ICAT) are generally used to compare
pairs of samples. Extracted proteins are labelled with the
light or heavy ICAT reagent, mixed, trypsin digested,
fractionated, and analysed by MS [14]. Isobaric tags for
relative and absolute quantitation (iTRAQ) can analyse 4–8
samples (4-plex, 8-plex) in the same experiment. After
trypsin digestion, samples are independently labelled with
the iTRAQ reagent. During MS analysis, the reporter
groups of the iTRAQ reagents separate from the peptides
and generate small fragments for each sample with mass-
to-charge (m/z) of 114, 115, 116, and 117 for 4-plex, plus
113, 118, 119, and 121 for 8-plex. The intensity of each
peak correlates with the quantity of each reporter group and
thus with the quantity of the peptide [15].
MS based proteomics
The MS analysis of proteins and peptides provides the
accurate measurement of their molecular weight and
charge (m/z ratio) that allows their identification. In order
to obtain these measurements, samples are ionised by the
ion source and travel through a mass analyser and then to a
mass detector [16]. Two ionisation methods are the most
commonly used: matrix-assisted laser desorption ionisation
(MALDI) and electrospray ionisation (ESI). In the first one,
proteins or peptides are mixed with an energy-absorbing
matrix, dried on a metal plate, and then blasted by a laser
that ionises the sample [10]. With ESI, the sample is
introduced in a liquid form and pumped through a capillary
tube at high voltages, resulting in a fine spray [16].
Advantages of MALDI include easy and rapid data anal-
ysis, high resolution for large molecules, and sensitivity to
small amounts of sample. However, small molecules may
not be detected [9, 10, 16]. Ionisation by ESI allows the
interface with LC, has a large mass range, however, it is
more susceptible to contamination and requires more
maintenance [9]. A variation of the MALDI method is the
surface-enhanced laser desorption/ionisation (SELDI)
method where chromatographic chip arrays selectively
bind subsets of proteins from a complex sample. It allows a
wider proteome coverage and quantitative information on a
large number of proteins. Nonetheless, it is technically
demanding and most samples require trypsin digestion
prior to their inclusion in the chips [10]. After this step,
ionised samples pass through a mass analyser that separate
ions according to their m/z ratio and the most commonly
used are time-of-flight (TOF), Fourier transform, and ion
traps (quadrupole -Q, linear quadrupole -LTQ, Orbitrap)
[16]. The addition of a second mass analyser (tandem mass
spectrometry or MS/MS) results in the identification of the
amino acid sequence of peptides. The obtained data is then
compared against protein sequence databases to allow
protein identification [9].
Samples for lung cancer proteomic studies
The lung is a heterogeneous organ composed by many
different cell types (bronchial, alveolar, inflammatory) and
vascular structures. Its main function is to perform gas
exchanges between the atmosphere and the bloodstream.
When studying lung cancer with proteomic tools, several
different samples can be used: lung tissue, blood (serum or
plasma), pleural effusions, and also urine [17].
Lung cancer tissue samples, either fresh-frozen or par-
affin-embedded, are the ultimate sample for any type of
cancer research. Nonetheless, the presence of adjacent non-
tumour cells, inflammatory cells and stromal components,
among others, can result in non-tumour protein contami-
nation. Using laser micro-dissection or a larger number of
samples, this issue might be overcome. In addition, tissue
samples from early disease stages are not easily obtained.
The accessibility of blood makes it a great sample for lung
cancer proteomic studies. Analysis of plasma or serum
assumes that the perfusion of tumours or host response
contributes to the modification of circulating proteins and
peptides, and that tumour-derived proteins may be in cir-
culation. However, due to the abundance of plasma
Clin Transl Oncol (2013) 15:671–682 673
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proteins, depletion of these proteins is necessary to reveal
the presence of less abundant ones, the ones likely to be
tumour-specific markers [11]. Pleural effusion is the path-
ological accumulation of fluid that occurs in inflammatory
conditions and in the lung cancer setting. In this case,
pleural effusions are often drained to search for cancer cell
infiltration. It has a similar protein composition to that of
plasma, but its proximity to tumour cells makes it useful
for lung cancer biomarker detection by proteomic tech-
niques. Bronchoalveolar lavage fluid and induced sputum
are also good samples, closely reflecting the content of the
lungs, nonetheless, their use has been so far limited to the
study of non-malignant conditions [18, 19]. More recently,
urine has been receiving attention as a potential sample,
given its non-invasive collection and also because urine
protein composition can demonstrate changes in the cir-
culatory system. The urinary proteome, usually applied to
proteomic studies of the kidney and urinary tract related
diseases, can also be used in non-urogenital diseases such
as lung cancer [20] In addition, one proteomic study
making use of saliva was also conducted [21].
Proteomic biomarkers in lung cancer
This section describes the potential diagnostic, prognostic,
and predictive biomarkers revealed by proteomic tech-
niques using biological lung cancer samples and that were
subsequently validated by western blot, immunohisto-
chemistry, or enzyme-linked immunosorbent assay
(ELISA), or using another group of samples.
Diagnostic
The identification of a lung cancer diagnostic biomarker
requires that the protein in question must be specific and
directly correlated with the presence of the disease. The
majority of studies have performed a comparison between
the protein profiles of tumour samples and normal lung
samples. We have divided the performed proteomic studies
according to the histological type of lung cancer used for
the study.
The following proteomic studies did not discriminate
between the different lung cancer histological subtypes,
giving a broad idea of the main molecular alterations that
occur between the patients with lung cancer and healthy
subjects. Proteomic studies involving tissue samples from
lung cancer patients have identified a great number of
differentially expressed proteins when compared to control
samples. The macrophage migration inhibitory factor
(MIF), cyclophilin A (CyP-A) [22], CD98, fascin, poly-
meric immunoglobulin receptor/secretory (PIGR), 14-3-3
g [23], thymosin b4 (TMSB4), ubiquitin, acyl-coA binding
protein (ACBP), cystatin A (CSTA), and cytochrome C
[24] were identified as lung cancer diagnostic tissue bio-
markers. The MIF and 14-3-3 g proteins have been known
to have an important role in the carcinogenic process: the
first one is a pro-inflammatory cytokine and its expression
correlates with the levels of several angiogenic chemokines
and a higher vessel density in lung cancer tissue, and the
14-3-3 g protein regulates many cellular processes that are
important in cancer biology [23, 25]. The use of tissue and
serum from lung cancer, other cancers and healthy indi-
viduals, allowed the identification of ubiquitin carboxy-
terminal hydrolase L1 (UCH-L1) as a possible diagnostic
biomarker for lung cancer [26].
Lung cancer proteomic studies that made use of serum
and plasma samples have identified different sets of pro-
teins such as leucine-rich alpha-2-glycoprotein (LRG1),
inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4),
plasma retinol-binding protein (plasmaRBP), complement
component C4 and C3, prothrombin [27] haptoglobin (HP)
[27–29], carcinoembryonic antigen (CEA), RBP, a-1-
antitrypsin (A1AT), transferrin (TF), squamous cell carci-
noma antigen 1 (SCCA1) [29], chaperonin, haemoglobin
[30], and serum amyloid A (SAA) [30–32] as over-
expressed and characteristic of lung cancer samples. The
most often identified proteins were acute phase reactant
proteins, which are produced in response to inflammation,
and can, therefore, have altered levels in the tumour
microenvironment. Haptoglobin is an acute phase protein
that has angiogenic and antioxidant properties, and has an
important role in cell migration [28]. The SAA protein,
also an acute phase protein, is secreted into circulation in a
number of inflammatory and malignant conditions. It is
involved in the transport of cholesterol to the liver, the
recruitment of immune cells, and the induction extracel-
lular matrix degrading enzymes [31]. Decreased levels of
transthyretin (TTR), identified in serum by SELDI–TOF–
MS, were detected in lung cancer samples in comparison to
benign lung diseases and healthy subjects [33].
Other sample types, such as pleural effusions and saliva
have been used with the purpose of finding diagnostic lung
cancer biomarkers. A 1D-PAGE–LC–ESI–MS/MS meth-
odology in pleural effusions from lung cancer patients and
non-malignant conditions, identified higher alpha-2-
HSglycoprotein (AHSG) and insulin-like growth factor-
binding protein 2 (IGFBP2) levels in malignant pleural
effusions compared to non-malignant ones [34]. A recent
study using 2D-DIGE, MALDI–TOF-MS, and LC–MS/MS
identified HP, calprotectin, and zinc-a-2-glycoprotein
(AZGP1) as capable of discriminating lung cancer from
healthy controls with high specificity and sensitivity [21].
Several studies on SCLC samples have revealed diag-
nostic biomarkers for this type of lung cancer that could be
helpful in the detection of this aggressive malignancy.
674 Clin Transl Oncol (2013) 15:671–682
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Using distinct proteomic techniques on tumour tissue
samples, several proteins were identified: b-tubulin, heat
shock protein 73 (HSP73), HSP90, lamin B, proliferating
cell nuclear antigen (PCNA) [35], coactosin-like protein-1
(COTL-1), gamma actin (ACTG1), alpha tubulin, laminin
B (LAMB1), UCH-L1, ubiquitin-conjugating enzyme E2
(UBE2), carbonic anhydrase 1 (CA1) [36], and stathmin
(STMN1) [37] were found to be over-expressed in SCLC
tissue samples, while calcyclin (S100A6) was under-
expressed when compared to adjacent normal tissue [38].
Lastly, HP was identified as a marker for SCLC in serum
samples [39]. Some of the identified proteins, such as HSPs
and CA, have an important role in cancer development.
Heat shock proteins are known for stabilising many
oncogenic and growth promoting proteins in cancer cells
[40]. Carbonic anhydrases have an important role in
maintaining the pH homeostasis. Extracellular acidification
has been associated with many tumour progression effects
and CA inhibitors may suppress the invasion capacity of
malignant cell lines [41].
Similarly, the use of NSCLC samples has also revealed
interesting diagnostic biomarkers. These could be used to
improve detection of the most common form of lung can-
cer. Studies that do not differentiate the histological sub-
types of NSCLC have identified alpha enolase (ENO1)
[42], peroxiredoxin 1 (PRDXI), PRDX3, thioredoxin
(TXN) [43], coatomer protein complex subunit gamma
(COPG), PRDX4, thymopoietin (TMPO) [44], MIF [45],
TMSB4, TMSB10, ribosomal protein L39 and S30,
S100A6, and histone H2A.2 [46] as over-expressed in
NSCLC tissue samples. In the same samples, the proteins
transgelin (TAGLN), HSP20-like protein, CA, selenium
binding protein 1 (SELENBP1), alloalbumin venezia [42],
and polymerase I and transcript release factor (PTRF or
cavin-1) [45] were found to be under-expressed in NSCLC.
Peroxiredoxins are a group of antioxidant enzymes that
also control cytokine-induced peroxide levels. Their up-
regulation in lung cancer may compensate the increased
ROS formation owing to elevated mitochondrial respira-
tion and the higher energy requirements of proliferating
lung cancers [42]. The use of serum samples in NSCLC
proteomic studies revealed the over-expression of SAA and
HP, compared to healthy individuals [47, 48]. A 2D-
DIGE–MALDI–TOF–MS study on pleural effusion and
serum from NSCLC and benign lung diseases patients
revealed that pigment epithelium-derived factor (PEDF),
gelsolin, and metalloproteinase inhibitor 2 (TIMP2) were
over-expressed, and that S100A8 and S100A9 were under-
expressed in cancer samples [49]. The analysis of urine and
also tissue from lung cancer patients and healthy subjects
by 1D-PAGE-nano HPLC–MS/MS found that LRG1 was
expressed at higher levels in urinary exosomes and lung
tissue of NSCLC patients [50]. The proteomic analysis of
the different histological subtypes of NSCLC has focused
mainly on adenocarcinoma and SCC.
The study of adenocarcinoma compared to healthy
controls or other lung diseases might reveal important
markers for this heterogeneous subtype and currently the
most commonly diagnosed NSCLC. The proteomic eval-
uation of adenocarcinoma tissue revealed several over-
expressed proteins, such as PRDX4, ATP synthase subunit
delta (ATP5D), beta 1,4-galactosyltransferase, cytosolic
inorganic pyrophosphatase, glutathione S-transferase Mu 4
(GSTM4), glucose-related Mr 58000 protein, propyl-4-
hydrolase beta subunit (P4HB), triose-phosphate isomerase
(TIM), UCH-L1 [51], CyP-A, TAGLN, TAGLN2 [52],
14-3-3 r (stratifin—SNF), which has been directly impli-
cated in the aetiology of human cancer, annexin 1
(ANXA1), an anti-inflammatory response protein, manga-
nese superoxide dismutase (SOD2) [53], cofilin-1 (CFL1),
and pyruvate kinase M2 (PKM2) [54]. The over-expression
of immunoglobulin lambda chain, transthyretin (TTR)
monomer, HP, and two isoforms of the SAA protein, and
the down regulation of a fragment of apolipoprotein A-I
(APO-AI) were detected in serum samples from lung
cancer adenocarcinoma subjects [55]. Pernemalm and
colleagues used iTRAQ-LC–MS/MS to analyse pleural
effusion and plasma samples from adenocarcinoma
patients and inflammatory pleuritis patients. This strategy
revealed the under-expression of a-2-macroglobulin
(A2M), tetranectin (CLEC3B), cystatin-C precursor, EGF-
containing fibulin-like extracellular matrix protein 1 (EF-
EMP1), gelsolin, and vascular cell adhesion protein 1
(VCAM1), and the over-expression of keratin type II
cytoskeletal 8 (CK8), A1AT, and epididymal secretory
protein E1 (NPC2) in lung cancer samples [56]. Urine
samples from adenocarcinoma and normal individuals
were compared by 1D-PAGE–HPLC–MS/MS revealing
clusterin (CLU), kallikrein 1 (KLK1), gelsolin, LRG1, and
a-1-antichymotrypsin (AACT) as proteins of importance to
adenocarcinoma diagnosis [20].
The proteomic evaluation of SCC patients could provide
useful biomarkers for the second most commonly diag-
nosed NSCLC subtype. Considering studies assessing tis-
sue samples from SCC patients, several proteins were
found to be over-expressed. They were ENO1, pre-B cell-
enhancing factor precursor (PBEF), TIM, phosphoglycer-
ate mutase 1 (PGAM1), fructose-biphosphate aldolase A
(ALDOA), guanine nucleotide-binding protein subunit
beta-like protein (GBN1L) [57] and HSPB1, that prevents
stress-induced cellular damage and is elevated in multiple
cancer types, S100A8 and S100A9 [58] and HSP60, that
plays an important role in regulating cell differentiation
and proliferation, ANXA5 and ANXA6, ACTG1 [59] and
isocitrate dehydrogenase 1 (IDH1), which play a role in the
antioxidant system by producing NADPH, SOD2, SNF,
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PRDX2, and receptor of activated protein kinase 1 [60].
Five proteins were found to be under-expressed in the same
samples: creatine kinase B (CKB), SCCA1 as down-regu-
lated [58], cathepsin D preprotein (CTSD), ferritin heavy
chain (FTH1), and ANXA3 (under-expressed) [59]. The
identified annexins in these proteomic studies have a
potential role in cellular signal transduction, exocytosis,
inflammation, coagulation, cellular growth and differenti-
ation. Using tissue and serum from SCC and healthy
individuals, Yang and co-workers detected an increase in
autoantibodies against TIM and SOD2 that could aid in the
diagnosis of this type of lung cancer [61]. Finally, by
comparing serum from SCC patients and controls, five
over-expressed (HP, APO-A4, complement component
C3c, SAA, and Ras-related protein 7B—RAB7B) and five
under-expressed (AHSG, hemopexin precursor—HPX,
proapolipoprotein, antithrombin III—SERPINC1, and
CLU) proteins were identified and were able to distinguish
SCC patients [62].
A summary of the most recurrently identified diagnostic
biomarkers on lung cancer tissue samples and in fluid
samples can be found on Tables 1 and 2, respectively.
Prognostic
When the expression levels of a protein correlate with the
natural history of the disease they are considered to have
prognostic value. The study of prognostic biomarkers in
lung cancer has been made by correlating the expression of
a molecule to the patient survival. An alternative approach
is to compare groups of patients with different clinical
stages of disease, based on the assumption that a more
advanced tumour is more aggressive and may express
proteins that drive the metastatic process. The published
proteomic studies that have focused on finding prognostic
biomarkers for lung cancer have only made use of samples
from NSCLC patients as a whole or in separate as adeno-
carcinoma or SCC patients.
The grand majority of studies using samples from
NSCLC patients were performed using tissue. The proteins
small ubiquitin-related modifier-2 protein (SUMO-2),
TMSB4, and ubiquitin were identified in a 15 MS peak
profile that distinguished between patients with resected
NSCLC who had poor or good prognosis [63]. Using a
similar approach, 25 proteins (not all identified, but
including TMSB4, TMSB10, ribosomal protein L39 and
S30, S100A6, and histone H2A.2) were associated with
survival among NSCLC patients and appeared to distin-
guish those with poor prognosis from those with good
prognosis [46]. In a different study, the levels of TMSB4,
TMSB10, and calmodulin were also associated with patient
survival. In addition, low levels of CFL1 were associated
with better outcome for patients with negative lymph nodes
and high levels of CFL1 with better outcome for those with
positive lymph nodes [64]. TMSB4 is a regulator of actin
polymerisation whose over-expression seems to stimulate
lung tumour metastasis [64]. Improved survival of NSCLC
was additionally associated with the levels of S100A6 [65].
The S100 proteins are involved in the regulation of a
number of cellular processes such as cell cycle progression,
differentiation, and also inflammation.
Proteomic studies of adenocarcinoma tissue samples
identified CFL1, an actin-modulating protein that is
increased in some invasive cancers, and PKM2, a key
glycolytic enzyme during tumorigenesis, as associated
with poor prognosis in adenocarcinoma patients [54]. The
comparison between adenocarcinoma and adjacent lung
tissue revealed that specific isoforms of CK7, 8, 18, and
19 were associated with patient survival [66]. Cytoskel-
etal reorganization is a central process regulating cell
migration and metastasis, and CKs, a family of cyto-
skeletal intermediate filaments, have been suggested to
play a role in carcinogenesis, by promoting cellular
architecture reorganisation during tumour development
and progression. Another adenocarcinoma study associ-
ated the expression of phosphoglycerate kinase 1 (PGK1),
HSP70, CK19, PGAM1, and G protein-coupled receptor 4
(GRK4) with poor survival [67]. Several annexins
(ANXA1, ANXA2, and ANXA3) were associated with
advanced clinical stage, by presenting higher expression
levels in lymph node metastatic tissue [68, 69]. The
deregulation of annexins has been reported in numerous
cancers and is thought to influence the patterns of cellular
behaviour, such as cell proliferation, motility, invasive-
ness and signalling pathways. Finally, Maeda and col-
leagues revealed that the absence of expression of LC–
MS/MS identified myosin IIA and vimentin, two proteins
associated with the cytoskeleton and cell motility, corre-
lated with good prognosis in adenocarcinoma patients
who did not receive post-operative adjuvant chemother-
apy, indicating that these patients do not require such
treatment [70].
Considering SCC proteomic studies searching for
prognostic biomarkers, the previously identified IDH1
protein was associated with poor overall survival [60]. The
evaluation of micro-dissected primary SCC and matched
lymph node metastatic tissues revealed the under-expres-
sion of SNF in lymph node metastatic tumour versus pri-
mary SCC [71]. Yao and co-workers compared tissue from
SCC with and without lymph node metastasis. The
ANXA2, HSP27, and CK17 proteins were over-expressed
in metastatic SCC, and SNF was under-expressed in these
tissues [72]. A summary of these potential prognostic
biomarkers can be found on Table 3.
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Table 1 Candidate proteomic diagnostic biomarkers for lung cancer identified in tissue samples
Diagnostic biomarker Lung cancer type Proteomic technique
S100
A6 SCC MALDI–TOF–MS [38]
NSCLC MALDI–MS [46]
A8 SCC iTRAQ, LC-Q-MS/MS [58]
A9 SCC iTRAQ, LC-Q-MS/MS [58]
SCCA1 (squamous cell carcinoma antigen 1) SCC iTRAQ, LC-Q-MS/MS [58]
Cystatin A Lung cancer MALDI–TOF–MS [24]
Tubulin (a, b) SCLC 2D-PAGE; 2D-PAGE, MALDI–TOF–MS [35, 36]
UCH-L1 (ubiquitin carboxy-terminal hydrolase
L1)
Lung cancer 2D-PAGE, MALDI–TOF–MS [26]
SCLC 2D-PAGE, MALDI–TOF–MS [36]
Adenocarcinoma 2D-PAGE, MALDI–MS [51]
Peroxiredoxin
PRDX4 NSCLC,
Adenocarcinoma
1D-LC–ESI–MS/MS [44]; 2D-PAGE, MALDI–MS [51]
PRDX1 NSCLC 2D-PAGE [43]
PRDX2 SCC 2D-DIGE, MALDI–TOF–TOF [60]
PRDX3 NSCLC 2D-PAGE [43]
PRDX6 SCC 2D-PAGE, MALDI–TOF–MS [61]
TIM (triose-phosphate isomerase) Adenocarcinoma 2D-PAGE, MALDI–MS [51]
SCC 2D-PAGE, MALDI–TOF–MS [57, 61]
MIF (macrophage migration inhibitory factor) Lung cancer MALDI–TOF–MS [22]
NSCLC MALDI–TOF–MS; IMAC, LC–MS/MS [24, 45]
CyP-A (Cyclophilin A) Lung cancer MALDI–TOF–MS [22]
Adenocarcinoma 2D-DIGE, LC–MS/MS [52]
TAGLN (Transgelin) NSCLC 2D-PAGE, MALDI–TOF–MS [42]
Adenocarcinoma 2D-DIGE, LC–MS/MS [52]
CA (Carbonic anhydrase) SCLC 2D-PAGE, MALDI–TOF–MS [36]
NSCLC 2D-PAGE, MALDI–TOF–MS [42]
ENO1 (Alpha enolase) NSCLC 2D-PAGE, MALDI–TOF–MS [42]
SCC 2D-PAGE, MALDI–TOF–MS [57, 61]
14-3-3
g Lung cancer 1D-PAGE, nanoESI–MS/MS [23]
r (SNF) Adenocarcinoma 2D-PAGE, MALDI–TOF–MS, Q-TOF–MS/MS [53]
SCC 2D-DIGE, MALDI–TOF–TOF [60]
SOD2 (Superoxide dismutase 2) Adenocarcinoma 2D-PAGE, MALDI–TOF–MS, Q-TOF–MS/MS [53]
SCC 2D-DIGE, MALDI–TOF–TOF; 2D-PAGE, MALDI–TOF–MS
[60, 61]
Heat shock protein
HSP73 SCLC 2D-PAGE [35]
HSP90 SCLC 2D-PAGE [35]
HSP20-like NSCLC 2D-PAGE, MALDI–TOF–MS [42]
HSP70 SCC 2D-PAGE, MALDI–TOF–MS [61]
HSP60 SCC 2D-PAGE, MALDI–TOF–MS [59, 61]
HSP27 SCC iTRAQ, LC-Q-MS/MS [58]
Annexin
ANXA1 Adenocarcinoma 2D-PAGE, MALDI–TOF–MS, Q-TOF–MS/MS [53]
ANXA2 SCC 2D-PAGE, MALDI–TOF–MS [61]
ANXA3 SCC 2D-PAGE, MALDI–TOF–MS [59]
ANXA5 SCC 2D-PAGE, MALDI–TOF–MS [59]
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Table 1 continued
Diagnostic biomarker Lung cancer type Proteomic technique
ANXA6 SCC 2D-PAGE, MALDI–TOF–MS [59]
ACTG1 (Gamma actin) SCLC 2D-PAGE, MALDI–TOF–MS [36]
SCC 2D-PAGE, MALDI–TOF–MS [59]
Thymosin
b4 Lung cancer MALDI–TOF–MS [24]
NSCLC MALDI–MS [46]
b10 NSCLC MALDI–MS [46]
CFL1 (Cofilin-1) Adenocarcinoma 2D-PAGE, ESI-Q-TOF–MS/MS [54]
NSCLC non-small cell lung cancer, SCLC small cell lung cancer, SCC squamous cell carcinoma
Table 2 Candidate proteomic diagnostic biomarkers for lung cancer identified in fluid samples
Diagnostic biomarker Sample type Lung cancer
type
Proteomic technique
CLU (Clusterin) Urine Adenocarcinoma 1D-PAGE, HPLC–MS/MS [20]
Serum SCC 2D-DIGE, MALDI–TOF–MS [62]
Gelsolin Urine Adenocarcinoma 1D-PAGE, HPLC–MS/MS [20]
Serum NSCLC 2D-DIGE, MALDI–TOF–MS [49]
Pleural effusion,
plasma
Adenocarcinoma iTRAQ, LC–MS/MS [56]
LRG1 (leucine-rich alpha-2-
glycoprotein)
Urine Adenocarcinoma 1D-PAGE, HPLC–MS/MS [20]
Serum Lung cancer 2D-DIGE, LC–MS/MS [27]
Urine NSCLC 1D-PAGE, nanoHPLC-MS/MS [50]
SAA (Serum amyloid A) Serum Lung cancer SELDI–TOF–MS; MALDI–MS [30, 32]
NSCLC MALDI–TOF–MS [48]
Adenocarcinoma 2D-PAGE, MALDI–TOF–PMF [55]
SCC 2D-DIGE, MALDI–TOF–MS [62]
Pleural effusion,
serum
Lung cancer 1D-PAGE, LC–ESI–MS/MS [31]
HP (haptoglobin) Serum Lung cancer 2D-DIGE, LC–MS/MS; 2D-DIGE, MALDI–TOF–MS
[27, 29]
SCLC SDS–PAGE, MALDI–TOF–MS [39]
NSCLC 2D-DIGE, MALDI–TOF/TOF [47]
Adenocarcinoma 2D-PAGE, MALDI–TOF–PMF [55]
SCC 2D-DIGE, MALDI–TOF–MS [62]
Plasma, serum Lung cancer 1D-PAGE, LC–ESI–MS/MS [28]
Saliva Lung cancer 2D-DIGE, MALDI–TOF–MS, LC–MS/MS [21]
TTR (Transthyretin) Serum Lung cancer SELDI–TOF–MS [33]
Adenocarcinoma 2D-PAGE, MALDI–TOF–PMF [55]
Complement component
C4 Serum Lung cancer 2D-DIGE, LC–MS/MS [27]
C3, C3c Lung cancer,
SCC
2D-DIGE, LC–MS/MS [27]; 2D-DIGE, MALDI–TOF–
MS [62]
A1AT (a-1-antitrypsin) Serum Lung cancer 2D-DIGE, MALDI–TOF–MS [29]
Pleural effusion,
plasma
Adenocarcinoma iTRAQ, LC–MS/MS [56]
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Table 2 continued
Diagnostic biomarker Sample type Lung cancer
type
Proteomic technique
Apolipoprotein
A1 Serum Adenocarcinoma 2D-PAGE, MALDI–TOF–PMF [55]
A4 SCC 2D-DIGE, MALDI–TOF–MS [62]
CK8 (Cytokeratin 8) Pleural effusion,
plasma
Adenocarcinoma iTRAQ, LC–MS/MS [56]
AHSG (alpha-2-HSglycoprotein) Pleural effusion Lung cancer 1D-PAGE, LC–ESI–MS/MS [34]
Serum SCC 2D-DIGE, MALDI–TOF–MS [62]
S100A8 and S100A9 Pleural effusion,
serum
NSCLC 2D-DIGE, MALDI–TOF–MS [49]
SCCA1 (Squamous cell carcinoma
antigen 1)
Serum Lung cancer 2D-DIGE, MALDI–TOF–MS [29]
Cystatin C3 Pleural effusion Lung cancer 1D-PAGE, LC–ESI–MS/MS [34]
Pleural effusion,
plasma
Adenocarcinoma iTRAQ, LC–MS/MS [56]
NSCLC non-small cell lung cancer, SCLC small cell lung cancer, SCC squamous cell carcinoma
Table 3 Candidate proteomic prognostic biomarkers for lung cancer
Prognostic biomarker Sample type Lung cancer
type
Proteomic technique
S100A6 Tissue NSCLC MALDI–MS [46]
Tissue, plasma, pleural
effusion
NSCLC SELDI–TOF–MS [65]
Thymosin
b4 Tissue NSCLC MALDI–MS; MALDI–TOF–MS [63, 64]
b10 NSCLC MALDI–MS; MALDI–TOF–MS [46, 64]
CFL1 (Cofilin-1) Tissue NSCLC MALDI–TOF–MS [64]
Adenocarcinoma 2D-PAGE, ESI-Q-TOF–MS/MS [54]
IDH1 (isocitrate
dehydrogenase 1)
Tissue SCC 2D-DIGE, MALDI–TOF–TOF [60]
Cytokeratin
CK7, CK8, CK18 Tissue Adenocarcinoma 2D-PAGE, MALDI–TOF–MS [66]
CK19 Adenocarcinoma 2D-PAGE, MALDI–TOF–MS; 2D-PAGE [66, 67]
SCC 2D-DIGE, MALDI–TOF–PMF [72]
Heat shock protein
HSP70 Tissue Adenocarcinoma 2D-PAGE, MALDI–MS [51]
HSP27 SCC 2D-DIGE, MALDI–TOF–PMF [72]
Annexin
ANXA1 Tissue Adenocarcinoma 2D-DIGE, MALDI–TOF–PMF [69]
ANXA2 Adenocarcinoma 2D-DIGE, MALDI–TOF–PMF [69]
SCC 2D-DIGE, MALDI–TOF–PMF [72]
ANXA3 Adenocarcinoma 2D-DIGE, MALDI–TOF–MS; 2D-DIGE, MALDI–TOF–
PMF [68, 69]
Myosin IIA Tissue Adenocarcinoma LC–MS/MS [70]
Vimentin
SNF (14-3-3 r) Tissue SCC 2D-PAGE, MALDI–TOF–MS; 2D-DIGE, MALDI–TOF–
PMF [71, 72]
NSCLC non-small cell lung cancer, SCC squamous cell carcinoma
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Predictive
A good predictive biomarker can anticipate the efficacy of
a specific treatment. It aims at individualising therapies in
lung cancer and studies have been based on studying
clinical samples from responding and non-responding
patients and then validating results on selected cohorts.
Proteomic studies developed with this purpose have
focused on the response to EGFR inhibitors.
Okano and co-workers analysed lung adenocarcinoma
tissue from patients who showed a different response to
gefitinib treatment by 2D-DIGE–LC–MS/MS. High levels
of fatty acid-binding protein heart (H-FABP) were asso-
ciated with partial and complete responses. This protein
participates in intracellular lipid transport, storage, and
metabolism, in addition to having a possible role in cancer
biology [73]. In addition to this study, a serum MALDI–
MS study conducted by Taguchi and co-workers in NSCLC
patients treated with gefitinib and erlotinib revealed an
8-peak profile predictive of outcome [74]. This 8-peak
signature was commercially launched as a commercial
product (Veristrat, Biodesix, Broom field, CO, USA) and
has been used to discriminate NSCLC patients treated with
combinations of erlotinib, gefitinib, bevacizumab, or ce-
tuximab with good and poor prognosis in a number of
studies [75–82]. The SAA1 protein was recently identified
as part of this proteomic signature [82]. A summary of the
abovementioned predictive biomarkers can be found on
Table 4.
Conclusions
The detection of new biomarkers is of foremost importance
in lung cancer research. The vast majority of lung cancers
are still diagnosed at advanced stages of the disease,
reducing in some cases the available therapeutic options to
only palliative care, resulting in one of the lowest 5-year
survival rates among cancers.
The proteomic field is expanding and the development
of high-throughput technologies has allowed the identifi-
cation of several protein profiles with diagnostic, prog-
nostic, and predictive value for lung cancer. Nonetheless,
it is necessary to take into account several key points
order to consider this proteins as biomarkers. First, an
extensive clinical validation with strict statistical criteria
is required to evaluate these profiles, to reduce the
occurrence of false positive results. Second, large cohorts
of carefully selected patients to determine the actual
usefulness of the biomarkers are necessary. Third, it
would be interesting to study the reproducibility of the
obtained protein profiles and this requires a validation in
different biological samples and different laboratories to
prove their sensitivity. Finally, it is necessary to address
the problems of heterogeneity to the lung cancer patients.
Studies considering the TNM classification, tumour grade,
and demographic characteristics of the population would
be required.
In summary, proteomics technologies are one of the
most powerful tools to expand the repertoire of known
biomarkers for lung cancer early diagnosis, prognosis, and
prediction of response to therapy. Moreover, many of the
identified candidate biomarkers could serve as targets for
more rationale and effective therapeutic strategies due to
their role in tumorigenesis and cancer progression.
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Abstract: Lung cancer (LC) and chronic obstructive pulmonary disease (COPD) 
commonly coexist in smokers, and the presence of COPD increases the risk of developing 
LC. Cigarette smoke causes oxidative stress and an inflammatory response in lung cells, 
which in turn may be involved in COPD and lung cancer development. The aim of this 
study was to identify differential proteomic profiles related to oxidative stress response that 
were potentially involved in these two pathological entities. Protein content was assessed 
in the bronchoalveolar lavage (BAL) of 60 patients classified in four groups: COPD, 
COPD and LC, LC, and control (neither COPD nor LC). Proteins were separated into spots 
by two dimensional polyacrylamide gel electrophoresis (2D-PAGE) and examined by 
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matrix-assisted laser desorption/ionization time of flight mass spectrometry  
(MALDI-TOF/TOF). A total of 16 oxidative stress regulatory proteins were differentially 
expressed in BAL samples from LC and/or COPD patients as compared with the control 
group. A distinct proteomic reactive oxygen species (ROS) protein signature emerged that 
characterized lung cancer and COPD. In conclusion, our findings highlight the role of the 
oxidative stress response proteins in the pathogenic pathways of both diseases, and provide 
new candidate biomarkers and predictive tools for LC and COPD diagnosis. 
Keywords: bronchoalveolar lavage; lung cancer; screening; biomarker; inflammation; 
proteomics; ROS; oxidative stress 
 
1. Introduction  
Cigarette smoking has been recognized as the most important causative factor of COPD and it is 
associated with more than 90% of lung cancer cases [1]. Lung cancer accounts for 12% of all cancer 
diagnoses worldwide, making it the largest cause of cancer-associated death worldwide, accounting for 
more than one million casualties per year worldwide. COPD is also a major independent risk factor for 
lung carcinoma, among long-term smokers. In fact, the presence of COPD increases the risk of lung 
cancer up to 4.5-fold. Indeed, 50%–70% of patients diagnosed with lung cancer have spirometric 
evidence of COPD [2]. Cigarette smoke (CS) contains over 1014 free radicals per puff that include 
reactive oxygen species (ROS) [3]. Inhaled oxidants from smoke generate cellular damage by directly 
targeting proteins, lipids, and nucleic acids, and deplete the level of antioxidants in the lung, thereby 
overwhelming the oxidant/antioxidant balance of the lung, leading to increased oxidative stress [4]. 
ROS can lead to the activation of various cell signaling components. Examples include the 
extracellular signal regulated kinases (ERKs), c-jun N-terminal kinases (JNKs), p38 MAPKs, PKC, 
PI3K/Akt, and growth factor tyrosine kinases receptors pathways, all of which lead to increased 
inflammatory gene transcription. Indeed, oxidative stress in the lungs has been implicated in COPD 
severity and lung carcinogenesis [5]. This process is one of the mechanisms proposed in the common 
pathogenesis of lung cancer and COPD, along with inflammation, epithelial-mesenchymal transition 
(EMT), altered DNA repair, and cellular proliferation [6]. Proteins are important molecular signposts 
of oxidative damage. Different proteomic approaches have been developed and used for the detection 
and identification of ROS related proteins [7]. In the last few years, combined proteomics, mass 
spectrometry (MS), and affinity chemistry-based methodologies have contributed in a significant way 
to provide a better understanding of protein oxidative modifications occurring in various biological 
specimens under different physiological and pathological conditions. Bronchoalveolar lavage (BAL) is 
the clinical biofluid sampling of the soluble proteins contents of the airway lumen. A comparison 
between serum and BAL proteomes reveals that a certain number of proteins are present at a higher 
level in BAL than in plasma, suggesting that they are specifically produced in the airways. These 
proteins are, therefore, potential candidates for becoming lung-specific biomarkers [8]. 2D-PAGE is 
considered one of the best techniques for separation of complex mixtures of soluble proteins [9]. 
Several studies of BAL protein profiles obtained by 2D-PAGE analysis aimed at revealing the 
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differences between smokers and never smokers [10,11] as well as studies directed to determine the 
risk of developing COPD [12–14]. However, to the best of our knowledge, there are no 2D-PAGE 
studies in lung cancer using BAL. The 2D-PAGE studies of LC have been performed mainly in plasma 
and tissue. These analyses have focused on a better understanding of the molecular basis of cancer 
pathogenesis [15–17], as well as on the identification of new diagnostic, prognostic, and predictive 
markers for lung cancer [18,19]. In this regard, analyzing the protein composition of BAL mediated by 
a high-throughput technology, given its vicinity to tumor cells and enrichment in tumor-derived 
proteins, would be insightful. In this study, we have investigated the changes occurring in the 
proteome of BAL samples from lung cancer and/or COPD patients, and found a set of redox regulative 
proteins differentially expressed in each disease. 
2. Results 
2.1. Proteome Profiles of Comparison of LC and/or COPD 
The experiments were performed in BAL samples extracted from a cohort of 60 patients divided 
into four groups (control group and LC and/or COPD groups) whose characteristics are described in 
Table 1. The spots that showed significant increment or reduction of their expression compared to 
control group (neither COPD nor LC) were identified by MALDI-TOF/TOF-MS. The MS/MS data 
were acquired and compared to the Swiss-Prot database using MASCOT software. Candidate proteins 
were selected from each spot, taking into consideration several variables such as isoelectric point, 
molecular mass, matched peptides, and sequence coverage (Figure 1). A total of 123 protein spots 
were successfully identified. Of these, 40 proteins spots had consistent significant differences (>2-fold, 
p < 0.05) between lung cancer and/or COPD groups and the control group. Among them, a major 
group of 16 proteins were oxidative stress regulatory proteins (Table 2). The spots corresponding to 
this group of ROS regulatory proteins are marked on the representative gel 2D image in Figure 1. The 
rest of identified proteins were distributed in other variable groups such as inflammation, glycolysis 
and gluconeogenesis (Data not show).  
Table 1. Patients characteristics.  
 Controls n = 15 COPD n = 15 LC n = 15 LC&COPD n = 15 
Gender     
Male 100.0% (15) 100.0% (15) 100.0% (15) 100.0% (15) 
Female 0.0% (0) 0.0% (0) 0.0% (0) 0.0% (0) 
Average age (range) 61.3 (41–80) 61.5 (45–78) 60.7 (46–69) 60.7 (49–68) 
Smoking status     
Smokers 73.3% (11) 53.3% (8) 53.3% (8) 80.0% (12) 
Ex-smokers 26.7% (4) 46.7% (7) 46.7% (7) 20.0% (3) 
Packs-year 21.82 32.20 35.21 30.78 
COPD     
Mild - 20.0% (3) - 53.3% (8) 
Moderate - 33.3% (5) - 26.7% (4) 
Severe - 26.7% (4) - - 
Very severe - 20.0% (3) - 20.0% (3) 
Histology     
Adenocarcinoma - - 73.3% (11) 66.7% (10) 
Squamous cell carcinoma  - - 26.7% (4) 33.3% (5) 
Abbreviations: COPD: chronic obstructive pulmonary disease; LC: lung cancer. 
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Figure 1. 2D-PAGE from a representative patient sample. A representative 7 cm Sypro 
stained gel of proteins in the non-lineal pH range 3–11.  
 
Venn diagrams were used to display the differentially expressed proteins that were up- or  
down-regulated in each pathological group. Among these, two proteins from the LC patients group 
were found to be up-regulated (CTSD, ERZ,) in comparison with the LC/COPD and COPD groups 
(Figure 2). At the same time, the LC and LC/COPD groups shared one up-regulated protein (PPIA) in 
comparison with the COPD group (Figure 2). Similarly, the COPD and LC/COPD groups shared four 
up-regulated proteins (CAT, PRDX1, PRDX2, and PRDX5) in contrast with the LC group (Figure 2). 
Finally, the three pathological groups shared nine proteins, six of them up-regulated (TXN, CRP, GSR, 
IDH1, SERPINB1, and ARHGDIB), three down-regulated proteins (GSTA1, GSTA2, and GSTP) 
(Figure 2).  
The 15 identified proteins associated with ROS were subsequently analyzed with IPA, a software 
tool capable of mapping proteins and existing networks. Interestingly, the transcriptional factor NF-κB 
was found as a link between the proteins network involving ROS. NF-κB may reflect a functional role 
of this pathway in lung carcinogenesis (Figure 3). 
2.2. Western Blotting 
From the results obtained in the previous section, and taking into account the characteristics 
described in Table 2 for each protein, four proteins (TXN, GSR, GSTA1, and CAT) were selected for 
validation. The western blot of TXN, GSR, GSTA1, and CAT and the corresponding β-actin are 
shown in Figure 4. Validation was performed in three random samples from each study group. The 
results of the western blot experiments indicate that TXN and GSR present similar increment of 
expression between LC and/or COPD groups in comparison with the control group. The GSTA1 
protein showed a decrease of expression in the three pathological groups in comparison with the 
control group. These data confirm the results obtained from initial proteomic analysis. 
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Table 2. Protein spots searched by MASCOT software in database.  
Spot 
no 
Protein name 
Protein 
symbol 
Accession no 
Protein 
MW 
Protein 
PI 
Peptide 
count 
Protein 
score 
Score 
C.I. % 
Total 
ion 
score 
Ion 
C.I. 
% 
COPD LC 
LC/ 
COPD 
1 Catalase CAT gi|4557014 59946.8 6.90 13 310 100 234 100 Up 2.5 -  Up 2.8 
2 Cathepsin D preprotein CTSD gi|4503143 45036.8 6.10 8 135 100 95 100 -  Up 3.0 .  
3 Ezrin EZR gi|46249758 69312.7 5.94 18 250 100 175 100 -  Up 3.0 -  
4 Glutathione reductase GSR gi|119583848 61464.6 8.71 7 131 100 108 100 Up 2.8 Up 3.1 Up 2.0 
5 
Glutathione S-transferase A1 
subunit 
GSTA1 gi|163310943 25628.7 8.72 15 384 100 268 100 Down 3.0 Down 3.2 Down 3.8 
6 
Glutathione S-transferase A2 
subunit 
GSTA2 gi|257476 25589.6 8.81 7 105 100 70 100 Down 2.5 Down 3.0 Down 2.6 
7 Glutathione S-transferase P GSTP1 gi|4504183 23569.1 5.43 10 633 100 541 100 Down 2.2 Down 2.4 Down 2.5 
8 Isocitrate dehydrogenase 1 IDH1 gi|89573979 42091.0 6.19 8 62 100 29 100 Up 2.2 Up 2.1 Up 2.5 
9 Leukocyte elastase inhibitor SERPINB1 gi|13489087 42828.7 5.90 18 403 100 274 100 Up 2.7 Up 2.6 Up 2.5 
10 
Peptidylprolyl isomerase A 
(Cyclophilin A) 
PPIA gi|1633054 18097.9 7.82 10 260 100 159 100 -  Up 2.2 Up 2.6 
11 Peroxiredoxin 1 PRDX1 gi|55959887 19134.7 6.41 8 170 100 98 100 Up 5.0 -  Up 4.2 
12 Peroxiredoxin 5 PRDX5 gi|6166493 22261.6 8.85 11 638 100 537 100 Up 2.3 -  Up 2.4 
13 Peroxiredoxin-2 isoform a PRDX2 gi|32189392 22049.3 5.66 12 451 100 325 100 Up 3.0 -  Up 2.9 
14 Rho GDP-dissociation inhibitor 2 ARHGDIB gi|56676393 23030.6 5.10 7 215 100 170 100 Up 2.9 Up 2.6 Up 2.3 
15 Thioredoxin TXN gi|135772 12345.0 7.93 10 241 100 203 100 Up 2.4 Up 2.3 Up 2.1 
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Figure 2. Venn diagram showing the overlap of up-regulated and down-regulated proteins 
in each pathological group. The up-regulated proteins are represented in black and the 
down-regulated proteins are represented in grey.  
 
Figure 3. Ingenuity Pathway analysis of lung cancer and/or COPD versus controls 
revealed NF-κB as a major foundation. 
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Figure 4. Western blotting for TXN, GSR, GSTA1, and CAT. The different expressions 
are seen in each of the groups and for each of the proteins. TXN and GSR present a similar 
increment of expression in all pathological groups. GSTA1 show a decrease of expression 
in the three pathological groups in comparison with the control group. These differences 
are also illustrated below with a bar chart.  
 
3. Discussion 
In this study, we presented a 2D-PAGE proteomic evaluation of BAL fluid in patients with the two 
most relevant smoking related diseases, lung cancer and COPD. Our results indicate that the protein 
composition of BAL showed relevant expression differences among the groups, especially between the 
control group and the disease groups. In concrete, we have observed 15 differentially expressed 
proteins involved in ROS metabolism.  
ROS are involved in a large number of diseases, degenerative changes, leading to tissue 
degradation, a hallmark in carcinogenesis [20]. In a metabolically active cell, these redox system 
pathways maintain the balance between oxidant and antioxidant factors, by regulating the activation of 
specific transcription factors and the production of substances that neutralize oxidants [21,22]. 
However, in cancer settings, alterations in these redox pathways occur and the cell is no longer able to 
produce antioxidant substances to adjust the balance between oxidant and antioxidant factors, being 
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therefore unable to respond appropriately to the body’s needs. This is usually the reason why many 
anticancer agents, including radiation, are ineffective, because the cytotoxicity induced by them to 
make the cancer regress affects the antioxidant activity of the redox system pathways [23]. Alterations 
in the physiological pathways involved in the regulation of the redox system have been identified in 
tumors [24].  
The proteins TXN and PPIA (Cyclophilin A) were up-regulated in lung cancer BALs as compared 
to the other groups. TXN is a potent growth and cell survival factor, which activates specific 
transcription factors such as NF-κB, p53, HIFa, and AP-1. TXN regulates gene decoding for the 
production of substances that protect cells from oxidative stress induced by oxygen free  
radicals [25,26]. Its expression rises in several types of tumors [27,28] and it is generally related to 
tumor aggressiveness and inhibition of the immune system. TXN has also been evaluated as a 
biomarker and therapeutic target for cancer [29,30], and it is known that TXN levels can be used to 
indicate potential chemotherapy resistance [31]. Indeed, an increase in TXN1 levels has been 
associated with decreased survival in patients with tumors [32]. PPIA is secreted in response to ROS 
from vascular smooth muscle cells (VSMC) [33]. This protein is a chaperone protein that has several 
functions including protein trafficking, such as the nuclear translocation of ERK1/2 [34] and 
apoptosis-inducing factor (AIF) [35]. In addition, there is evidence that PPIA might be a valuable 
biomarker. Several studies evaluating the proteomic profile of different types of cancer as gastric, 
colorectal [36], and prostate have associated PPIA with a favorable outcome.  
The proteins GSTA1, GSTA2, and GSTP1 were down-regulated in pathological groups compared 
with control group. These proteins belong to GST family of proteins, which are Phase II detoxification 
enzymes that catalyze detoxifying endogenous reactions with reduced GSH and protect cellular 
macromolecules from damage caused by cytotoxic and carcinogenic agents [37]. 
A sub-network of interacting peroxiredoxins (PRDX1, PRDX2, and PRDX5) and catalase enzymes 
were up-regulated in the COPD groups. The overexpression of these proteins is protective to cells 
given that they increase life span and decreases injuries that arise from ROS generation [38,39]. In 
addition, the increased levels of PRDX1 in BAL were observed in patients with acute lung injury 
compared with normal subject [40].  
Finally, we have observed several deregulated proteins involved with the second line of defense 
against oxidative stress such as cathepsin D and ezrin. These proteins act when the first defense 
mechanism by non-enzymatic molecules and enzymatic scavengers, such as superoxide dismutases, 
catalase, and glutathione peroxidase, does not work properly against oxidative stress. Cathepsin D has 
been involved in the oxidative stress-induced apoptotic pathways. Furthermore, cathepsin D and ezrin 
are secreted aberrantly and excessively in various types of cancers [41,42], and are associated with 
increased cancer growth, invasion, and metastasis [41–45].  
The re-establishment of homeostasis within the physiological pathways of the redox and 
immunological system is an important therapeutic goal in oncology. For this achievement, the 
identification of adequate biomarkers and molecular targets is essential. One advantage of integrating 
our proteomic approach with network analysis is its potential ability to provide an insight into existing 
molecular mechanisms. The analysis of the proteins found in our study by Ingenuity System Pathway 
Analysis software, in order to identify any common links beyond oxidative stress, revealed NF-κB, an 
important transcription factor, which is a redox-sensitive transcription factor [46,47].  
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NF-κB regulated genes include cytokines, adhesion molecules, angiogenic factors, anti-apoptotic 
factors, and matrix metalloproteinases (MMPs), which are involved in different steps of 
carcinogenesis. It has been suggested that NF-κB promotes lung cancer mainly through mediating 
inflammatory cytokines secretion to establish a cancer-prone inflammatory microenvironment [48]. 
Similarly, NF-κB pathways play a crucial role in the pathogenesis/development of COPD by 
increasing the release of pro-inflammatory mediators leading to chronic inflammation in the lung. In 
bronchial biopsies of airway mucosa from patients with COPD, protein expression of the p65 subunit 
of NF-κB was increased compared with its expression in non-smokers, and correlated with airflow 
obstruction [49]. Our results suggest that oxidative stress induced in lung airways might alter redox 
detoxifying enzymes, which end up activating NF-κB node. This activation might contribute to cancer 
development and therapy resistance. Both chemo and radiation therapies induce NF-κB activation in 
cancer cells, which contributes to resistance to those same therapies [50]. Indeed, inhibition of NF-κB 
signaling by various approaches has been shown to augment the efficacy of chemotherapeutics and 
radiation in killing cancer cells in vitro and in vivo [51,52]. Some of the NF-κB inhibitors that 
enhanced lung cancer cell death induced by chemotherapeutics are genistein with cisplatin or 
docetaxel [53,54], embelin with paclitaxel [55], expression of IκBα mutant with cisplatin, 
gemcitabline, adriamicin and etoposide [56,57]. Increasing evidences shows that NF-κB plays a 
critical role in lung cancer development and suggests NF-κB as a target for lung  
cancer chemoprevention. 
In summary, this study in BAL suggests that cigarette smoking produces a free radical scavenging 
and oxidative stress response shared by the pathogenic pathways of lung cancer and COPD. 
Furthermore, the pivotal networking signaling is NF-κB. The proteins included in each specific disease 
signature may provide new biomarkers and predictive tools for LC and COPD. Additional validation 
of the identified proteins in independent patient cohorts is warranted. 
4. Materials and Methods 
4.1. Patients and Samples 
Samples were obtained from four groups of patients: control group (without COPD or LC), COPD 
group, LC group, and LC with COPD. A description of all included patients can be found on Table 1. 
From 2009 to 2011, a total of 60 patients who had required flexible bronchoscopy for diagnostic 
purposes, were chosen for the study. All samples were collected from patients of the Virgen del Rocío 
Hospital (Seville, Spain). The selection criteria to be included in the study were (1) patients had to 
have been evaluated by pneumology services by haemoptysis and/or a pulmonary nodule, (2) patients 
were smokers or ex-smokers of >20 pack year, (3) over 40 years of age. The exclusion criteria for this 
study were (1) Prior diagnosis of malignancy, (2) active pulmonary tuberculosis, (3) previous lung 
resection, (4) history of drug abuse, and (5) presence of other acute or chronic inflammatory disease. 
The present study was approved by the Hospital’s Ethical Committee and a written informed consent 
was obtained from all patients prior to their inclusion in the study. 
Subjects were prepared with a combination of topical anaesthesia (20% benzocaine spray to the 
pharynx plus 2% topical lidocaine as needed) and conscious sedation using midazolam and meperidine 
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according to institutional guidelines. Bronchioalveolar lavage (BAL) samples were obtained by 
installation and aspiration of 4 to 6 mL aliquots of 0.9% sterile saline in the bronchopulmonary 
segment. Recovered fluid was immediately passed through a 100 μm sterile nylon filter (Becton 
Dickinson, San Jose, CA, USA) to remove mucus and transported on ice to the laboratory. The total 
volume was then centrifuged for 10 min at 1800g and 4 °C. The supernatant was aliquoted into 2 mL 
tubes and frozen at −80 °C until further use. 
4.2. Sample Treatment 
Approximately 4–8 mL of sample was available to our experiments. Due to its low protein content, 
BAL samples needed to be concentrated before use. BAL samples were thawed on ice with a Protease 
Inhibitor Cocktail kit (Thermo Scientific, Franklin, MA, USA). Samples were then aliquoted into new 
tubes and placed on the vacuum concentrator (Concentrator plus-Eppendorf, Hamburg, Germany). The 
next step of the sample treatment protocol was the depletion of two of the most abundant proteins 
present in BAL (albumin and immunoglobulin G) that may obscure the presence of low abundant ones. 
This was accomplished by the use of SpinTrap columns (GE Healthcare) following the manufacturer’s 
instructions. The depleted BAL samples were then cleaned to remove contaminants, such as salts, 
thiols, denaturants, that would interfere with the two dimensional gel electrophoresis (2D-PAGE) 
protocol. A 2-D Clean-up kit (GE Healthcare) was used according to the manufacturer’s instructions 
with a rehydration solution containing urea (7 M), thiourea (2 M) and CHAPS (2%). Protein 
quantitation was assessed by the RCDC method (Bio-Rad, Hercules, CA, USA). 
4.3. 2D-PAGE  
BAL samples were used from the 60 patients included in the four groups (all samples were 
analyzed independently), by taking equal amounts of protein from each individual sample. A mixture 
of 75 μg of protein from each sample, DeStreak rehydration solution (GE Healthcare) and 0.5% of  
3–10 nL pH IPG Buffer (GE Healthcare), in a final volume of 125 μL, were submitted to isoelectric 
focusing (IEF) in 7 cm IPG DryStrips (GE Healthcare) with a 3–10 nL pH range. Subsequent to IEF, 
strips were then placed on 12.5% acrylamide gels and proteins separated by electrophoresis. After this 
second dimension, gels were SYPRO® stained according to the manufacturer’s instructions (Bio-Rad, 
Hercules, CA, USA). Gel images were scanned by using Typhoon TRIO (Amersham Biosciences, 
Piscataway, NJ, USA).  
4.4. Image Analysis and Mass Spectrometry 
Two-dimensional gel image analysis protein spot detection, spot matching, and semi-quantitative 
statistical analysis were performed using the Progenesis SameSpots (Nonlinear Dynamics, Durham, 
NC, USA). For each study group, four different gel images were analyzed, and a corresponding 
synthetic reference image was obtained. After computer matching, detected spots and spot matches 
were manually edited for greater accuracy. The detection of differentially expressed protein spots was 
performed using the test INCA volume and proteins that were two-fold or higher differentially 
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expressed were considered significant. Protein spots of interest were excised from the stained gel using 
a ProXcision robot (PerkinElmer, Boston, MA, USA) and sent for MS analysis. 
4.5. Protein Identification by Mass Spectrometry 
MS experiments were performed by the Proteomics platform of the University of Cordoba 
Proteomics Service (Cordoba, Spain). Protein spots of interest were washed with water and their 
trypsin digestion was performed. Tryptic peptides were mixed with a CCA matrix solution. The 
mixture was analyzed with a Voyager System DE-STR 7307 MALDI-TOF/TOF Mass Spectrometer 
(ABI) to obtain a peptide mass fingerprint (PMF). Peptide matching and protein searches against the 
Swiss-Prot database were done using the Mascot search engine with a mass tolerance of ±50 ppm. 
Protein scores >60 (threshold) indicated identity or extensive homology (p < 0.05) and were 
considered significant.  
4.6. Functional Analysis of the Identified Proteins 
From each spot only identified proteins with a probability higher than 95% and with at least two 
matched unique peptides were considered in the analysis, except for keratins, which were not 
considered. The experimental molecular weight and isoelectric point of each identified protein were 
determined based on the location of the original spot on the 2-D gel using the Progenesis software.  
4.7. Western Blot  
BAL proteins (30 μg) were separated in 12% gels polyacrylamide (SDS-PAGE) and transferred to 
polyvinylidene fluoride (PVDF) membranes (Bio-Rad, Hercules, CA, USA). After blocking, the blots 
were incubated overnight at 4 °C with primary antibodies according to the manufacturer’s instructions: 
anti-TXN, anti-GSR, anti-GSTA1, anti-CAT (1:1000, EPITOMICS, Burlingame, CA, USA), 
Secondary antibodies, peroxidase-conjugated anti-mouse (GE Healthcare, Uppsala, Sweden) and  
anti-rabbit (Cell Signaling, Beverly, MA, USA), were then applied to the individual membranes 
(1:2000) for 1 h at room temperature. Protein bands were revealed using enhanced chemiluminescence 
ECL (GE Healthcare, Uppsala, Sweden) and visualized in an image analyzer (Mini LAS-3000, 
Fujifilm, Tokyo, Japan). The relative protein levels were calculated by comparison to the amount of  
β-actin protein (1:1000 Abcam, Cambridge, MA, USA). The analysis of the expression values of the 
proteins of interest obtained by western blot was performed by densitometry, using Image J software 
and the results were expressed as fold change relative to the control protein (β-actin). The experiments 
were repeated three times independently. 
4.8. Bioinformatics 
The biological functions, in terms of gene ontology and interaction network, were analyzed using 
Ingenuity Pathways Analysis (IPA, version 7.1). Based on the local networks created by computational 
algorithms, identified proteins were connected with hub proteins, forming a functional protein cluster. 
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Lung cancer (LC) and chronic obstructive pulmonary disease (COPD) commonly coexist in
smokers, and the presence of COPD increases the risk of developing LC. The aim of this
study was to identify distinct proteomic profiles able to discriminate these two pathological
entities. Protein content was assessed in the bronchoalveolar lavage (BAL) of 60 patients
classified in four groups: COPD, COPD and LC, LC without COPD, and control with neither
COPD nor LC. Proteins were separated into spots by bidimensional polyacrylamide gel
electrophoresis (2D-PAGE) and examined by matrix-assisted laser desorption/ionization
time of flight mass spectrometry (MALDI-TOF/TOF). A total of 40 proteins were differentially
expressed in the LC and/or COPD groups as compared with the control group. Distinct
protein profiles were identified and validated for each pathological entity (LC and COPD). The
main networks involved were related to inflammatory signalling, free radical scavenging and
oxidative stress response, and glycolysis and gluconeogenesis pathways. The most relevant
signalling link between LC and COPD was through the NF-κB pathway.
In conclusion, the protein profiles identified contribute to elucidate the underlying pathogenic
pathways of both diseases, and provide new tools of potential use as biomarkers for the early
diagnosis of LC.
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Biological significance
Sequence coverage. The protein sequence coverage (95%) was estimated for specific proteins
by the percentage of matching amino acids from the identified peptides having confidence
greater than or equal to 95% divided by the total number of amino acids in the sequence.
Ingenuity Pathways Analysis. Mapping of our proteins onto biological pathways and disease
networks demonstrated that 22 proteins were linked to inflammatory signalling (p-value:
1.35 * 10−08–1.42 * 10−02), 15 proteins were associated with free radical scavenging and
oxidative stress response (p-value: 4.93 * 10−11–1.27 * 10−02), and 9 proteins were related
with glycolysis and gluconeogenesis pathways (p-value: 7.39 * 10−09–1.58 * 10−02).
© 2013 Elsevier B.V. All rights reserved.
1. Introduction
Lung cancer (LC) is the leading cause of cancer death worldwide,
with a 5-year survival rate of 15%, which is among the lowest of
all cancers [1]. The most important risk factor for the develop-
ment of lung cancer is the smoking of tobacco, with smokers
presenting a 10-fold higher risk to develop LC, on average, than
non-smokers. Cigarette smoking is also the most important risk
factor for chronic obstructive pulmonary disease (COPD). Inter-
estingly, COPD, which is characterized by a chronic inflamma-
tion of the lower respiratory tract, is also a major independent
risk factor for the development of lung carcinoma among
long-term smokers. In fact, the presence of COPD increases the
risk of LC up to 4–5 fold [2]. Furthermore, 50–70% of patients
diagnosed with LC have spirometric evidence of COPD [3]. Lung
cancer and COPD share risk factors andmay therefore also likely
share similar pathogenic pathways. Numerous mechanisms
have been proposed for the common pathogenesis of LC and
COPD, which involve chronic inflammation, epithelial-to-
mesenchymal transition, oxidative stress, altered DNA repair
and cellular proliferation [3–5]. Understanding the common
mechanisms of these lung diseases is critical for the develop-
ment of new methods of prevention, diagnosis and treatment.
Bronchoalveolar lavage (BAL) is a unique biological fluid that
allows for appropriate sampling of the soluble protein content of
the airway lumen. Comparative analyses have documented that
certain proteins are present at higher levels in BAL than in
plasma, suggesting that they are specifically produced in the
airway tract [6]. However the plasma could be used as a source of
biomarkers for early lung cancer diagnosis, blood has the great
advantage of being readily accessible and that its collection is
minimally invasive [7].
These proteins are therefore good candidates for becoming
lung-specific biomarkers [8]. Proteomic technologies such as
2D-PAGE, 2D-DIGE, SELDI-TOF-MS technology, ICAT and
iTRAQ, are valuable tools to expand the understanding of
these processes. These technologies have been used to
analyse different biological fluids including cell lysates, cell
secretome, serum, plasma, tumour tissue, BAL, sputum and
saliva [9,10]. Several studies have assessed differential BAL
protein profiles obtained by 2D-PAGE analysis in smokers
versus never smokers [11,12] and have also tried to identify
profiles associated with a higher risk of developing COPD
[13–15]. Regarding LC patients, a number of 2D-PAGE studies
have been performed to explore the protein content of plasma or
tumour tissue, focusing onunderstanding themolecular basis of
cancer pathogenesis [16–18], as well as on the identification of
new diagnostic, prognostic or predictive markers in lung cancer
[19,20]. However, to the best of our knowledge, no study has
evaluated to date the protein profile by 2D-PAGE in BAL of lung
cancer patients. We believe that analysing the protein compo-
sition of BAL by a high-throughput technology, given its vicinity
to tumour cells and potential enrichment in tumour-derived
proteins may provide more reliable information and may
therefore prove to be a more accurate tool for clinical use.
In the present study, the soluble protein content of the
airway tract was assessed by 2D-PAGE and MALDI-TOF/TOF in
the BAL of 60 patients classified in four groups: COPD, COPD
and LC, LC without COPD, and control (neither COPD nor LC).
AsCOPDandLCmayshare somecommonpathogenicpathways,
the aim of this study was to identify distinct proteomic profiles
that were able to discriminate these two pathological entities.
Analysis of the main protein networks involved could also
contribute to improve our understanding of the underlying
mechanisms implicated in the development of each disease, and
lead to the discovery of new biomarkers of potential diagnostic or
therapeutic utility.
2. Materials and methods
2.1. Patients and samples
From 2009 to 2011, a total of 60 patients from the Hospital
Universitario Virgen del Rocío were included in the study.
Samples were obtained from four groups of patients: patients
with COPD (n = 15), patients with LC (n = 15), patients with LC
and COPD (n = 15), and patients with neither LC nor COPD
(control group; n = 15). Characteristics of the study population
are summarized in Table 1. Patientswere required tomeet all the
following eligibility criteria: 1) patients were under pneumologist
consultation due to haemoptysis and/or a pulmonary nodule; 2)
patients were requested by their treating physician a flexible
bronchoscopy for diagnostic purposes; 3) patients were smokers
or ex-smokers of >20 pack-year; and 4) patients had to be older
than 40 years of age. Exclusion criteria included: 1) diagnosis of a
neoplastic disease other thannon-small cell lung cancer (NSCLC);
2) active pulmonary tuberculosis; 3) previous lung resection;
4) history of drug abuse; and 5) the presence of other acute or
chronic inflammatory disease. The study protocol was approved
by the Hospital's Ethical Committee and a written informed
consent was obtained from all patients prior to study entry.
Subjects were prepared with a combination of topical
anaesthesia (20% benzocaine spray to the pharynx plus 2%
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topical lidocaine as needed) and conscious sedation using
midazolam and meperidine according to institutional guide-
lines. All BAL samples were obtained by instillation and
aspiration of 4 to 6 ml aliquots of 0.9% sterile saline in the
appropriate bronchopulmonary segment. Recovered fluid was
immediately passed through a 100 μm sterile nylon filter
(Becton Dickinson, San Jose, CA) to remove mucus and
transported on ice to the laboratory. The total volume was then
centrifuged for 10 min at 1800 ×g and 4 °C. The supernatant was
aliquoted into 2 ml tubes and frozen at –80 °C until further use.
2.2. BAL sample processing
A sample of approximately 4–8 ml of BAL was obtained from
each patient for study purposes. Due to its low protein
content, BAL samples had to be concentrated before use. BAL
samples were thawed on ice with a Protease Inhibitor Cocktail
kit (Thermo Scientific, Franklin, MA, USA), aliquoted into new
tubes and placed on the vacuum concentrator (Concentrator
plus — Eppendorf, Hamburg, Germany). Samples were then
depleted of the twomost abundant BAL proteins (albumin and
immunoglobulin G) to allow an adequate identification of
the less abundant ones. This was accomplished by the
use of SpinTrap columns (GE Healthcare) following the
manufacturer's instructions. The depleted BAL samples were
then cleaned to remove contaminants, such as salts, thiols or
denaturants that would interfere with the 2D-PAGE protocol.
A 2-D Clean-up kit (GE Healthcare) was used according to
the manufacturer's instructions with a rehydration solution
containing urea (7 M), thiourea (2 M) and CHAPS (2%). Protein
quantitation was assessed by the RC–DC method (Bio-Rad,
Hercules, CA, USA).
2.3. 2D-PAGE
Amixture of 75 μg of protein from each individual BAL sample,
DeStreak rehydration solution (GE Healthcare) and 0.5% of 3–10
NL pH IPG Buffer (GE Healthcare), in a final volume of 125 μl,
were submitted to isoelectric focusing (IEF) in 7 cm IPG
DryStrips (GE Healthcare) with a 3–10 NL pH range. Subse-
quent to IEF, strips were equilibrated and placed on 12.5%
acrylamide gels to allow protein separation by electrophoresis.
After this second dimension, gels were SYPRO® stained
according to themanufacturer's instructions (Bio-Rad, Hercules,
CA,USA). TyphoonTRIO (AmershamBiosciences, USA)wasused
to scan gel images.
2.4. Gel image analysis
Two-dimensional gel image analysis, protein spot detection,
spot matching and semi-quantitative statistical analysis
were performed using the Progenesis SameSpots software
(Nonlinear Dynamics, Durham, NC). For each studied group,
four different gel images were analysed and a corresponding
reference synthetic image was obtained. After computer
matching, detected spots and spot matches were manually
edited for improved accuracy. The detection of differentially
expressed protein spots was performed using the test INCA
volume and proteins that had >2-fold differential expression
were considered significant. Protein spots of interestwere excised
from the stained gel using a ProXcision robot (PerkinElmer) and
sent for MS analysis.
2.5. Protein identification by mass spectrometry
MS experiments were performed by the Proteomics platform
of the Cordoba University Proteomics Service (Cordoba,
Spain). Protein spots of interest were washed with water and
then trypsin digestion was performed. Tryptic peptides were
mixed with a CCA matrix solution. The mixture was analysed
with a Voyager System DE-STR 7307 MALDI-TOF/TOF Mass
Spectrometer (ABI) to obtain a peptide mass fingerprint (PMF).
Peptide matching and protein searches against the Swiss-Prot
database were done using the Mascot search engine (http://
www.matrixscience.com/) with a mass tolerance of ±50 ppm.
Candidate proteins were selected from each spot, taking into
consideration several variables such as isoelectric point, molec-
ular mass, matched peptides, and sequence coverage.
2.6. Functional analysis of identified proteins
The protein sequence coverage (95%) was estimated for specific
proteins by the percentage of matching amino acids from the
identified peptides having confidence greater than or equal to
95%dividedby the total number of amino acids in the sequence.
The experimental molecular weight and isoelectric point of
each identified protein were determined based on the location
of the original spot on the 2D-PAGE gel using the Progenesis
software.
2.7. Validation by western blotting
BAL proteins (30 μg) were separated in 12% gels polyacrylamide
(SDS-PAGE) and transferred to polyvinylidene fluoride (PVDF)
membranes (Bio-Rad, Hercules, CA, USA). After blocking, the
blots were incubated overnight at 4 °C with the following
selected primary antibodies according to the manufacturer's
Table 1 – Characteristics of the patients.
Controls
n = 15
COPD
n = 15
LC n = 15 LC + COPD
n = 15
Gender
Male 100.0% (15) 100.0% (15) 100.0% (15) 100.0% (15)
Female 0.0% (0) 0.0% (0) 0.0% (0) 0.0% (0)
Average age
[range]
61.3 [41–80] 61.5 [45–78] 60.7 [46–69] 60.7 [49–68]
Smoking status
Smokers 73.3% (11) 53.3% (8) 53.3% (8) 80.0% (12)
Ex-smokers 26.7% (4) 46.7% (7) 46.7% (7) 20.0% (3)
Packs-year 21.82 32.20 35.21 30.78
COPD
Mild – 20.0% (3) – 53.3% (8)
Moderate – 33.3% (5) – 26.7% (4)
Severe – 26.7% (4) – –
Very severe – 20.0% (3) – 20.0% (3)
LC histology
ADC – – 73.3% (11) 66.7% (10)
SCC – – 26.7% (4) 33.3% (5)
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instructions: anti-HSP 70, AKR1B10, PRDX1 (1:1000, EPITOMICS,
CA, USA), anti-PKM, anti-NF-κBp65, and anti-pNF-κBp65
(1:1000 Cell Signaling, Beverly, MA, USA). Secondary anti-
bodies, peroxidase-conjugated anti-mouse (GE Healthcare,
Uppsala, Sweden) and anti-rabbit (Cell Signaling, Beverly, MA,
USA), were then applied to the individualmembranes (1:2000)
for 1 h at room temperature. Protein bands were revealed
using enhanced chemiluminescence ECL (GE Healthcare,
Uppsala, Sweden) and visualized in an image analyser (Mini
LAS-3000, Fujifilm, Tokyo, Japan). The relative protein levels
were calculated by comparison to the amount of the control
protein β-actin (1:1000 Abcam, Cambridge, MA, USA). Analy-
sis of the expression values obtained by western blot of the
proteins of interest was performed by densitometry, using
Image J software (http://rsbweb.nih.gov/ij/), and the results
were expressed as fold change relative to the control protein
(β-actin). Each experiment was independently repeated three
times.
2.8. Bioinformatics
The biological functions, in terms of gene ontology and inter-
action network, were analysed using Ingenuity Pathways
Analysis (IPA, version 7.1; http://www.ingenuity.com). Based
on the local networks created by computational algorithms,
identified proteinswere connectedwithhubproteins, forming a
functional protein cluster.
3. Results
3.1. Distinct proteomic profiles of LC and COPD
A total of 123 protein spots were successfully identified. Of
these, the expression of 40 proteins had significant differ-
ences (≥2-fold, p < 0.05) between LC and/or COPD groups and
the control group. All spots are marked on a representative gel
2D image in (Fig. 1). Detailed information of these identified
proteins is summarized in Table 2.
Venn diagrams were used to display the differentially
expressed proteins in each pathological subgroup studied.
Among patients belonging to the LC group, 6 proteins were
found to be up-regulated (CTSD, ALDO A, FBP1, ERZ, AKR1B10,
TKT) and 1 down-regulated (SELENBP1) as compared to those
in the control group, that were not found to be differentially
expressed in patients belonging to the COPD or COPD/LC
groups (Fig. 2). On the other hand, the LC and LC/COPD groups
shared 5 proteins (ALDH3A1, AKR1C3, PKM2, PYGM and PPIA)
that were significantly up-regulated compared to the control
group, that were not deregulated in the COPD group (Fig. 2).
Similarly, the COPD and COPD/LC groups shared 4 up-regulated
proteins (CAT, PRDX1, PRDX2 and PRDX5) in contrast with the
LCgroup (Fig. 2). Finally, the threepathological groups shared 24
deregulated proteins, 17 of them up-regulated (HSP70, TXN,
ENO1, AMY1A, AMY2A, ANXA1, ANXA2, ANXA5, CA1, CRP,
TPPP3, C3A, GSR, IDH1, SERPINB1, PEBP4, and ARHGDIB), 5
down-regulated (GSTA1, GSTA2, GSTP, LCN2, andUCHL1), and 2
proteins (CAPS 2 and CFL1) down-regulated in the COPD group
and up-regulated in the LC and LC/COPD groups (Fig. 2) as
compared to the control group.
3.2. Validation of selected proteins
Four proteins with high fold changes (PKM2, HSP70, AKR1B10
and PRDX1) representative of each study subgroup were
selected for validation by western blot. These proteins showed
a high search score, which is a probability based on the observed
frequency of peptides in a given molecular weight range and is
used to determine the quality of a given match, with higher
scores indicating greater confidence. A close-up of the region of
the gels showing differentially expressed proteins between LC
and/or COPD and control groups is depicted in Fig. 3A.
Western blotting of PKM2, HSP70, AKR1B10, PRDX1 and the
corresponding β-actin are shown in Fig. 3B. Validation was
performed in three random samples from each study group.
Results indicate that HSP70 expression is increased in all 3
pathological study groups (COPD, LC, LC/COPD) as compared
with the control group. The PKM2 protein expression is clearly
increased only in patients with LC, with or without COPD, but
not in the COPD (without LC) or control groups. On the other
hand, PDX1 shows an increment of expression in COPD groups
(±LC), as compared to the LC (without COPD) and control groups.
Finally, ARK1B10 shows greater expression only in the LC group
(without COPD) (Fig. 3B). These results confirmed the data
obtained in the 2D-PAGE analysis, and illustrate that there are
protein profiles that are common to COPD and LC, whereas
others are able to discriminate among both pathological entities.
3.3. Bioinformatic analysis
Human homologues of the 40 unique proteins identified in
this study were subsequently analysed with IPA, software
capable of mapping proteins onto known existing networks
and pathways. Cellular compartments as designated by IPA
(gene ontology based) indicated that the majority of identified
proteins were of cytoplasmatic origin. Mapping of our proteins
onto biological pathways and disease networks demonstrated
that 22 proteins were linked to inflammatory signalling
(p-value: 1.35 * 10−08–1.42 * 10−02), 15 proteins were associated
with free radical scavenging and oxidative stress response
(p-value: 4.93 * 10−11–1.27 * 10−02), and 9 proteins were related
with glycolysis and gluconeogenesis pathways (p-value:
7.39 * 10−09–1.58 * 10−02). The complex NF-κB appeared as a
hallmark in the identified IPA networks, although it was not
detected in the 2D-PAGE study (Fig. 4A).
In order to confirm the presence of the NF-κB complex in the
BAL of our study subjects, NFkBp65 and pNFkBp65 expressions
were assessed by western blot in the study samples as
described before (Fig. 4B). The results show that NFkBp65 is
expressed in all study groups including controls, with slightly
higher expression in the COPD group. However, the phosphor-
ylated NFkBp65 showed increased expression only in patholog-
ical groups (COPD, LC, COPD/LC), particularly in the LC group.
The result suggests that the activation ofNFkBp65 is involved in
the pathogenesis of both diseases (COPD and LC).
4. Discussion
We present the first shotgun 2D-PAGE proteomic study of lung
cancer in BAL fluid where we have established specific protein
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profile characteristics of LC and COPD. Our results indicate
that the protein composition of BAL shows significant
differences among the four groups of studied individuals (LC,
COPD, LC & COPD and control), especially when comparisons
are made between the control group and the disease groups.
These alterations were observed in 40 differentially expressed
proteins, which showed changes in expression ≥2 fold (p < 0.05).
Most proteins were up-regulated in LC and COPD, reflecting a
common link. We have validated the bidimensional proteomic
results for some proteins by western blotting. Further validation
of the described proteomic signature independent cohorts is
warranted.
Some of the identified proteins with differential expression
appeared only in the LC and LC/COPD groups (Fig. 2). For
example, CTSD, Ezrin, and SELENBP1 have been associated
with increased cancer growth, invasion, and metastasis in
various types of cancers [21–23]. Indeed, different studies have
highlighted the potential role of these proteins as prognostic
markers of progression in lung cancer [24–26]. ALDH3A1
belongs to the phase II group of drug-metabolizing enzymes
and is highly expressed in the stomach, lung, keratinocytes,
and cornea. Cytosolic ALDH3A1, which is induced by polycyclic
aromatic hydrocarbons or chlorinated compounds, plays an
important role in alveolar pneumocyte physiology, and increases
during carcinogenesis [27]. Over-expression of AKR1B10, is
associated, in most cases with smoking [28,29], suggesting a
possible involvement of this enzyme in tobacco-induced lung
cancer. Indeed, AKR1B10 has a high catalytic efficiency for the
reduction of retinoids, and retinoic acid deficiency has been
linked to airway epithelial squamous metaplasia and epithelial-
to-mesenchymal transition [30]. Thus, increased airway epithe-
lial expression of AKR1B10 may play an important role in the
pathogenesis of lung cancer [31]. In addition, AKR1B10 has also
been involved in the resistance to different chemotherapeutic
drugs, such as cisplatin [32].
Another group of identified proteins up-regulated in the LC
and/or LC/COPD groups in our comparative proteomic study
included TKT, FBP1, ALDOA, PYGM and PKM2. All these proteins
are involved in the regulation of glycolysis, probably contributing
to the Warburg effect, that leads to a state that has been termed
“aerobic glycolysis”. Previous studies showed the role of PKM2 in
the production of lactic acid through glycolysis rather than
producing energy throughmitochondrial oxidative phosphoryla-
tion. This may help tumour cells to survive in low glucose and
low oxygen environments, and facilitate tumour invasion [33,34].
The largest number of proteins found in our profiles appears
commonly up-regulated in three pathological groups (LC, COPD
and LC/COPD) compared with control group. The expression of
one of these proteins, HSP70, in NSCLC has been linked to the
number of daily smoked cigarettes [35]. HSP70 has also been
Fig. 1 – 2D-PAGE of a representative patient sample. (A) A representative 7 cm Sypro® stained gel of proteins in the pH range
3–11 non-lineal. The spots represented with a circle correspond to the selected proteins for validation.
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Table 2 – Protein spots searched by MASCOT software in database.
Spots
no.
Protein name Symbol Accession
no.
Protein
MW
Protein
PI
Pep.
count
Protein
score
Score C.I.
%
Total ion
score
Ion C.I.
%
COPD LC LC/COPD
1 Aldehyde dehydrogenase ALDH3A1 gi│178375 50702.9 5.99 15 445 100 339 100 – Up 2.9 Up 2.9
2 Aldo-keto reductase family 1 member B10 AKR1B10 gi│4503285 37111.1 7.13 7 108 100 70 100 – Up 4 –
3 Aldo-keto reductase family 1 member C3 AKR1C3 gi│24497583 37229 8.06 10 248 100 186 100 – Up 2.5 Up 2.1
4 Aldolase A ALDOA gi│28614 39706.4 8.34 11 229 100 156 100 – Up 2 –
5 Alpha enolase ENO gi│2661039 36627.7 6.53 9 128 100 70 100 Up 2 Up 2.5 Up 2.3
6 Alpha-amylase 1 precursor AMY1A gi│40254482 58415.2 6.47 18 469 100 326 100 Up 2.1 Up 2.3 Up 2.2
7 Amylase alpha AMY2A gi│224980 58443.2 6.47 15 323 100 221 100 Up 2.5 Up 2.2 Up 2.9
8 Annexin A1 ANX1 gi│4502101 38918.1 6.57 17 495 100 354 100 Up 2.3 Up 2.2 Up 2.3
9 Annexin A2 ANX2 gi│18645167 38779.9 7.57 20 326 100 159 100 Up 2.5 Up 2.3 Up 2.7
10 Annexin A5 ANX5 gi│4502107 35971.4 4.94 19 472 100 301 100 Up 2.4 Up 2.2 Up 2.1
11 Calcyphosin 2 CAPS 2 gi│4757908 21068.3 4.74 11 543 100 460 100 Down 2.2 Up 2.8 Up 2.6
12 Carbonic anhydrase 1 CA1 gi│4502517 28909.4 6.59 14 770 100 627 100 Up 2.2 Up 2.5 Up 2.7
13 Catalase CAT gi│4557014 59946.8 6.9 13 310 100 234 100 Up 2.5 – Up 2.8
14 Cathepsin D preproprotein CTSD gi│4503143 45036.8 6.1 8 135 100 95 100 – Up 3 –
15 CGI-38 protein TPPP3 gi│4680715 19144.7 9.1 8 79 100 30 88 Up 2.4 Up 2 Up 2.1
16 Cofilin-1 CFL1 gi│5031635 18718.7 8.22 6 98 100 57 100 Down 3 Up 2.2 Up 2.8
17 Complement C3 C3A gi│119589476 144417.1 8.24 25 472 100 332 100 Up 2.4 Up 3 Up 2.6
18 C-reactive protein CRP gi│1942435 23146.7 5.28 8 341 100 281 100 Up 3 Up 3.2 Up 2.7
19 Ezrin EZR gi│46249758 69312.7 5.94 18 250 100 175 100 – Up 3 –
20 Fructose-1, 6-bisphosphatase FBP1 gi│3293553 37058.9 6.6 6 124 100 101 100 – Up 2.5 –
21 Glutathione reductase GSR gi│119583848 61464.6 8.71 7 131 100 108 100 Up 2.8 Up 3.1 Up 2
22 Glutathione S-transferase A1 subunit GSTA1 gi│163310943 25628.7 8.72 15 384 100 268 100 Down 3 Down 3.2 Down 3.8
23 Glutathione S-transferase A2 subunit GSTA2 gi│257476 25589.6 8.81 7 105 100 70 100 Down 2.5 Down 3 Down 2.6
24 Glutathione S-transferase P GSTP1 gi│4504183 23569.1 5.43 10 633 100 541 100 Down 2.2 Down 2.4 Down 2.5
25 Glycogen phosphorylase PYGM gi│225897 97386.8 6.57 17 515 100 436 100 – Up 3 Up 2.1
26 HSP70 HSP 70 gi│4529893 70280.1 5.48 12 325 100 269 100 Up 4 Up 3.1 Up 3.8
27 Isocitrate dehydrogenase 1 IDH1 gi│89573979 42091 6.19 8 62 100 29 85 Up 2.2 Up 2.1 Up 2.5
28 Leukocyte elastase inhibitor SERPIN B1 gi│13489087 42828.7 5.9 18 403 100 274 100 Up 2.7 Up 2.6 Up 2.5
29 Lipocalin 2 LCN2 gi│119608155 28089.4 9.53 9 513 100 426 100 Down 3 Down 3.5 Down 2.9
30 Peptidylprolyl isomerase A (cyclophilin A) PPIA gi│1633054 18097.9 7.82 10 260 100 159 100 – Up 2.2 Up 2.6
31 Peroxiredoxin 1 PRDX 1 gi│55959887 19134.7 6.41 8 170 100 98 100 Up 5 – Up 4.2
32 Peroxiredoxin 5 PRDX 5 gi│6166493 22261.6 8.85 11 638 100 537 100 Up 2.3 Up 2.4
33 Peroxiredoxin-2 isoform a PRDX 2 gi│32189392 22049.3 5.66 12 451 100 325 100 Up 3 – Up 2.9
34 Phosphatidylethanolamine-binding protein 4 PEBP4 gi│4505621 21157.7 7.01 11 311 100 209 100 Up 2.9 Up 2.3 Up 2.6
35 Pyruvate kinase 2 PKM2 gi│35505 58411.2 7.58 22 416 100 249 100 – Up 3 Up 3.2
36 Rho GDP-dissociation inhibitor 2 ARHGDIB gi│56676393 23030.6 5.1 7 215 100 170 100 Up 2.9 Up 2.6 Up 2.3
37 Selenium-binding protein 1 SELENBP1 gi│197097476 52987.9 6.13 12 278 100 207 100 – Down 2.2 –
38 Thioredoxin TXN 12345 7.93 10 241 100 203 100 Up 2.4 Up 2.3 Up 2.1
39 Transketolase TKT gi│388891 68528 7.89 17 405 100 246 100 – Up 2.5 –
40 Ubiquitin carboxyl-terminal hydrolase isozyme L1 UCHL1 gi│21361091 25150.6 5.33 7 126 100 76 100 Down 2.7 Down 2.2 Down 2.8
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studied invarious inflammatory diseases as COPD,where itwas
significantly elevated in serum samples of patients suffering
from COPD compared to controls [36]. Different proteomic
approaches have confirmed the correlation between HSP70
over-expression and the differentiation level and/or aggressive-
ness of various types of cancer, such as gastric adenocarci-
nomas [37], hepatocarcinoma [38] and oesophageal cancer [39].
In addition, various oncoproteomics studies correlate the
elevated levels of HSP70 with therapeutic resistance [40–43].
Other interesting protein is carbonic anhydrase 1 (CA1). This
protein constitutes an endogenousmarker of cellular hypoxia, a
natural phenotype of solid tumours, and its predictive and
prognostic potential has been demonstrated in various clinical
studies [44]. Up-regulated expression of CA1 was reported in
carcinoma cells derived from various organs including breast,
cervix, bladder, oesophagus, lung, kidney, colon and rectum,
head and neck [45]. IDH1 is an enzyme essential for cell
metabolism and energy production. Several studies suggest
the potential oncogenicity of IDH1 in acute myeloid leukaemia
[46]. A recent report on IDH1 showed that it is up-regulated in
more than 70% of NSCLC tumours and that it is correlated with
lower 5-year survival rates. Furthermore, IDH1was proved to be
an independent unfavourable prognostic factor for overall
survival of NSCLC patients by multivariate analysis [47].
Recent studies have described the role of the protein
PEBP4 in the inhibition of the MAPK signalling pathway and
its involvement in the inhibition of the JNK pathway that
promotes the activation of AKT [48]. It has also been shown that
the over-expression of PEBP4 was related to the development,
invasion, and metastasis of a variety of tumours [49,50].
Finally, four proteins appeared up-regulated in the COPD
and LC/COPD groups. These proteins are enzymatic antioxi-
dants, and represent the first line of defence against oxidative
stress. Studies evaluating the involvement of these genes on
COPD patients and healthy smokers have revealed conflicting
results; some studies have claimed for a down-regulation of
enzymatic antioxidants such as peroxiredoxins and catalase in
COPD patients [51–53], while others stated their up-regulation
in this population [54]. Studies in LC have showed that
up-regulation of different members of the peroxiredoxin family
correlates with poor prognosis [55–57].
The proteomic signatures found in our study were
analysed by Ingenuity System Pathway Analysis software,
in order to identify any common pathways or relationships
between proteins within the data. The three major pathways
associated with the diseases involved within the data were
inflammation, free radical scavenging and oxidative stress
response, and glycolysis and gluconeogenesis. The results
indicated NF-κB, an important transcription factor involved
in inflammation, as the main link between the three pathways.
This fact contributes to demonstrate the important role of
inflammation as a link between the development of lung cancer
and COPD. NF-κB regulated genes include cytokines, adhesion
molecules, angiogenic factors, anti-apoptotic factors, and matrix
metalloproteinases (MMPs) which are involved in the different
steps of carcinogenesis. It has been suggested that NF-κB
promotes lung cancer mainly through mediating inflammatory
cytokine secretion to establish a cancer-prone inflammatory
microenvironment [58]. Similarly, NF-κB pathways play a crucial
role in the pathogenesis/development of COPD by increasing the
release of pro-inflammatory mediators leading to chronic
inflammation in the lung. In bronchial biopsies of airwaymucosa
in patients with COPD, protein expression of the p65 subunit of
NF-κBwas increased comparedwith expression in non-smokers,
and correlated with airflow obstruction [59]. In addition, both
chemotherapy and radiation treatments induce NF-κB activation
in cancer cells, which contributes to resistance to those same
therapies [60,61]. Indeed, inhibition of NF-κB signalling by various
approaches has been shown to augment the efficacy of chemo-
therapeutics and radiation in killing cancer cells in vitro and in
Fig. 2 – A Venn diagram showing the overlaps of up- or down-regulated proteins in each pathological group. Up-regulated
proteins are represented in black. Down-regulated proteins are represented in grey. In black and with an asterisk are the
proteins up-regulated in LC and down-regulated COPD.
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vivo [62,63]. Some of the NF-κB inhibitors that enhanced lung
cancer cell death induced by chemotherapeutics are genistein
[64] with cisplatin or docetaxel, embelin with paclitaxel [65],
expression of IkBα mutant with cisplatin, gemcitabline,
adriamicin [66] and etoposide [67].
5. Conclusions
Our proteomic study in BAL suggests that lung cancer and
COPD share some pathogenic pathways such as inflammation,
Fig. 3 – (A). The panel shows the different densities of spots 2, 35, 26 and 31 (in Fig. 1) in each study group, which correspond to
proteins ARK1B10, PKM2, HSP70 and PDRX1, respectively. (B) Western blotting for ARK1B10, PDX1, PKM2 and HSP70. The
different expressions are seen in each of the groups for each of the selected proteins. ARK1B10 is only expressed in the LC
group, PDX1 presents an increment of expression in COPD and LC & COPD groups, PKM2 expression is increased in LC and LC &
COPD groups, and HSP70 presents a similar increment of expression in all pathological groups. These differences are also
illustrated on the right panel with a bar chart.
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Fig. 4 – (A) Ingenuity Pathways Analysis of lung cancer and/or COPD versus controls revealed three networks that were
statistically significant based on the number of differentially expressed proteins. Network 1 revealed processes associated
with inflammatory signalling and family members are represented in green colour. Network 2 revealed processes associated
with free radical scavenging and oxidative stress response and family members are represented in yellow colour. And
Network 3 revealed processes associated with glycolysis and gluconeogenesis pathways and family members are represented
in blue colour. (B) Western blotting for the NF-κB activation. Increased expression was seen in all pathological groups,
particularly in the LC group. These differences are also illustrated on the right panel with a bar chart.
235J O U R N A L O F P R O T E O M I C S 8 9 ( 2 0 1 3 ) 2 2 7 – 2 3 7
free radical scavenging and oxidative stress response, and
glycolysis and gluconeogenesis. In fact, the pivotal networking
signalling is through NF-κB. In addition, we have identified
distinct proteomic profile characteristic of LC, COPD and LC &
COPD. The proteins included in this signature deserve valida-
tion andwarrant further study as potential biomarkers for early
diagnosis and prognosis, and as therapeutic targets.
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1. Introduction 
With more than 1 million annual deaths, among both females and males, lung cancer is the 
world leading cause of cancer-related death (1). The most important risk factor for lung 
cancer is smoking, with smokers presenting a 10 fold risk increase compared to non-
smokers. Lung cancers are usually divided into two categories: small-cell lung cancer 
(SCLC), representing approximately 15% of cases, and non-small cell lung cancer (NSCLC). 
This sub-division represents around 85% of all lung cancer cases and includes the 
histological sub-types adenocarcinoma, large-cell carcinoma and squamous cell carcinoma 
(2). The lung cancer 5-year survival rate is one of the lowest at 10-15% and treatment 
depends on the extent of the disease at the time of diagnosis (3). Approximately 30% of 
patients have early stage lung cancer when diagnosed and those tumours can be surgically 
removed, 20% have local and/or regionally advanced tumours and are treated with chemo 
and radiotherapy, and almost half of the patients have advanced metastatic disease when 
only palliative treatments are available (4). Consequently there is a pressing need for new 
screening and early diagnostic techniques that are specific and non-invasive, and also for 
tools that can predict prognosis, optimize treatments and identify new therapeutic targets. 
Genomic approaches have been used to that end in the last years. Nonetheless, given the 
importance of proteins to a cells’ phenotype, post-translational modifications, and the poor 
correlation between mRNA and protein expression levels (5, 6), proteomic analyses may 
enlighten the pathogenesis of lung cancer. A variety of techniques such as two dimensional 
gel electrophoresis (2D-PAGE, 2D-DIGE), protein arrays, protein labelling and tagging 
(ICAT, iTRAQ, SILAC), are being used in cancer research (7, 8) and have the potential to aid 
clinical practice as a complement to histopathology, as a selection method for individualized 
therapy, and in the assessment of drug efficacy, resistance, and toxicity (9). 
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2. Lung cancer 
In the beginning of the 20th century, lung cancer was a rare disease. Nowadays it has the 
highest incidence and mortality rates in the world with lifestyle and environmental factors 
thought to be the major contributors to the development of this disease (10).  
Epidemiological evidence has shown that two to three decades after a peak in smoking 
prevalence in a given population, there is a peak in lung cancer deaths, making tobacco 
smoking the main cause of lung cancer development. This relationship was established in 
the 1950’s and 60’s (10-12). Other causes include environmental tobacco smoking, air 
pollution, indoor radon, occupational exposure to respiratory carcinogens, asbestos, and 
fumes from cooking stoves and fires (10). Even though smoking is undeniably the major 
cause of lung cancer, making it the leading cause of preventable death in the world, it is 
important to recognize that the majority of smokers will not develop this neoplasia over 
time and that this is probably due to individual variation in the susceptibility to respiratory 
carcinogens and the existence of a previous lung disease (13, 14). Tobacco components can 
induce DNA damage through several mechanisms including gene point mutations, 
deletions, insertions, recombinations, rearrangements, and chromosomal alterations, which 
drive the development of the disease (15). Nonetheless, the current classification of lung 
cancer does not emphasize the important of specific molecular and genetic alterations that 
can differentiate between SCLC and NSCLC. This is also true for the NSCLC subtypes 
adenocarcinoma, large cell carcinoma, and squamous cell carcinoma, that were until 
recently, treated similarly, regardless of their biological heterogeneity (16). Lung cancer is 
characterized by genetic instability of the chromosomes, nucleotides, and the transcriptome. 
These abnormalities are usually targeted to proto-oncogenes, tumour suppressor genes, 
DNA repair genes, among others. The silencing of telomerase is present in normal cells, but 
in almost all SCLC and over 80% of NSCLC, telomerase is activated, promoting cell 
immortalization (17). The epidermal growth factor receptor (EGFR) is overexpressed or 
abnormally activated by mutation in 50-90% of all NSCLC, especially in squamous cell 
carcinomas, leading to increased cell proliferation and survival through the 
RAS/RAF/MEK/MAPK and PI3K/AKT pathways (18). Activating mutations of the KRAS 
gene from the RAS proto-oncogene family are present in 20% of all NSCLS and between 30-
50% of lung adenocarcinomas (19). The fusion of the echinoderm microtubule-associated 
protein-like 4 (EML4) and the anaplastic lymphoma kinase (ALK) genes occurs in 
approximately 7% of NSCLC and is associated with a persistent mitogenic signal. The 
EML4-ALK, EGFR, and KRAS mutations are almost always mutually exclusive (19). Tumour 
suppressor genes are also affected in lung cancer. Mutations in TP53 are the most common 
genetic alterations found in human cancers and occur in approximately 75% of SCLC and in 
50% of NSCLC (17). Alterations in the PI3K/AKT pathway, the CDKN2A/RB1 pathway, 
VEGF, and epigenetic changes are also present in lung cancer (19). Several drugs have been 
developed to target these alterations and improve survival of lung cancer patients, such as 
tyrosine kinase inhibitors and monoclonal antibodies, revealing the importance of the 
molecular characterization of tumours in order to improve detection, diagnosis, treatment 
and prognosis of lung cancer. 
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Proteins are crucial operators in the majority of biological systems and a comprehensive 
knowledge of their expression, modifications, and function in the lung cancer setting, may 
be more informative than DNA and RNA studies alone. New technologies are being 
developed that allow the analysis of thousands of cancer cell proteins, possibly generating 
new therapeutic targets and biomarkers that will have an impact on early detection, therapy 
and prognostic evaluation of lung cancer patients. 
3. Proteomic techniques in lung cancer research 
The proteomic technologies which are being implemented in lung cancer research are 
mainly based on two dimensional gel electrophoresis, as seen on Figure 1 where the 2D-
PAGE and 2D-DIGE workflows are represented, or proteomics based on isotope labelling 
methods as ICAT, iTRAQ, SILAC, followed by mass spectrometry (MS) analysis.  
 
Figure 1. Basic workflow of gel-based proteomic approaches. In 2D-PAGE, protein samples are 
separated according to their isoelectric point in a process termed isoelectric focusing, using gel strips 
with a fixed pH range. Then, the focused strip is placed on top of a polyacrylamide gel to allow proteins 
to separate according to their molecular weight during electrophoresis, generating a gel with protein 
spots. In 2D-DIGE, proteins from up to three samples are labelled with fluorescent dyes prior to their 
isoelectric focusing and subsequent gel electrophoresis. Gels are scanned with different wavelengths 
revealing spots and differences in expression between analysed samples. Protein spots of interest in 
both techniques are then excised, digested, and identified by MS. 
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4. Two dimensional gel electrophoresis 2D-PAGE 
2D-PAGE is the most used proteomic technique for studying the proteome as well as to 
search for cancer biomarkers (20, 21). In this methodology intact proteins are firstly 
separated by their isoelectric point (pI) and then according to their molecular weight. This 
procedure generates protein spots that are separated from the gel and digested into peptides 
for MS identification. Multidimensional separation of peptides may also be required given 
that, although the digestion step facilitates the identification process, it increases sample 
complexity, decreasing the sensitivity and coverage of the technique. Disadvantages of 2D-
PAGE include the separation of low abundant proteins and of membrane proteins. The use 
of fractioning methods or higher protein concentrations for less detectable proteins and the 
use of mild detergents to increase the solubility of membrane proteins may be a solution for 
the aforementioned issues (22, 23). Other problems include co-migration of different 
proteins, the separation of a protein with different post-translational modifications, proteins 
with pI values below 4 or above 9, or the separation of very small or very large proteins. 
Differential gel electrophoresis (2D-DIGE), a modification of 2D-PAGE with fluorescent 
dyes (Cy3, Cy5 and Cy2), is able to increase reproducibility and throughput and also allows 
the accurate quantitation of protein expression difference (24). Differential analysis software 
can recognize the differentially expressed proteins and these can later be trypsin digested 
into peptides generating peptide mass fingerprints (PMF). The absolute masses of these 
peptides can be measured by matrix assisted laser desorption ionization time-of-flight mass 
spectrometry (MALDI-TOF MS), a technique that is both relatively easy to use and 
reasonably sensitive for identifying proteins. Additionally other MS techniques, such as 
electrospray ionization (ESI-MS/MS), are capable of providing amino acid sequence 
information on peptide fragments of the initial protein (25). Liquid chromatography coupled 
to tandem mass spectrometry workflow (LC-MS/MS) has become a standard method to 
identify proteins from complex biological samples. Also, direct MS analysis of tissue, known 
as MALDI imaging, is a method that has been used to elucidate proteome features 
characterizing histological differences in lung cancer between adenocarcinoma and 
squamous- cell carcinoma (26). Another example of a novel way to generate proteomic data 
is presented in the study of dynamic proteome changes on lung cancer cells (H1299) treated 
with the cytotoxic drug camptothecin using single-protein labelling on large scale (27). 
5. Isotope-labelled mass spectrometry 
Isotope-labelling methods, as seen on Figure 2, are gel-free procedures that introduce stable 
isotope tags to proteins through chemical reactions using isotope-coded affinity tags (ICAT) 
(28) and isobaric tag for relative and absolute quantitation (iTRAQ) (29), or through 
metabolic labelling with isotope labelled amino acids in cell culture (SILAC) (30). 
ICAT is used to analyse pairs of protein samples, such as a treated sample and its control. 
Extracted proteins from both samples are labelled with a light or heavy ICAT reagent by 
reacting with a specific amino acid (cysteine). Samples are then mixed, trypsin digested, 
fractioned, and analysed by LC-MS/MS (31). Isotope peak ratios for each peptide determine 
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the differential protein expression. The drawback of this technique is that it can only analyse 
cysteine containing proteins, two samples, and it can only identify 300-400 peptides. 
 
Figure 2. Basic workflow of gel-free quantitative approaches in proteomics. In SILAC, one cellular 
culture is grown in normal medium and the other with a growth medium with heavy labelled amino-
acids. In ICAT, one protein extract is labelled with a light ICAT reagent and the other with a heavy 
ICAT reagent. In both techniques, samples are mixed, digested, separated and analysed by MS to 
determine protein identity and differential expression. In iTRAQ, special isobaric tags are applied in 4 
to 8 samples up for comparison. They are then pooled together, fractionated and analysed by MS, 
allowing protein identification and quantitation among studied samples. 
iTRAQ is another labelling technique first developed by Ross and co-workers (32) which 
uses isobaric tags to label and compare proteins extracted from samples. iTRAQ contains a 
set of four or eight isobaric reagents and therefore can analyse up to four or eight protein 
samples at one time. After trypsin digestion samples are labelled with four or eight (4-plex 
or 8-plex) independent iTRAQ reagents. The reporter groups of the iTRAQ reagents 
separate from the peptides and generate small fragments for each sample with mass-to-
charge (m/z) of 114, 115, 116, and 117 for 4-plex, plus 113, 118, 119, and 121 for 8-plex. The 
intensity of each peak correlates with the quantity of each reporter group and thus with the 
quantity of the peptide. This method allows the analysis of various samples at a time and 
also, given that most peptides are suitable to be labelled by iTRAQ, it minimizes 
information loss and allows the identification of proteins with different post-translational 
modifications. Disadvantages of iTRAQ include a separate lengthy sample processing, that 
increases the chances of experimental errors, and the generation of chemical side products 
during the labelling process that can reduce the sensitivity of the method (33). 
SILAC, first developed by Mann and co-workers, is based on the metabolic incorporation of 
“heavy” and “light” forms of amino acids into the proteins of living cultured cells (34) . 
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Typically, heavy (13C or 15N) arginine or lysine are used in the culture medium of a cell 
culture while the other cell culture is supplied with regular amino acids. After several 
division rounds, these amino acids are incorporated into the newly synthesized proteins. 
Following trypsin digestion, peptides are analysed by MS and the light and heavy peptides 
appear in two distinct peaks and, by comparing the signal intensities differences, relative 
quantitation can be performed. This technique has been widely used for cancer biomarker 
discovery (35), and cell signalling dynamics (36).  
6. Label-free mass spectrometry 
Multidimensional Protein Identification Technology (MudPIT) is a generic label-free LC-MS 
shotgun screening method (36). It separates peptides according to two independent 
physicochemical properties using liquid chromatography (LC/LC) online with the ion 
source of a mass spectrometer, allowing the separation and identification of peptides 
without labelling. The success of this technique depends on the experimental workflow, 
from protein extraction to sample stability, given that the reproducibility of technical 
replicates is better than that of experimental replicates. Drawbacks of this method include 
the fact that not all peptides are equally detectable given the competition between ions, 
dynamic range limitations and MS sensitivity (37). With time and improvements, label-free 
MS could be widely used for biomarker discovery and validation. 
7. Detection of post-translational modifications (PTMs) 
PTMs are the chemical alterations that occur to a protein after translation. They include 
proteolytic cleavage, glycosylation, phosphorylation, acetylation, ubiquitination, 
farnesylation, methylation, sialylation, oxidation, prolyl isomerization and hydroxylation 
(38). Glycosylation and phosphorylation are two of the most biologically relevant PTMs and 
appear to be key processes in tumour progression in many types of cancers including lung 
cancer (39, 40) 
Glycosylation, the process of adding saccharides to proteins, plays a fundamental role in 
protein stabilization, molecular and cellular recognition, growth and cellular 
communication, and can also be a part of immune responses and cancer progression (41). 
The comparative study of the carbohydrate chains of glycoproteins may provide useful 
information for the diagnosis, prognosis, and immunotherapy of tumours (42). The 
proteomic analysis of glycoproteins starts with the enrichment of these molecules from a 
complex protein sample by the use lectins. This step is followed by a separation of 
glycoproteins by procedures such as 2D-PAGE and 2D-DIGE coupled with glycoprotein 
staining methods, for example Pro-Q Emerald 488 glycoprotein stain (43), lectin fluorescence 
stain (44), and isotope labelling (45). Identification of separated glycoproteins and their 
glycan structures can be accomplished by chromatographic methods (nano-LC with 
hydrophilic columns, nano-LC with graphitized carbon packing, anion-exchange 
chromatography), electromigration approaches (capillary electrophoresis, capillary 
electrochromatography), capillary LC/MALDI-TOF/TOF MS & tandem MS (MS/MS), and 
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chip-based approaches (46). Although there are some difficulties when analysing lung 
tumours, one study has identified 34 glycoproteins with significant differences between 
lung adenocarcinomas and healthy controls. The α1,6-fucosylation levels were incremented 
in the lung cancer group in comparison with healthy group (47). 
Phosphorylation is the addition of a phosphate group to a protein and is a key regulatory 
mechanism of cellular signalling processes. Phosphoproteomics and the characterization of 
phosphorylation sites, which less than 2% are currently known, are some of the most 
challenging tasks in current proteomic research (48). To isolate and identify phosphorylated 
proteins one must use immunoaffinity or immunoprecipitation with a specific antibody, 
chromatofocusing, ion exchange chromatography and affinity chromatography, such as 
immobilized metal ion affinity chromatography (IMAC) (49). Separation methods include 
electrophoresis, 2D-PAGE or 2D-DIGE coupled with phosphoprotein staining (Pro-Q 
Diamond phosphoprotein gel stain) or isotope labelling (ICAT, SILAC) (50, 51). Analysis 
and identification methods of phosphoproteins and phosphopeptides are mass 
spectrometry-based approaches, such MALDI-TOF MS, LC-ESI-MS and MS/MS (52). Given 
that the key regulators of signalling cascades are kinases and phosphatases, lung cancer 
phosphoproteomics might reveal the correlation between phosphorylation and cancer 
mechanisms.  
8. Samples in lung cancer proteomics 
The lung is a heterogeneous organ composed by several highly differentiated cells 
(bronchial, alveolar, inflammatory) and vascular structures. Its main function is to 
perform gas exchanges between the atmosphere and the bloodstream. When studying 
lung cancer with proteomic tools, several different samples can be used: tumour tissue, 
blood, pleural effusions, among others (53). The accessibility of blood makes for a great 
sample for oncoproteomic studies. Moreover, it contains many circulating molecules 
secreted by the tumour that can be used as biomarkers. Nonetheless, due to the 
abundance of plasma proteins, depletion of these proteins is necessary to reveal the 
presence of less abundant ones. Tumour tissue samples, fresh-frozen or formalin-fixed 
and paraffin-embedded, are the ideal for any oncoproteomic study. However, adjacent 
normal tissue, inflammatory cells, stromal components, and others might also be present. 
This will result in non-tumour derived protein contamination. To compensate tumour 
heterogeneity careful sample cell content analysis and the increase of sample numbers is 
required to obtain relevant results. The pleura is a thin double-layered tissue that 
surrounds the lung and it is filled with pleural fluid. This liquid is constantly produced 
and reabsorbed, and its main function is to facilitate respiratory movements and reduce 
attrition between the lungs and the thorax wall. Pleural effusion is the pathological 
accumulation of fluid that occurs in inflammatory conditions and lung cancer. In the latter 
case, pleural effusion is often drained to search for cancer cell infiltration. Its protein 
composition is similar to plasma, but its proximity to tumour cells makes it useful for lung 
cancer biomarker detection by proteomic techniques. 
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9. Proteomics in the discovery and validation of lung cancer biomarkers 
9.1. Diagnostic biomarkers 
To discover a lung cancer diagnostic biomarker, a molecule that is specific and directly 
correlates with the presence of this disease, the majority of studies perform a comparison 
between the protein profiles of tumour samples and normal lung tissue. The ideal would be 
to study the development of the carcinogenic process from normal tissue, to metaplasia, to 
dysplasia, and finally to invasive cancer, in order to discover early markers of disease before 
the onset of clinical features. 
In response to inflammation, a cancer enabling characteristic, acute-phase reactant proteins 
(APRPs) are produced. Recent proteomic studies have shown that APRPs haptoglobin (Hp) 
β chain (54), serum amyloid A (SAA) (55), and apolipoprotein A-1 (Apo A-1) (56) proteins 
are potential lung cancer diagnostic biomarkers. SAA proteins are involved in the transport 
of cholesterol to the liver, the recruitment of immune cells, and the induction extracellular 
matrix degrading enzymes. SAA1 and SAA2, which are synthesised in response to activated 
monocytes/macrophages, were recently identified, by LC-MS/MS, ELISA and 
immunohistochemistry analyses, as lung cancer biomarkers given their higher expression 
levels in blood and tissue from lung cancer patients when compared to healthy subjects and 
patients with other cancers and respiratory diseases (55). In another related study, serum 
and pleural effusions from NSCLC patients were compared by 2D-DIGE to those from 
patients with benign lung diseases. Gelsolin, possibly involved in cancer invasion, 
metalloproteinase inhibitor 2 (TIMP2), involved in lung parenchyma disorganization, and 
pigment epithelium derived factor (PEDF), an angiogenesis inhibitor, were among the 
candidate biomarkers (57). A study by Patz and co-workers, that aimed to test the diagnostic 
performance of four lung cancer biomarkers (carcinoembryonic antigen and squamous-cell 
carcinoma antigen, and 2D-PAGE and MALDI-MS discovered retinol binding protein – RBP 
- and α-1 antitrypsin), demonstrated that the four markers have inadequate diagnostic 
power when tested independently but proved useful when used in combination (58). A 
glycoproteomic study revealed plasma kallikrein (KLKB1), pleural effusion periostin, 
multimerin-2, CD166 and lysosome-associated membrane glycoprotein-2 (LAMP-2) as 
potential lung cancer biomarkers (59).  
9.2. Prognostic biomarkers 
Prognostic biomarkers, those that have expression levels correlating with the natural history 
of the disease, have the potential to influence survival by identifying high-risk patients and 
thus improve their management. The study of prognostic biomarkers in lung cancer has 
been made by correlating the expression of a molecule to the patient survival. An alternative 
approach is to compare groups of patients with different clinical stages of disease, based on 
the assumption that a more advanced tumour is more aggressive and may express proteins 
that drive the metastatic process. Proteomic studies have aimed at discovering altered 
protein levels and subsequently validating those differences using immunohistochemistry 
on archive samples. Using 2D-PAGE, Chen and co-workers associated 11 components of the 
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glycolysis pathway to poor survival in lung adenocarcinoma (39) and also demonstrated 
their prognostic role in lung cancer at the mRNA level. Nonetheless, glycolysis involved 
enzyme phosphoglycerate kinase 1 was found to limit tumour growth in mice 
subcutaneously injected with the Lewis lung carcinoma cell line, by promoting antitumor 
immunity (60). A study using 2D-DIGE, MS, western blot, and immunohistochemistry 
correlated the up-regulation of annexin A3, a protein associated with cancer metastasis by 
angiogenic promotion, with advanced clinical stage, lymph node metastasis, increased 
relapse time, and overall decreased survival in lung adenocarcinoma, indicating that 
annexin A3 might be a prognostic lung cancer biomarker (61). The involvement of S100A11, 
a small calcium-binding protein implicated in the prognosis and metastasis in several 
tumours, has also been evaluated in lung cancer. Comparative proteomic analysis of two 
NSCLC cell lines, the non-metastatic CL1-0 and highly metastatic CL1-5, revealed that 
S100A11 was up-regulated in metastatic CL1-5 cells (62). Moreover, immunohistochemical 
analyses in NSCLC tissues showed that the up-regulation of S100A11 was significantly 
associated with a higher TNM stage and a positive lymph node status, indicating its 
importance in promoting invasion and metastasis of NSCLC. Altered expression of S100A6 
was also implicated in NSCLC progression: elevated levels of this protein were associated 
with longer survival compared to S100A6-negative cases (63). Cytoskeletal reorganization is 
a central process regulating cell migration and metastasis and cytokeratins (CKs), a family of 
cytoskeletal intermediate filaments, have been suggested to play a role in carcinogenesis, by 
promoting cellular architecture reorganization during tumour development and 
progression. A 2D-PAGE and MS analysis has revealed that isoforms of CK7, 8, 18, and 19 
were found in higher levels in adenocarcinoma samples than in adjacent tissues (64). 
Specific isoforms of the CKs were associated with unfavourable prognosis, CYFRA21-1 was 
a more accurate diagnostic marker, and CK18 was a stronger prognostic factor (65). Other 
cytoskeletal proteins found to be correlated with a poor prognosis in lung adenocarcinoma 
are non-muscle myosin IIA and vimentin proteins, involved in epithelial-mesenchymal 
transition, a process at the basis of invasive and metastatic behaviour (66). Phosphohistidine 
phosphatase (PHP14) was proposed to be another lung cancer prognostic biomarker, 
regulating cell migration and invasion by cytoskeleton rearrangement. Indeed, it has been 
shown that PHP14 knockdown in highly metastatic lung cancer cells (CL1-5) inhibited 
migration and invasion, whereas its over-expression in NCI H1299 cells enhanced these 
processes (67). Calmodulin, a protein implicated in cytoskeletal alterations during cell death, 
thymosin β4, a regulator of actin polymerization whose over-expression seems to stimulate 
lung tumour metastasis, thymosin β10 and cofilin proteins, regulators of actin dynamics,  
were identified and their expression and prognostic role validated on cohort of 188 lung 
cancer cases (68). 
9.3. Predictive biomarkers  
The discovery of predictive biomarkers, those on which the efficacy of a specific treatment 
can be foreseen, has been based on studying clinical samples from responding and non-
responding patients and then validating results on selected cohorts. This type of biomarker 
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aims at individualizing therapies in lung cancer but relies on extremely well characterized 
samples from cohorts of patients receiving a uniform treatment and closely monitored 
therapeutic responses. A recent MALDI-TOF-MS study that profiled serum from patients 
treated with cisplatin-gemcitabine in combination with the proteasome inhibitor 
bortezomib,  revealed a 13-peptide signature that was able to distinguish with high 
accuracy, sensitivity, and specificity, patients with short and long progression-free survival 
(69). The epidermal growth factor receptor (EGFR) tyrosine kinase is an important target for 
treatment of NSCLC, and EGFR-inhibitor-based therapies have showed promising results. 
The serum MALDI-MS study conducted by Taguchi and co-workers in NSCLC patients  
 
Type of Biomarker Proteins Techniques 
Diagnostic 
Hp β chain (54) LC-ESI-MS/MS, ELISA 
SAA1
SAA2 (55) LC-MS/MS, ELISA, IHC 
Apo A1 (56) 2D-PAGE, MALDI-TOF 
Gelsolin
TIMP2 
PEDF (57) 
2D-DIGE 
RBP
α-1 antitrypsin (58) 2D-DIGE, MALDI-TOF-MS 
KLKB1
Periostin 
Multimerin-2 
CD166 
LAMP-2 (59) 
LC-MS/MS 
Prognostic 
Glycolysis
(11 components) (39) 2D-PAGE 
Annexin A3 (61) 2D-DIGE, MS, IHC* 
S100A11 (62) 2D-PAGE, MALDI-TOF-MS/MS, IHC 
S100A6 (63) SELDI-TOF-MS 
CK 7, 8, 9 and 19 (64) 2D-PAGE, MS 
CYFRA21-1
CK18 (65) ELISA 
Myosin IIA
Vimentin (66) LC-MS/MS 
PHP14 (67) 2D-PAGE, ESI-TOF-MS/MS 
Calmodulin
Thymosin β4 
Thymosin β10 (68)
MALDI-MS, IHC 
Predictive 13-peptide signature (69) MALDI-TOF-MS 
8-peak signature (70) MALDI-MS 
* Immunohistochemistry 
Table 1. Potential lung cancer biomarkers discovered by the use of proteomic tools 
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treated with gefitinib and erlotinib revealed an 8-peak profile predictive of outcome (70). 
This 8-peak signature was commercially launched as a commercial product (Veristrat ®, 
Biodesix, Broom field, CO, US) and its clinical relevance is being validated in the context of a 
randomized phase III clinical trial where patients with advanced NSCLC progressing after 
first-line treatment, stratified according to serum MALDI-MS profiling, are subsequently 
randomly allocated to receive either erlotinib or chemotherapy as second-line therapy 
(PROSE, Proteomics Stratified Erlotinib trial). To the best of our knowledge, this is the only 
clinical trial investigating the predictive role of a proteomics biomarker in lung cancer 
patients. A summary of all mentioned biomarkers can be found on Table 1. 
10. Conclusions 
Proteomic approaches are improving rapidly and the development of high-throughput 
platforms is showing promising results as the list of candidate biomarkers for lung cancer is 
continuously growing. However, there is a great need for careful interpretation of this 
intricate data in order to generate biologically relevant hypotheses. The proteome is highly 
complex and current tools cannot yet provide a definitive solution for its exploration. In 
addition, cancer is a multifactorial disease so diverse that a great deal of time and effort will 
be necessary to define its associated proteome modifications and to translate these into 
practical clinical applications. In fact for many of the identified proteins, their functional role 
in lung cancer development is not yet known and a solid clinical validation is still lacking. 
Nonetheless, it is likely that some of these candidate biomarkers will serve to identify new 
possible therapeutic strategies. 
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